Cereblon binding compounds, compositions thereof, and methods of use thereof

Abstract

Provided herein are piperidinedione compounds having the following structure: (I), wherein R N , R 1 , R 2 , R 3 , R 4 , R N , L, V, X, a, m and n are as defined herein; a composition comprising an effective amount of a piperidinedione compound; and a method for treating or preventing androgen receptor-mediated diseases.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 043,555, filed on June 24, 2020, the disclosure of which is incorporated herein by reference in its entirety. Technical Field

[0003] Provided herein are compounds, compositions comprising an effective amount of such compounds, and methods for treating or preventing androgen receptor-mediated diseases, comprising administering an effective amount of such compounds to a subject in need thereof. Also provided herein are these compounds and compositions for use in these methods. Background Art

[0004] Androgen receptor signaling is known to play a key role in the pathogenesis of prostate cancer and is involved in the development of other androgen receptor-positive cancers (Chen Y et al., Lancet Oncol, 2009, 10:981-91; Mills IG, Nat Rev Cancer, 2014, 14:187-98; Taplin ME, Nat Clin Pract Oncol, 2007, 4:236-44; Wirth MP et al., Eur Urol, 2007, 51(2):306-13). Inhibition of androgen receptor signaling with antiandrogen drugs that antagonize androgen receptors has been used or suggested for the treatment of prostate cancer.

[0005] The androgen receptor is usually located in the cytoplasm and binds to molecular chaperones such as HSP90 (Brinkmann AO et al., J Steroid Biochem Mol Biol [Journal of Steroid Biochemistry and Molecular Biology], 1999, 69: 307-13). After binding to dihydrotestosterone (DHT), the androgen receptor changes its conformation and translocates to the nucleus, where it binds to the androgen response element (ARE) and drives the transcription of typical targets such as KLK3 (also known as prostate-specific androgen (PSA)), TMPRSS2 and KLK2 (Tran C et al., Science [Science], 2009, 324: 787-90; Murtha P et al., Biochemistry [Biochemistry] (Mosc.), 1993, 32: 6459-64).

[0006] Prostate cancer (PCa) is one of the most commonly diagnosed non-skin cancers in American men, with more than 200,000 new cases and more than 30,000 deaths each year in the United States, making it the second leading cause of cancer death.

[0007] Androgen deprivation therapy (ADT) is the standard treatment for advanced PCa. Patients with advanced PCa undergo ADT with luteinizing hormone-releasing hormone (LHRH) agonists, LHRH antagonists, or with bilateral orchiectomy. Despite initial response to ADT, disease progression is inevitable and the cancer eventually presents as castration-resistant prostate cancer (CRPC). Up to 30% of patients with prostate cancer who have received radiation or surgery as primary therapy will develop metastatic disease within 10 years of primary therapy. Approximately 50,000 patients will develop metastatic disease (also known as metastatic CRPC (mCRPC)) each year.

[0008] There remains an urgent need for safe and effective methods to treat, prevent and manage AR-mediated diseases, particularly AR-mediated diseases that are refractory to standard therapies (e.g., such as surgery, radiotherapy, chemotherapy and hormone therapy), while reducing or avoiding the toxicities and / or side effects associated with conventional therapies.

[0009] Citation or identification of any reference in this section of the present application shall not be construed as an admission that such reference is prior art to the present application. Summary of the invention

[0010] Provided herein are compounds having the following formula (I):

[0011]

[0012] or a pharmaceutically acceptable salt, tautomer, isotopomer, or stereoisomer thereof, wherein R N , R 1 , R 2 , R 3 , R 4 , X, L, V, a, m and n are as defined herein.

[0013] The compound of formula (I) or a pharmaceutically acceptable salt, tautomer, isotopomer or stereoisomer thereof can be used to treat or prevent androgen receptor-mediated diseases in a subject.

[0014] In one aspect, provided herein are compounds as described in the disclosure (eg, as in Table 1).

[0015] In one aspect, provided herein are pharmaceutical compositions comprising an effective amount of a compound as described herein, and a pharmaceutically acceptable carrier, excipient, or vehicle. In one aspect, provided herein are pharmaceutical compositions comprising an effective amount of a compound as described herein, and a pharmaceutically acceptable carrier, excipient, or vehicle. In some embodiments, the pharmaceutical compositions are suitable for oral, parenteral, mucosal, transdermal, or topical administration.

[0016] In one aspect, provided herein are methods for treating or preventing androgen receptor-mediated diseases in a subject, comprising administering to a subject in need thereof an effective amount of a compound as described herein; and a pharmaceutically acceptable carrier, excipient, or vehicle. In one aspect, provided herein are methods for treating or preventing androgen receptor-mediated diseases in a subject, comprising administering to a subject in need thereof an effective amount of a compound as described herein; and a pharmaceutically acceptable carrier, excipient, or vehicle. In another aspect, provided herein are compounds for use in methods for treating androgen receptor-mediated diseases. In another aspect, provided herein are compounds for use in methods for treating androgen receptor-mediated diseases.

[0017] In another aspect, provided herein are methods for preparing the compounds as described herein. In another aspect, provided herein are methods for preparing the compounds as described herein.

[0018] Embodiments of the present invention may be more fully understood by referring to the detailed description and examples, which are intended to illustrate non-limiting embodiments. DETAILED DESCRIPTION

[0019] definition

[0020] As used herein, the terms "comprising" and "including" are used interchangeably. The terms "comprising" and "including" should be interpreted as specifying the presence of the stated features or components mentioned, but not excluding the presence or addition of one or more features or components or groups thereof. In addition, the terms "comprising" and "including" are intended to include examples covered by the term "consisting of". Therefore, the term "consisting of" can be used to replace the terms "comprising" and "including" to provide more specific embodiments of the present invention.

[0021] The term "consisting of" means that the subject matter has at least 90%, 95%, 97%, 98%, or 99% of the features or components of its stated composition. In another embodiment, the term "consisting of" excludes any other features or components from the scope of any subsequent description, except those that are not necessary for the technical effect to be achieved.

[0022] As used herein, the term "or" should be interpreted as an inclusive "or", meaning any one or any combination. Thus, "A, B or C" means any one of the following: "A; B; C; A and B; A and C; B and C; A, B and C". Exceptions to this definition will only occur when elements, functions, steps or actions are inherently mutually exclusive in some way.

[0023] "Alkyl" group is a saturated, partially saturated or unsaturated straight or branched non-cyclic hydrocarbon with 1 to 10 carbon atoms, typically 1 to 8 carbons or in some embodiments, 1 to 6, 1 to 4, or 2 to 6 carbon atoms. In some embodiments, the alkyl group is a saturated alkyl group. Representative saturated alkyl groups include-methyl,-ethyl,-n-propyl,-n-butyl,-n-pentyl and-n-hexyl; and saturated branched alkyl groups include-isopropyl,-sec-butyl,-isobutyl,-tert-butyl,-isopentyl,-neopentyl, tert-pentyl,-2-methylpentyl,-3-methylpentyl,-4-methylpentyl,-2,3-dimethylbutyl, etc. In some embodiments, the alkyl group is an unsaturated alkyl group (also referred to as alkenyl or alkynyl group). "Alkenyl" group is an alkyl group containing one or more carbon-carbon double bonds. "Alkynyl" group is an alkyl group containing one or more carbon-carbon triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, allyl, -CH=CH(CH3), -CH=C(CH3)2, -C(CH3)=CH2, -C(CH3)=CH(CH3), -C(CH2CH3)=CH2, -C≡CH, -C≡C(CH3), -C≡C(CH2CH3), -CH2C≡CH, -CH2C≡C(CH3), and -CH2C≡C(CH2CH3), etc. The alkyl group may be substituted or unsubstituted. When alkyl groups described herein are referred to as "substituted," they may be substituted with any one or more substituents such as those found in the exemplary compounds and examples disclosed herein, as well as halogen; hydroxy; alkoxy; cycloalkyloxy, aryloxy, heterocyclyloxy, heteroaryloxy, heterocyclylalkyloxy, cycloalkylalkyloxy, aralkyloxy, heterocyclylalkyloxy, heteroarylalkyloxy, heterocyclylalkylalkyloxy; oxo (=O); amino, alkylamino, cycloalkylamino, arylamino, heterocyclylamino, heteroarylamino, heterocyclylalkylamino, cycloalkylalkyloxy, aralkyloxy, heterocyclylalkyloxy, heteroarylalkyloxy, heterocyclylalkylalkyloxy; alkylamino, arylalkylamino, heterocyclylalkylamino, heteroarylalkylamino, heterocyclylalkylalkylamino; imino; imino; amidino; guanidino; enamino; acylamino; sulfonylamino; urea, nitrourea; oxime; hydroxyamino; alkoxyamino; arylalkyloxyamino; hydrazine; hydrazide; hydrazono; azido; nitro; thio (-SH), alkylthio; =S; sulfinyl; sulfonyl; aminosulfonyl; phosphonate; phosphinyl; acyl; formyl; carboxyl; ester; carbamate; acylamino; cyano; isocyanato; isothiocyanato; cyanato; thiocyanato; or -B(OH)2.In certain embodiments, when alkyl groups described herein are referred to as "substituted," they may be substituted with any one or more substituents such as those found in the exemplary compounds and embodiments disclosed herein, as well as halogen (chloro, iodo, bromo, or fluoro); alkyl; hydroxy; alkoxy; alkoxyalkyl; amino; alkylamino; carboxyl; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfone; sulfonamide; ketone; aldehyde; ester; urea; urethane; oxime; hydroxylamine; alkoxyamine; aralkyloxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; B(OH)2, or O(alkyl)aminocarbonyl.

[0024] "Cycloalkyl" group is a saturated or partially saturated cyclic alkyl group of 3 to 10 carbon atoms, which has a single ring or multiple condensed rings or bridged rings that can be optionally substituted. In certain embodiments, the cycloalkyl group has 3 to 8 ring members, and in other embodiments, the number of ring carbon atoms ranges from 3 to 5, 3 to 6 or 3 to 7. In certain embodiments, the cycloalkyl group is a saturated cycloalkyl group. Such saturated cycloalkyl groups include, for example, monocyclic structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, or polycyclic structures or bridged ring structures such as 1-bicyclo [1.1.1] pentyl, bicyclo [2.1.1] hexyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl, adamantyl, etc. In other embodiments, the cycloalkyl group is an unsaturated cycloalkyl group. Examples of unsaturated cycloalkyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, hexadienyl, etc. The cycloalkyl group may be substituted or unsubstituted. Such substituted cycloalkyl groups include, for example, cyclohexanol, etc.

[0025] "Aryl" groups are aromatic carbocyclic groups with 6 to 14 carbon atoms, having a monocyclic (e.g., phenyl) or polycyclic condensed rings (e.g., naphthyl or anthracenyl). In some embodiments, the aryl group contains 6-14 carbons in the ring portion of the group, in other embodiments, 6 to 12 or even 6 to 10 carbon atoms. Special aryl groups include phenyl, biphenyl, naphthyl, etc. The aryl group can be substituted or unsubstituted. The phrase "aryl group" also includes groups containing condensed rings, such as condensed aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, etc.).

[0026] "Heteroaryl" groups are aromatic ring systems having one to four heteroatoms as ring atoms in the heteroaromatic ring system, wherein the remainder of the ring atoms are carbon atoms. In some embodiments, the heteroaryl group contains 3 to 6 ring atoms in the ring portion of the group, in other embodiments, 6 to 9 or even 6 to 10 atoms. Suitable heteroatoms include oxygen, sulfur and nitrogen. In certain embodiments, the heteroaryl ring system is monocyclic or bicyclic. Non-limiting examples include, but are not limited to, groups such as pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, benzisoxazolyl (e.g., benzo[d]isoxazolyl), thiazolyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, benzothienyl, furanyl, benzofuranyl, indolyl (e.g., indol-2-one or isoindolin-1-one), azaindolyl (pyrrolopyridinyl or 1H-pyrrolo[2,3-b]pyridinyl), indazolyl, benzimidazolyl (e.g., 1H-benzo[d]imidazolyl), imidazole The heteroaryl groups may be substituted or unsubstituted.

[0027] "Heterocyclyl" is an aromatic cycloalkyl (also referred to as heteroaryl) or non-aromatic cycloalkyl, wherein one to four of the ring carbon atoms are independently replaced by heteroatoms from the group consisting of O, S and N. In certain embodiments, the heterocyclyl group includes 3 to 10 ring members, while other such groups have 3 to 5, 3 to 6 or 3 to 8 ring members. The heterocyclyl group can also be combined with other groups at any ring atom (i.e., at any carbon atom or heteroatom of the heterocycle). The heterocycloalkyl group can be substituted or unsubstituted. The heterocyclyl group encompasses unsaturated, partially saturated and saturated ring systems, such as imidazolyl, imidazolinyl and imidazolidinyl (e.g., imidazolidinyl-4-one or imidazolidinyl-2,4-diketo) groups. The phrase heterocyclyl includes fused ring species, including those containing fused aromatic and non-aromatic groups, such as, for example, 1- and 2-aminotetralin, benzotriazolyl (e.g., 1H-benzo[d][1,2,3]triazolyl), benzimidazolyl (e.g., 1H-benzo[d]imidazolyl), 2,3-dihydrobenzo[1,4]dioxinyl, and benzo[1,3]dioxolyl. The phrase also includes bridged polycyclic ring systems containing heteroatoms, such as, but not limited to, quinuclidine.Representative examples of heterocyclyl groups include, but are not limited to, aziridinyl, azetidinyl, azepanyl, oxetanyl, pyrrolidinyl, imidazolidinyl (e.g., imidazolidin-4-one or imidazolidin-2,4-dione), pyrazolidinyl, thiazolidinyl, tetrahydrothienyl, tetrahydrofuranyl, dioxolyl, furanyl, thienyl, pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, benzisoxazolyl (e.g., benzo[d]isoxazolyl), thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, piperidinyl, piperazinyl (e.g., piperazin-2-one), morpholinyl, thiomorpholinyl, linyl, tetrahydropyranyl (e.g., tetrahydro-2H-pyranyl), tetrahydrothiopyranyl, oxathiolanyl, dioxyl, dithianyl, pyranyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, dihydropyridyl, dihydrodithiinyl, dihydrodisulfinyl, 1,4-dioxaspiro[4.5]decyl, homopiperazinyl, quinuclidine, indolyl (e.g., indol-2-one or isoindol-1-one), dihydroindolyl, isoindolyl, isoindolyl, azaindolyl (pyrrolopyridinyl or 1H-pyrrolo[2,3-b]pyridinyl), indazolyl, indolizinyl, benzotriazolyl ( For example, 1H-benzo[d][1,2,3]triazolyl), benzimidazolyl (e.g., 1H-benzo[d]imidazolyl or 1H-benzo[d]imidazolyl-2(3H)-onyl), benzofuranyl, benzothiophenyl, benzothiazolyl, benzoxadiazolyl, benzoxazinyl, benzodithiinyl, benzothiothienyl, benzothiazinyl, benzoxazolyl (i.e., benzo[d]oxazolyl), benzothiazolyl, benzothiadiazolyl, benzo[l,3]dioxolyl, pyrazolopyridyl (e.g., 1H-pyrazolo[3,4-b]pyridyl, 1H-pyrazolo[4,3-b]pyridyl), imidazopyridyl (e.g., azabenzimidazolyl or 1H

[00136] Examples of the present invention include 3,4-dihydroisoquinolin-1(2H)-one, quinolizinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, pteridinyl, thiazinyl, dihydrobenzothiazinyl, dihydrobenzofuranyl, dihydroindolyl, dihydrobenzodioxinyl, tetrahydroindolyl, tetrahydroindazolyl, tetrahydrobenzimidazolyl, tetrahydrobenzotriazolyl, tetrahydropyrrolopyridinyl, tetrahydropyrazolopyridinyl, tetrahydroimidazopyridinyl, tetrahydrotriazolopyridinyl, tetrahydropyrimidin-2(1H)-one, and tetrahydroquinolinyl groups. Representative non-aromatic heterocyclyl groups do not include fused ring species containing a fused aromatic group.Examples of non-aromatic heterocyclyl groups include aziridinyl, azetidinyl, azepanyl, pyrrolidinyl, imidazolidinyl (e.g., imidazolidin-4-one or imidazolidin-2,4-dione), pyrazolidinyl, thiazolidinyl, tetrahydrothienyl, tetrahydrofuranyl, piperidinyl, piperazinyl (e.g., piperazin-2-one), morpholinyl, thiomorpholinyl, tetrahydropyranyl (e.g., tetrahydro-2H-pyranyl), tetrahydrothiopyranyl, oxathianyl, dithianyl, 1,4-dioxaspiro[4.5]decanyl, homopiperazinyl, quinuclidinyl, or tetrahydropyrimidin-2(1H)-one. Representative substituted heterocyclyl groups can be mono- or multiply substituted, such as, but not limited to, pyridyl groups or morpholinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted or disubstituted with a variety of substituents, such as those listed below.

[0028] As used herein and unless otherwise indicated, a "cycloalkylalkyl" group is a group having the formula: -alkyl-cycloalkyl, wherein the alkyl and cycloalkyl are defined above. Substituted cycloalkylalkyl groups can be substituted at both the alkyl, cycloalkyl, or alkyl and cycloalkyl portions of the group. Representative cycloalkylalkyl groups include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclopropylethyl, cyclobutylethyl, cyclopentylethyl, cyclohexylethyl, cyclopentylpropyl, cyclohexylpropyl, etc.

[0029] As used herein and unless otherwise indicated, an "aralkyl" group is a group having the formula: -alkyl-aryl, wherein the alkyl and aryl are defined above. Substituted aralkyl groups may be substituted at the alkyl, aryl, or both the alkyl and aryl portions of the group. Representative aralkyl groups include, but are not limited to, benzyl and phenethyl groups and aralkyl groups wherein the aryl group is fused to a cycloalkyl group, such as indan-4-ylethyl.

[0030] As used herein and unless otherwise specified, a "heterocyclylalkyl" group is a group having the formula: -alkyl-heterocyclyl, wherein alkyl and heterocyclyl are defined above. A "heteroarylalkyl" group is a group having the formula: -alkyl-heteroaryl, wherein alkyl and heteroaryl are defined above. A "heterocyclylalkylalkyl" group is a group having the formula: -alkyl-heterocyclyl, wherein alkyl and heterocyclyl are defined above. A substituted heterocyclylalkyl group can be substituted at both the alkyl, heterocyclyl, or alkyl and heterocyclyl moieties of the group. Representative heterocyclylalkyl groups include, but are not limited to, morpholin-4-ylethyl, morpholin-4-ylpropyl, furan-2-ylmethyl, furan-3-ylmethyl, pyridin-3-ylmethyl, tetrahydrofuran-2-ylethyl, and indol-2-ylpropyl.

[0031] "Halogen" is fluorine, chlorine, bromine or iodine.

[0032] A "hydroxyalkyl" group is an alkyl group as described above substituted with one or more hydroxy groups.

[0033] An "alkoxy" group is an -O-(alkyl) group wherein alkyl is as defined above.

[0034] An "alkoxyalkyl" group is a -(alkyl)-O-(alkyl) where alkyl is as defined above.

[0035] An "amino" group is a group having the formula: -NH2, -NH(R # ), or -N(R # )2, where each R # is independently an alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl (e.g., heteroaryl or heterocycloalkyl), or heterocyclylalkyl (e.g., heteroarylalkyl or heterocycloalkylalkyl) group as defined above, each of which is independently substituted or unsubstituted.

[0036] In one embodiment, the "amino" group is an "alkylamino" group, which is a group having the formula: -NH-alkyl or -N(alkyl), wherein each alkyl is independently defined above. The terms "cycloalkylamino", "arylamino", "heterocyclylamino", "heteroarylamino", "heterocycloalkylamino", etc. are the same as described above for "alkylamino", wherein the term "alkyl" is replaced by "cycloalkyl", "aryl", "heterocyclyl", "heteroaryl", "heterocycloalkyl", etc., respectively.

[0037] A "carboxy" group is a group having the formula: -C(O)OH.

[0038] As used herein and unless otherwise specified, an "acyl" group is a group having the formula: -C(O)(R # ) or -C(O)H, where R # Defined above. A "formyl" group is a group having the formula: -C(O)H.

[0039] As used herein and unless otherwise specified, an "amido" group is a group having the formula: -C(O)-NH2, -C(O)-NH(R # )、-C(O)-N(R # )2、-NH-C(O)H、-NH-C(O)-(R # )、-N(R # )-C(O)H, or -N(R # )-C(O)-(R # ), where each R # are independently defined above.

[0040] In one embodiment, the "amido" group is an "aminocarbonyl" group, which is a group having the formula: -C(O)-NH2, -C(O)-NH(R # )、-C(O)-N(R # )2, where each R # are independently defined above.

[0041] In one embodiment, the "acylamino" group is an "acylamino" group, which is a group having the formula: -NH-C(O)H, -NH-C(O)-(R # )、-N(R # )-C(O)H, or -N(R # )-C(O)-(R # ), where each R # are independently defined above.

[0042] A "sulfonylamino" group is a group having the formula: -NHSO2(R # ) or -N(alkyl)SO2(R # ), wherein each alkyl group and R # Defined above.

[0043] A "urea" group is a group having the formula: -N(alkyl)C(O)N(R # )2, -N(alkyl)C(O)NH(R # )、-N(alkyl)C(O)NH2、-NHC(O)N(R # )2、-NHC(O)NH(R # ), or -NH(CO)NH2, wherein each alkyl group and R # Independently as defined above.

[0044] When groups described herein (except alkyl groups) are referred to as "substituted", they may be substituted with any one or more suitable substituents. Illustrative examples of substituents are those found in the exemplary compounds and embodiments disclosed herein, as well as halogen (chlorine, iodine, bromine, or fluorine); alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxyl; nitro; cyano; mercapto; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonate; phosphine; thiocarbonyl; sulfinyl; sulfone; sulfonamide; ketone; aldehyde; ester; urea; urethane; oxime; hydroxylamine; alkoxyamine; aralkyloxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; oxygen (=O); B(OH)2, O(alkyl)aminocarbonyl; cycloalkyl, which may be The term "alkyl" may be a monocyclic or fused or non-fused polycyclic group (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocyclic group, which may be a monocyclic or fused or non-fused polycyclic group (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiazinyl); a monocyclic or fused or non-fused polycyclic aryl or heteroaryl group (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolyl, isoquinolyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothienyl, or benzofuranyl); an aryloxy group; an aralkyloxy group; a heterocyclyloxy group; and a heterocyclylalkoxy group.

[0045] As used herein, the term "pharmaceutically acceptable salt(s)" refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases, including inorganic acids and bases and organic acids and bases. Suitable pharmaceutically acceptable base addition salts of compounds of formula (I) include, but are not limited to, metal salts prepared from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, or organic salts prepared from lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methyl-glucamine) and procaine. Suitable non-toxic acid includes but is not limited to inorganic acid and organic acid such as acetic acid, alginic acid, anthranilic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, formic acid, fumaric acid, furoic acid, galacturonic acid, gluconic acid, glucuronic acid, glutamic acid, glycolic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, propionic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, sulfuric acid, tartaric acid and p-toluenesulfonic acid. Special non-toxic acid includes hydrochloric acid, hydrobromic acid, maleic acid, phosphoric acid, sulfuric acid and methanesulfonic acid. Therefore the example of special salt includes hydrochloride, formate and mesylate. Others are well known in the art, see, e.g., Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990) or Remington: The Science and Practice of Pharmacy, 19th ed., Mack Publishing, Easton PA (1995).

[0046] As used herein and unless otherwise indicated, the term "stereoisomer" or "stereoisomerically pure" means a stereoisomer of a compound provided herein that is substantially free of other stereoisomers of the compound. For example, a stereoisomerically pure compound with one chiral center will be substantially free of the opposite enantiomer of the compound. A stereoisomerically pure compound with two chiral centers will be substantially free of other diastereomers of the compound. A typical stereoisomerically pure compound contains one stereoisomer of the compound greater than about 80% by weight and less than about 20% by weight of other stereoisomers of the compound, one stereoisomer of the compound greater than about 90% by weight and less than about 10% by weight of other stereoisomers of the compound, one stereoisomer of the compound greater than about 95% by weight and less than about 5% by weight of other stereoisomers of the compound, or one stereoisomer of the compound greater than about 97% by weight and less than about 3% by weight of other stereoisomers of the compound. These compounds may have chiral centers and may exist as racemates, single enantiomers or diastereomers, and mixtures thereof. The embodiments disclosed herein include all such isomeric forms, including mixtures thereof.

[0047] The embodiments disclosed herein encompass the use of stereoisomerically pure forms of such compounds as well as the use of mixtures of these forms. For example, mixtures of enantiomers comprising equal or unequal amounts of a particular compound can be used in the methods and compositions disclosed herein. These isomers can be asymmetrically synthesized or separated using standard techniques such as chiral columns or chiral resolving agents.See, e.g., Jacques, J. et al., Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen, SH et al., Tetrahedron 33:2725 (1977); Eliel, EL, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, SH, Tables of Resolving Agents and Optical Resolutions, p. 268 (E.L. Eliel, ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972); Todd, M., Separation Of Enantiomers: Synthetic Methods [Enantiomer Separation: Synthetic Methods] (Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2014); Toda, F., Enantiomer Separation: Fundamentals and Practical Methods [Enantiomer Separation: Fundamentals and Practical Methods] (Springer Science & Business Media, 2007); Subramanian, G. Chiral Separation Techniques: A Practical Approach [Chiral Separation Techniques: A Practical Approach] (John Wiley & Sons, 2008); Ahuja, S., Chiral Separation Methods for Pharmaceutical and Biotechnological Products [Chiral Separation Methods for Pharmaceutical and Biotechnological Products] (John Wiley & Sons, 2011).

[0048] It should also be noted that these compounds can include E and Z isomers or mixtures thereof, as well as cis and trans isomers or mixtures thereof. In certain embodiments, these compounds are separated into E or Z isomers. In other embodiments, these compounds are mixtures of E and Z isomers.

[0049] "Tautomers" refers to isomeric forms of a compound that are in equilibrium with each other. The concentration of the isomeric forms will depend on the environment in which the compound is located and will vary, for example, depending on whether the compound is a solid or in an organic or aqueous solution. For example, in aqueous solution, pyrazole can exist in the following isomeric forms, which are referred to as tautomers of each other:

[0050]

[0051] As will be readily appreciated by those skilled in the art, various functional groups and other structures may exhibit tautomerism and all tautomers of compounds having formula (I) are within the scope of the present invention.

[0052] It should also be noted that the compounds provided herein may contain unnatural proportions of atomic isotopes at one or more atoms. For example, the compounds may be treated with radioactive isotopes such as tritium ( 3 H), iodine-125 ( 125 I), sulfur-35( 35 S), or carbon-14 ( 14 C) can be radiolabeled, or deuterium ( 2 H), carbon-13 ( 13 C), or nitrogen-15( 15 N) isotopically enriched. As used herein, an "isotopologue" is an isotopically enriched compound. The term "isotopically enriched" refers to atoms having an isotopic composition other than the natural isotopic composition of atoms. "Isotopically enriched" can also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of atoms. The term "isotopic composition" refers to the amount of each isotope present for a given atom. Radiolabeled and isotopically enriched compounds can be used as therapeutic agents such as cancer therapeutics, research reagents such as binding assay reagents, and diagnostic agents such as in vivo imaging agents. All isotopic variants of the compounds described herein, whether or not radioactive, are intended to be covered within the scope of the embodiments provided herein. In some embodiments, isotopologues of compounds are provided, for example, isotopologues are deuterium, carbon-13, and / or nitrogen-15 enriched compounds. As used herein, "deuterated" means a compound in which at least one hydrogen (H) is replaced by deuterium (by D or 2 H indicates), i.e., the compound is enriched in deuterium in at least one position.

[0053] It is understood that, independently of stereoisomer or isotope composition, each compound mentioned herein can be provided in the form of any pharmaceutically acceptable salt discussed herein. Equally, it is understood that the isotope composition can vary independently of the stereoisomer composition of each compound mentioned herein. Further, the isotope composition, while limited to the elements present in each compound or its salt, can additionally vary independently of the selection of the pharmaceutically acceptable salt of each compound.

[0054] It should be noted that if there is a discrepancy between a depicted structure and the name of that structure, the depicted structure shall prevail.

[0055] As used herein, "treatment" means the complete or partial alleviation of an obstacle, disease or condition, or one or more symptoms associated with the obstacle, disease or condition, or the slowing down or stopping of the further development or deterioration of these symptoms, or the alleviation or elimination of one or more causes of the obstacle, disease or condition itself. In one embodiment, the obstacle is an androgen receptor-mediated disease as described herein, or a symptom of the disease.

[0056] As used herein, "prevention" means delaying and / or preventing the complete or partial onset, recurrence or spread of a disorder, disease or condition; preventing a subject from developing a disorder, disease or condition; or a method of reducing the risk of a subject developing a disorder, disease or condition. In one embodiment, the disorder is an androgen receptor-mediated disease as described herein, or multiple symptoms of the disease.

[0057] The term "effective amount" with respect to a compound means an amount capable of treating or preventing a disorder, disease or condition disclosed herein, or a symptom thereof.

[0058] As used herein, the terms "subject" and "patient" include animals, including but not limited to animals such as cows, monkeys, horses, sheep, pigs, chickens, turkeys, quail, cats, dogs, mice, rats, rabbits or guinea pigs, in one embodiment mammals, in another embodiment humans. In one embodiment, the subject is a person suffering from an androgen receptor-mediated disease or a symptom thereof or a person who is at risk of an androgen receptor-mediated disease or a symptom thereof.

[0059] As used herein, the term "androgen receptor" or "AR" or "NR3C4" refers to a nuclear hormone receptor activated by binding to androgen (including testosterone or dihydrotestosterone). The term "androgen receptor" can refer to the nucleotide sequence or protein sequence of human androgen receptor (e.g., Entrez 367, Uniprot P10275, RefSeq NM_000044, or RefSeqNP_000035).

[0060] As used herein, the term "AR-full length" (AR-FL) refers to an AR protein that contains all four functional domains, including the N-terminal transcriptional activation domain (NTD, exon 1), the DNA binding domain (DBD, exons 2-3), the hinge domain (exon 4), and the C-terminal ligand binding domain (LBD, exons 4-8).

[0061] The term "castration-resistant prostate cancer" (CRPC) refers to advanced prostate cancer that worsens or progresses while the patient is maintaining androgen deprivation therapy or other therapies for reducing testosterone, or is considered hormone-refractory, hormone-naive, androgen-independent, or chemical or surgical castration-resistant prostate cancer. Castration-resistant prostate cancer (CRPC) is advanced prostate cancer that has developed despite ongoing ADT and / or surgical castration. Castration-resistant prostate cancer is defined as prostate cancer that has progressed despite previous surgical castration, continued treatment with gonadotropin-releasing hormone (e.g., leuprolide) or antagonists (e.g., degarelix or abarelix), antiandrogens (e.g., bicalutamide, flutamide, enzalutamide, ketoconazole, aminoglutethimide), chemotherapeutic agents (e.g., docetaxel, paclitaxel, cabazitaxel, doxorubicin, mitoxantrone, estradiol mustard, cyclophosphamide), kinase inhibitors (imatinib), and chemotherapeutic agents (e.g., tadalafil ... Gefitinib Cabozantinib ( Also known as XL184) or other prostate cancer therapies (e.g., vaccines (sipuleucel-T GVAX, etc.), herbal inhibitors (PC-SPES), and lytic enzyme inhibitors (abiraterone)), which still continue to progress or worsen or adversely affect the patient's health, as evidenced by elevated or higher serum prostate-specific antigen (PSA) levels, metastasis, bone metastasis, pain, lymph node involvement, increase in volume or serum markers representing tumor growth, worsening of prognostic diagnostic markers, or worsening of the patient's condition.

[0062] Compound

[0063] Provided herein are compounds having the following formula (I):

[0064]

[0065] or a pharmaceutically acceptable salt, tautomer, isotopomer, or stereoisomer thereof, wherein:

[0066] R N It is H;

[0067] n is 0-4;

[0068] Each R 1independently selected from halogen, CN and C 1-3 alkyl;

[0069] a is 1 or 2;

[0070] R 2 and R 3 Each independently selected from H and C 1-3 Alkyl, or R 2 and R 3 and the carbon to which they are attached to form substituted or unsubstituted C 3-6 Cycloalkyl;

[0071] m is 0-8;

[0072] Each R 4 are independently substituted or unsubstituted C 1-3 Alkyl, or two R 4 The groups, together with the same carbon atom or adjacent carbon atoms to which they are attached, form a substituted or unsubstituted C 3-6 Cycloalkyl, or two R 4 The groups, together with the non-adjacent carbon atoms to which they are attached, form a substituted or unsubstituted 4-7 membered heterocyclyl;

[0073] X is N or CR X ;

[0074] R X is hydrogen, halogen, -O(C 1-6 alkyl) or -(C 1-9 alk

[0075] L is substituted or unsubstituted -O(C 1-6 Alkyl)-, (C 1-6 Alkyl)O-, -O(C 1-6 alkyl)O-, or -(C 1-9 alkyl)-;

[0076] V is

[0077]

[0078] in

[0079] B is N, CH or CR B ;

[0080] Each R B are independently selected from halogen, and substituted or unsubstituted C 1-6 alkyl;

[0081] R C is halogen, CF3 or SF5;

[0082] R 5 and R6 It is C 1-3 Alkyl, or R 5 and R 6 Together with the carbon atom to which they are attached, they form a substituted or unsubstituted C 3-6 Cycloalkyl, or 3-6 membered heterocyclic group; and

[0083] b is 0-2.

[0084] Provided herein are compounds having the following formula (I):

[0085]

[0086] or a pharmaceutically acceptable salt, tautomer, isotopomer, or stereoisomer thereof, wherein:

[0087] R N It is H;

[0088] n is 0-4;

[0089] Each R 1 independently selected from halogen, CN and C 1-3 alkyl;

[0090] a is 1 or 2;

[0091] R 2 and R 3 Each independently selected from H and C 1-3 Alkyl, or R 2 and R 3 and the carbon to which they are attached to form substituted or unsubstituted C 3-6 Cycloalkyl;

[0092] m is 0-8;

[0093] Each R 4 are independently substituted or unsubstituted C 1-3 Alkyl, or two R 4 The groups, together with the same carbon atom or adjacent carbon atoms to which they are attached, form a substituted or unsubstituted C 3-6 Cycloalkyl, or two R 4 The groups, together with the non-adjacent carbon atoms to which they are attached, form a substituted or unsubstituted 4-7 membered heterocyclyl;

[0094] X is N or CR X ;

[0095] R X is hydrogen, halogen, -O(C 1-6 alkyl) or -(C 1-9 alk

[0096] L is substituted or unsubstituted -O(C 1-6 Alkyl)-, (C 1-6 alkyl)O-, or -(C 1-9 alkyl)-;

[0097] V is

[0098]

[0099] in

[0100] B is N, CH or CR B ;

[0101] Each R B are independently selected from halogen, and substituted or unsubstituted C 1-6 alkyl;

[0102] R C is halogen, CF3 or SF5;

[0103] R 5 and R 6 It is C 1-3 Alkyl, or R 5 and R 6 Together with the carbon atom to which they are attached, they form a substituted or unsubstituted C 3-6 Cycloalkyl, or 3-6 membered heterocyclic group; and

[0104] b is 0-2.

[0105] In some embodiments of compounds of formula (I), n is 0. In some embodiments of compounds of formula (I), a is 1, and R 2 and R 3 Both are H. In some embodiments of compounds of formula (I), each R 4 is a substituted or unsubstituted methyl. In some embodiments of compounds of formula (I), each R 4 In some embodiments of compounds of formula (I), m is 0, 1, 2, 3, or 4. In some embodiments of compounds of formula (I), m is 1 or 2. In some embodiments of compounds of formula (I), X is N. In some embodiments of compounds of formula (I), X is CR X , where R X is hydrogen, halogen, -O(C 1-6 alkyl) or -(C 1-9 alkyl).

[0106] In some embodiments of compounds of formula (I), L is substituted or unsubstituted -O(CH2) p -、-O(CH2)p O- or -(CH2) p -, and p is 1-4. In some embodiments of the compound of formula (I), L is substituted or unsubstituted -O(CH2) p -or-(CH2) p -, and p is 1-4. In some embodiments of the compound of formula (I), L is substituted or unsubstituted -O(CH2) p -、-O(CH2) p O- or -(CH2) p -, and p is 2 or 3. In some embodiments of the compound of formula (I), L is substituted or unsubstituted -O(CH2) p -, and p is 2 or 3. In some embodiments of compounds having formula (I), L is substituted or unsubstituted -(CH2) p -, and p is 3 or 4.

[0107] In some embodiments of compounds of formula (I), L is -O(CH2)(CH2)-, -O(CH2)(CH2)(CH2)-, -O(CH2)(CH2)O-, -(CH2)(CH2)-, -(CH2)(CH2)(CH2)-, or -(CH2)(CH2)(CH2)(CH2)-. In some embodiments of compounds of formula (I), L is -O(CH2)(CH2)-, -O(CH2)(CH2)(CH2)-, -(CH2)(CH2)-, -(CH2)(CH2)(CH2)-, or -(CH2)(CH2)(CH2)(CH2)-. In some embodiments of compounds of formula (I), L is -O(CH2)(CH2)- or -(CH2)(CH2)(CH2)-.

[0108] In some embodiments of compounds of formula (I), B is CH. In some embodiments of compounds of formula (I), B is N. In some embodiments of compounds of formula (I), b is 0. In some embodiments of compounds of formula (I), R C is CF3, Cl or SF5. In some embodiments of compounds of formula (I), R C is CF3. In some embodiments of compounds of formula (I), R 5 and R 6 It's methyl.

[0109] In some embodiments of compounds of formula (I), the compound is

[0110]

[0111] or a pharmaceutically acceptable salt, tautomer, isotopomer, or stereoisomer thereof, wherein

[0112] R N It is H;

[0113] Each R 4m are independently hydrogen or substituted or unsubstituted methyl, wherein these substituents when present are selected from 1 to 5 halo;

[0114] X is N or CR X ;

[0115] R x is hydrogen, halogen, -O(C 1-6 alkyl) or -(C 1-9 alkyl);

[0116] L is substituted or unsubstituted -O(C 1-3 Alkyl)-, -O(C 1-3 alkyl)O- or -(C 1-4 alkyl)-;

[0117] V is

[0118]

[0119] B is N or CH;

[0120] R C is halogen, CF3 or SF5; and

[0121] R 5 and R 6 It is C 1-3 alkyl.

[0122] In some embodiments of compounds of formula (I), the compound is

[0123]

[0124] or a pharmaceutically acceptable salt, tautomer, isotopomer, or stereoisomer thereof, wherein

[0125] R N It is H;

[0126] X is N or CR X ;

[0127] R X is hydrogen, halogen, -O(C 1-6 alkyl) or -(C 1-9 alkyl);

[0128] L is substituted or unsubstituted -O(C 1-3 Alkyl)-, O(C1-3 alkyl)O- or -(C 1-4 alkyl)-;

[0129] V is

[0130]

[0131] B is N or CH;

[0132] R C is halogen, CF3 or SF5; and

[0133] R 5 and R 6 It is C 1-3 alkyl.

[0134] In some embodiments of compounds of formula (I), the compound is

[0135]

[0136] or a pharmaceutically acceptable salt, tautomer, isotopomer, or stereoisomer thereof, wherein

[0137] R N It is H;

[0138] X is N or CR X ;

[0139] R X is hydrogen, halogen, -O(C 1-6 alkyl) or -(C 1-9 alkyl);

[0140] L is substituted or unsubstituted -O(C 1-3 Alkyl)-, O(C 1-3 alkyl)O- or -(C 1-4 alkyl)-;

[0141] V is

[0142]

[0143] B is N or CH;

[0144] R C is halogen, CF3 or SF5; and

[0145] R 5 and R 6 It is C 1-3 alkyl.

[0146] In some embodiments of compounds of Formula (I), (II), (III), and (IV), n is 0; X is N or CR X , RX is hydrogen, halogen, -O(C 1-6 alkyl) or -(C 1-9 alkyl); L is substituted or unsubstituted -O(CH2) p -or-(CH2) p -, p is 1-4; B is CH or N; b is 0; R C is CF3, Cl or SF5; R C is CF3; and R 5 and R 6 It's methyl.

[0147] In some embodiments of compounds of Formula (I), (II), (III), and (IV), L is -O(CH2)(CH2)-, -O(CH2)(CH2)(CH2)-, -O(CH2)(CH2)O-, -(CH2)(CH2)-, -(CH2)(CH2)(CH2)-, or -(CH2)(CH2)(CH2)(CH2)-. In some embodiments of compounds of Formula (I), (II), (III), and (IV), L is -O(CH2)(CH2)-, -O(CH2)(CH2)(CH2)-, -(CH2)(CH2)-, -(CH2)(CH2)(CH2)-, or -(CH2)(CH2)(CH2)(CH2)-.

[0148] Additional embodiments provided herein include any combination of one or more of the specific embodiments described above.

[0149] In some embodiments of compounds having Formula (I), the compound is a compound from Table 1.

[0150] The compounds described in Table 1 were tested in the AR-mediated assays described herein and found to be active. In one embodiment, a compound described herein at a concentration of 1 μM resulted in degradation of AR protein by at least about 50% or more.

[0151] Preparation method of piperidinedione compound

[0152] The compounds described herein can be prepared using conventional organic synthesis and commercially available starting materials, or methods provided herein. For example, but not limited to, compounds having formula (I), wherein R N , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R B , R C, L, V, X, n, m, a and b are as defined herein and can be prepared as outlined in the schemes shown below and in the examples described herein. It should be noted that those skilled in the art know how to modify the procedures described in the illustrative schemes and examples to obtain the desired products.

[0153]

[0154] As shown in Scheme 1, a compound having formula (I) (wherein X is N or CR X and L is -O(C 1-3 Alkyl)-, -(C 1-3 alkyl)O-, or -(C 1-4 alkyl)-) can be prepared by reacting a piperidine derivative a with an ester intermediate b (wherein LG is a leaving group such as Cl, Br, I, triflate or alkylsulfonate, and alk is an alkyl group such as Me, Et, Bn, or tert-Bu) in the presence of a base in a solvent (e.g., N,N-diisopropylethylamine in DMF, or K2CO3 in acetonitrile) at elevated temperature (e.g., between about 40°C and about 100°C) to provide intermediate c. In some cases, an iodide salt (e.g., sodium iodide or potassium iodide) is used to facilitate this transformation. Removal of the ester protecting group from intermediate c (e.g., when alk = Me, Et or other alkyl, by treatment with a hydroxide base in a solvent (e.g., LiOH in THF and water), or when alk = tert-butyl, by treatment with an acid in a solvent (e.g., trifluoroacetic acid in dichloromethane or hydrochloric acid in 1,4-dioxane)) provides intermediate d. Intermediate d is coupled with piperidinedione intermediate e in the presence of a coupling agent such as HATU, HBTU, or EDC or TCFH, optionally in combination with HOBt, and a base such as N,N-diisopropylethylamine, triethylamine, or N-methylimidazole in a solvent such as DCM, DMF, NMP, or a mixture thereof at a temperature of 0°C to about 70°C to provide a compound of formula (I) wherein X is N or CR X and L is -O(C 1-3 Alkyl)-, -(C 1-3 alkyl)O-, or -(C 1-4 Alternatively, intermediate c (wherein X is N and L is -O(C 1-3 Alkyl)- or -(C 1-4The intermediate c can be prepared by reacting a derivative VL-LG (LG is a suitable leaving group such as Cl, Br, I, triflate or alkyl sulfonate) with a suitably derivatized piperidinyl ester derivative f (e.g., wherein alk is an alkyl group such as Me, Et, Bn, or tert-Bu) in the presence of a base in a solvent (e.g., N,N-diisopropylethylamine in DMF, or K2CO3 in acetonitrile) at elevated temperature (e.g., between about 40°C and about 80°C) to provide the intermediate c.

[0155]

[0156]

[0157] A compound of formula (I) wherein X is N and L is -O(C 1-3 Alkyl)- or -(C 1-4 Alkyl)-) can also be prepared by reacting a derivative VL-LG (LG is a suitable leaving group such as Cl, Br, I, triflate or alkyl sulfonate) with a suitably derivatized piperidinyl derivative g in the presence of a base in a solvent (e.g., N,N-diisopropylethylamine in DMF or K2CO3 in acetonitrile) at elevated temperature (e.g., between about 40°C and about 100°C) according to an alternative sequence as shown in Scheme 2. In some cases, an iodide salt (e.g., sodium iodide or potassium iodide) is used to facilitate this transformation. Alternatively, compounds of formula (I) wherein X is N or CR X and L is -O(C 1-3 Alkyl)-, -(C 1-3 alkyl)O-, or -(C 1-4 (alkyl)-) can be prepared by reacting compound e with an appropriately functionalized carbonyl intermediate h (wherein LG is a leaving group such as Cl, Br, I, triflate or alkyl sulfonate) in the presence of a base in a solvent (e.g., N,N-diisopropylethylamine in DCM, or triethylamine in pyridine) at a temperature of 0°C to about 60°C to provide intermediate i. Reacting i (wherein LG is a leaving group such as Cl, Br, I, triflate or alkyl sulfonate) with an amine intermediate a in the presence of a base in a solvent (e.g., N,N-diisopropylethylamine in DMF, or K2CO3 in acetonitrile) at an elevated temperature (e.g., between about 40°C and about 80°C) provides compounds of formula (I) (wherein X is N or CR X and L is -O(C 1-3 Alkyl)-, -(C 1-3 alkyl)O-, or -(C 1-4 alkyl)-).

[0158]

[0159] Intermediates such as amines g can be prepared according to Scheme 3. Starting by reacting an appropriately functionalized piperazine j with an ester intermediate b (wherein LG is a leaving group such as Cl, Br, I, triflate or alkylsulfonate, and alk is an alkyl group such as Me, Et, Bn, or tert-Bu) in the presence of a base in a solvent such as N,N-diisopropylethylamine in DMF, or K2CO3 in acetonitrile, at elevated temperature (e.g., between about 40°C and about 100°C) to provide intermediate k. In some cases, an iodide salt such as sodium iodide or potassium iodide is used to facilitate this transformation. Removal of the ester protecting group from intermediate k (e.g., when alk = Me, Et or other alkyl, by treatment with a hydroxide base in a solvent such as LiOH in THF and water, or when alk = tert-butyl, by treatment with an acid in a solvent such as trifluoroacetic acid in dichloromethane or hydrochloric acid in 1,4-dioxane) provides intermediate l. Intermediate 1 is coupled with piperidine dione intermediate e in the presence of a coupling agent (e.g., HATU, HBTU, or EDC or TCFH, optionally in combination with HOBt) and a base (e.g., N,N-diisopropylethylamine, triethylamine, or N-methylimidazole) in a solvent (e.g., DCM, DMF, NMP, or a mixture thereof) at a temperature of 0° C. to about 70° C. to provide amine intermediate g. Intermediates such as amine f can be prepared by removing the N-protecting group P from intermediate k. N (For example, when P N When Boc is obtained, the reaction mixture is prepared by treatment with an acid in a solvent (e.g., HCl in dioxane or EtOAc) at room temperature, or with TFA in DCM at room temperature, or when P is N In the case of Bn or Cbz, it is prepared by hydrogenation using a metal catalyst in a solvent (eg palladium on carbon in methanol).

[0160]

[0161] Intermediates such as a (wherein X is N and L is -O (C 1-3 Alkyl)- or -(C 1-4 Alkyl)-) can be prepared according to Scheme 4. VL-LG (wherein L is -O(C 1-3 Alkyl)- or -(C 1-4 alkyl)- and LG is a leaving group such as Cl, Br, I, triflate or alkyl sulfonate) is treated with an amine n in the presence of a base in a solvent (e.g., N,N-diisopropylethylamine in DMF, or K2CO3 in acetonitrile) at elevated temperature (e.g., between about 40°C and about 100°C) to provide intermediate o. In some cases, an iodide salt (e.g., sodium iodide or potassium iodide) is used to promote this transformation. Removal of the N-protecting group P from intermediate o N(For example, when P N When Boc is obtained, the reaction mixture is prepared by treatment with an acid in a solvent (e.g., HCl in dioxane or EtOAc) at room temperature, or with TFA in DCM at room temperature, or when P is N When X is Bn or Cbz, hydrogenation with a metal catalyst in a solvent (e.g., palladium on carbon in methanol) provides intermediate a (wherein X is N and L is -O(C 1-3 Alkyl)- or -(C 1-4 alkyl)-).

[0162]

[0163] Intermediates such as VLR Z (e.g. intermediate r) (where R Z is an alcohol, a protected alcohol, a leaving group or a heterocycle (e.g., a substituted piperidine or piperazine)) can be prepared according to Scheme 5. Ester intermediate p (where alk is an alkyl group such as Me, Et, Bn, or tert-Bu) is treated with an appropriately derivatized 4-cyanophenylisothiocyanate or 5-isothiocyanatopicolinonitrile q in the presence of a base such as triethylamine in a solvent such as EtOAc at elevated temperature (e.g., between about 70° C. and about 90° C.) to provide intermediate r. Intermediates such as u (where LG is a leaving group such as Cl, Br, I, triflate or alkylsulfonate) and L is —O(C 1-3 Alkyl)- or -(C 1-4 Alkyl)-) can be prepared from intermediate s (where P O is an alcohol protecting group such as THP, TBS, acetate or benzyl). Removal of the protecting group P in S O (For example, when P O When LG is THP, treatment with a catalytic acid in a solvent (e.g., HCl in dioxane) provides the alcohol intermediate t. Activation of the alcohol functionality in t as a leaving group (e.g., when LG is Br, by treatment of t with thionyl bromide in dichloromethane) provides the intermediate u (wherein LG is a leaving group (e.g., Cl, Br, I, triflate, or alkylsulfonate), and L is -O(C 1-3 Alkyl)- or -(C 1-4 alkyl)-), which can be further reacted to provide compounds having formula (I).

[0164]

[0165] Intermediate p (wherein L is -O(C 1-3 alkyl)- and R Z It is a protected alcohol OP O(e.g. THP ether or TBS ether)) For example aa can be prepared according to Scheme 6. From alcohol intermediate v (wherein P N is an amine protecting group such as Bn or Boc) and reacts it with an electrophile w (where LG is a leaving group such as Cl, Br, I, triflate or alkyl sulfonate, and P O The reaction of the intermediate x with a protecting group P in the presence of a base and optionally a catalyst in a solvent (eg, KOH and tetrabutylammonium bromide in xylene) at elevated temperature (eg, between 70° C. and 130° C.) provides the intermediate x. N (For example, when P N When Bn is present, by hydrogenation with palladium on carbon in methanol, or when P N is Boc, by treatment with HCL in dioxane) provides the amine intermediate y. Reaction of the amine y with an ester z (where alk is an alkyl group such as Me, Et, Bn, or tert-Bu, and LG is a leaving group such as Cl, Br, I, triflate or alkylsulfonate) in the presence of a base and, possibly, an iodide salt, in a solvent (such as potassium carbonate and potassium iodide in acetonitrile) at elevated temperature (e.g., between about 70° C. and 130° C.) provides intermediate aa, which can be further reacted to provide compounds of formula (I) (where L=-O(C 1-3 alkyl)-).

[0166]

[0167] Intermediate p (wherein L is -(C 1-3 alkyl)- and R Z is an alcohol or a protected alcohol (eg, THP ether or TBS ether) such as hh can be prepared according to Scheme 6. From the aldehyde intermediate bb (wherein P N Starting with an amine protecting group such as Bn or Boc), reaction with an olefinating agent in the presence of a base in a solvent (e.g., ethyl 2-(diethoxyphosphoryl)acetate and sodium hydride in THF) at a temperature between 0°C and 60°C provides the olefin intermediate cc. Reduction of cc by hydrogenation in the presence of a catalyst in a solvent (e.g., palladium on carbon in methanol under a hydrogen atmosphere) at high pressure (e.g., between 10 and 100 psi) provides the intermediate dd. Reduction of the ester functionality is accomplished by treatment with a reducing agent in a solvent (e.g., diisobutylaluminum hydride in DCM) at a temperature between -78°C and 25°C, which provides the intermediate ee (where R Yis H). Alternatively, intermediate ee can be prepared by treating intermediate cc with a reducing agent in a solvent (e.g., diisobutylaluminum hydride in DCM) at a temperature between -78°C and 25°C to provide intermediate ff. Hydrogenation of ff in the presence of a catalyst in a solvent (e.g., palladium on carbon in methanol under a hydrogen atmosphere) at high pressure (e.g., between 10 and 100 psi) provides intermediate ee. Removal of the protecting group P in ee N (For example, when P N When Bn is present, by hydrogenation with palladium on carbon in methanol, or when P N is Boc, by treatment with HCL in dioxane) provides the amine intermediate gg. Reaction of the amine gg with an ester z (where alk is an alkyl group such as Me, Et, Bn, or tert-Bu, and LG is a leaving group such as Cl, Br, I, triflate or alkyl sulfonate) in the presence of a base and, optionally, an iodide salt, in a solvent (such as potassium carbonate and potassium iodide in acetonitrile) at elevated temperature (e.g., between about 70°C and 130°C) provides the intermediate hh (where R Y is H or an alcohol protecting group (e.g. THP, TBS or Tr), which can be further reacted to provide a compound of formula (I) (wherein L-(C 1-3 alkyl)-).

[0168]

[0169] Intermediate p (wherein L is -(C 1-3 alkyl)O- and R Z is a heterocyclic or cycloalkyl group) such as mm can be prepared according to Scheme 8. From intermediate ii (P N’ is an amine protecting group such as Bn or Boc, and LG is a leaving group such as Cl, Br, I, triflate or alkyl sulfonate) and reacts it with an alcohol jj (where P N is an amine protecting group such as Bn or Boc), in the presence of a base and, optionally, a catalyst, in a solvent (such as KOH and tetrabutylammonium bromide in xylene) at elevated temperature (such as between 70°C and 130°C) to provide the ether intermediate kk. Removal of the protecting group P in kk N’ (For example, when P N’ When Bn is present, by hydrogenation with palladium on carbon in methanol, or when P N In the case of Boc, treatment with HCl in dioxane) afforded the amine intermediate 11.

[0170] Reaction of amine ll with ester z (where alk is an alkyl group such as Me, Et, Bn, or tert-Bu, and LG is a leaving group such as Cl, Br, I, triflate or alkyl sulfonate) in the presence of a base and, optionally, an iodide salt, in a solvent (e.g., potassium carbonate and potassium iodide in acetonitrile) at elevated temperature (e.g., between about 70° C. and 130° C.) provides intermediate mm, which can be further reacted to provide compounds of formula (I) (where L is -(C 1-3 alkyl)O-).

[0171]

[0172] For some intermediates p(where L is -O(C 1-3 alkyl)- and R Z is a protected heterocyclic or cycloalkyl group) such as qq, the altered sequence shown in Scheme 9 may be used. From alcohol v (where P N is an amine protecting group such as Bn or Boc), and reacts it with an electrophilic intermediate nn (wherein LG is a leaving group such as Cl, Br, I, triflate or alkyl sulfonate, and P N’ is an amine protecting group such as Bn or Boc) in the presence of a base and, optionally, a catalyst, in a solvent (such as KOH and tetrabutylammonium bromide in xylene) at elevated temperature (such as between 70°C and 130°C) to provide the ether intermediate oo. Removal of the protecting group P in oo N (For example, when P N’ When Bn is present, by hydrogenation with palladium on carbon in methanol, or when P N is Boc, by treatment with HCl in dioxane) provides the amine intermediate pp. Reaction of the amine pp with an ester z (where alk is an alkyl group such as Me, Et, Bn, or tert-Bu, and LG is a leaving group such as Cl, Br, I, triflate or alkylsulfonate) in the presence of a base and, optionally, an iodide salt, in a solvent (such as potassium carbonate and potassium iodide in acetonitrile) at elevated temperature (e.g., between about 70° C. and 130° C.) provides the intermediate qq, which can be further reacted to provide compounds of formula (I) (where L is -O(C 1-3 alkyl)-).

[0173]

[0174] Intermediate nn (where X is CR Z ) are prepared according to Scheme 10. NOlefination of an amine protecting group (e.g., Bn, Boc, or Cbz) with an olefination agent and a base in a solvent (e.g., ethyl 2-(diethoxyphosphoryl)acetate and sodium hydride in THF) at a temperature between 0°C and 60°C provides the olefin intermediate ss. Hydrogenation of ss in the presence of a catalyst in a solvent (e.g., palladium on carbon in methanol under a hydrogen atmosphere) at high pressure (e.g., between 10 and 100 psi) provides the intermediate tt. Reduction of the ester functionality in tt is accomplished by treatment with a reducing agent in a solvent (e.g., diisobutylaluminum hydride in DCM) at a temperature between -78°C and 25°C, which provides the intermediate uu. Activation of the alcohol uu to a leaving group LG (e.g., if LG is Br, by treatment with thionyl bromide in dichloromethane and DMF, or if LG is a triflate, by treatment with trifluoromethanesulfonic anhydride in dichloromethane) provides intermediate vv, which can be further reacted to provide compounds of formula (I) (wherein L is -O(C 1-3 alkyl)- and X is CR X ).

[0175]

[0176] From R 1 -derivatized 3-nitroaniline ww Prepare appropriately derivatized 3-((3-aminophenyl)amino)piperidine-2,6-dione e and protect it with an amine protecting group P N Protection (where P N When it is, for example, Boc, by treatment with Boc2O in the presence of a base such as TEA, DIEA, or DBU in a solvent such as THF, NMP, or DMF to form intermediate xx. The nitro group in intermediate xx is reduced (by treatment with a reducing agent such as H2 in the presence of a catalyst such as Pd / C in a solvent such as EtOH or MeOH; or by treatment with Fe and NH4Cl in a solvent such as EtOH and H2O) to provide a mono-protected, derivatized diphenylamine intermediate yy. Intermediate yy is coupled with 3-bromopiperidine-2,6-dione in the presence of a base in a solvent such as NaHCO3, CsCO3, or K2CO3 in DMF or NMP at elevated temperature such as between about 50°C and about 80°C; or DIEA in DMF or NMP at elevated temperature such as about 150°C), followed by removal of the protecting group P N (For example, when P NWhen it is Boc, treatment with an acid in a solvent (e.g., TFA in DCM; or with HCl in dioxane or EtOAc) provides intermediate e. Alternatively, intermediate e is obtained by iron-catalyzed reductive coupling of intermediate xx and 3-bromopiperidine-2,6-dione (e.g., by reaction in the presence of Zn, TMSCl, FeCl2*4H2O, in a solvent (e.g., NMP), at elevated temperature (e.g., between about 80°C and about 100°C), followed by removal of the protecting group P N (For example, when P N In the case of Boc, treatment with an acid in a solvent (eg, TFA in DCM; or HCl in dioxane or EtOAc).

[0177] How to use

[0178] In one embodiment, the compounds described herein have the use of drugs to treat, prevent or improve the condition of animals or humans. The compounds described herein have the use of drugs to treat, prevent or improve the condition of animals or humans. Therefore, many uses of the compounds are provided herein, including the treatment or prevention of those diseases described below. In one embodiment, the methods provided herein include administering an effective amount of the compound to a subject in need.

[0179] The methods provided herein comprise administering to a subject in need thereof an effective amount of one or more compounds.

[0180] Provided herein are methods for treating or preventing an androgen receptor (AR)-mediated disease in a subject, the method comprising administering to a subject in need thereof an effective amount of a compound as described herein.

[0181] Provided herein are methods for treating or preventing an AR-mediated disease in a subject, the method comprising administering to a subject in need thereof an effective amount of a compound as described herein.

[0182] On the other hand, provided herein are compounds for use in treating or preventing AR-mediated diseases in subjects, including administering an effective amount of a compound as described herein to a subject in need thereof. In some embodiments, provided herein are compounds for use in treating AR-mediated diseases in subjects, including administering an effective amount of a compound as described herein to a subject in need thereof. In some embodiments, provided herein are compounds for use in preventing AR-mediated diseases in subjects, including administering an effective amount of a compound as described herein to a subject in need thereof.

[0183] In some embodiments, the compound used in the methods herein is a compound as described herein. In some embodiments, the compound is a compound of formula (I). In some embodiments, the compound is a compound of formula (II). In some embodiments, the compound is a compound of formula (III). In some embodiments, the compound is a compound of formula (IV). In some embodiments, the compound is a compound from Table 1.

[0184] In some embodiments, the AR-mediated disease is a disease mediated by the wild-type AR. In other embodiments, the AR-mediated disease is the result of AR amplification.

[0185] In certain embodiments, the disease mediated by AR is prostate cancer. In some such embodiments, prostate cancer is castration-resistant prostate cancer (CRPC). In some such embodiments, prostate cancer is metastatic castration-resistant prostate cancer (mCRPC). In still another embodiment, prostate cancer is non-metastatic CRPC (nmCRPC). In some embodiments, prostate cancer is hormone-refractory. In some embodiments, prostate cancer is resistant to treatment with AR antagonists. For example, prostate cancer is resistant to treatment with enzalutamide, bicalutamide, abiraterone, ARN-509, ODM-201, EPI-001, EPI-506, AZD-3514, galeterone, ASC-J9, flutamide, hydroxyflutamide, nilutamide, cyproterone acetate, ketoconazole or spironolactone.

[0186] Provided herein is a method for reducing AR levels, the method comprising administering an effective amount of a compound to a subject. Also provided herein is a compound for use in a method for reducing AR levels in vivo, in vitro or in vitro cells, the method comprising contacting the cell with an effective amount of a compound. In one embodiment, the cell is in the patient's body. In one embodiment, the cell is not in the patient's body. In one embodiment, provided herein is a method for reducing wild-type AR levels in a tumor, the method comprising administering a therapeutically effective amount of a compound to reduce wild-type AR levels in a tumor. In one embodiment, provided herein is a method for reducing AR-full length (AR-FL) levels in a tumor, the method comprising administering a therapeutically effective amount of a compound to reduce AR-full length (AR-FL) levels in a tumor. In some embodiments, compared with AR levels before compound administration, AR levels are reduced. In some embodiments, compared with AR levels before compound administration, AR levels are reduced by 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99%.

[0187] Also provided herein are methods for regulating the activity of AR proteins in patients in need, comprising administering a certain amount of a compound to the patient. In some such embodiments, also provided herein are methods for reducing the activity of AR proteins in patients in need, comprising administering a certain amount of a compound to the patient. In some embodiments, AR protein activity is reduced compared to AR protein activity before compound administration. In some embodiments, AR protein activity is reduced by 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% compared to AR protein activity before compound administration.

[0188] In some embodiments of the methods described herein, the methods further comprise administering one or more second agents selected from AR antagonists (e.g., cyproterone acetate, spironolactone, bicalutamide, and enzalutamide), 5α-reductase inhibitors (e.g., finasteride and dutasteride), CYP17A1 inhibitors (e.g., abiraterone acetate), gonadotropin-releasing hormone (GnRH) analogs (e.g., leuprolide and cetrorelix), and anti-gonadotropin drugs (e.g., megestrol acetate and medroxyprogesterone acetate).

[0189] In some embodiments, the compounds provided herein can be used in any of the above methods.

[0190] In some embodiments, the compounds provided herein can be used in any of the above methods.

[0191] Pharmaceutical compositions and routes of administration

[0192] The compounds provided herein can be administered to a subject orally, topically or parenterally in conventional forms of formulations, such as capsules, microcapsules, tablets, granules, powders, dragees, pills, suppositories, injections, suspensions, syrups, patches, creams, lotions, ointments, gels, sprays, solutions and emulsions.

[0193] The compound can be administered orally, topically or parenterally to a subject in the conventional form of a preparation, such as capsules, microcapsules, tablets, granules, powders, lozenges, pills, suppositories, injections, suspensions, syrups, patches, creams, lotions, ointments, gels, sprays, solutions and emulsions. Suitable formulations can be prepared by conventional methods using conventional organic or inorganic additives, such as excipients (e.g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate or calcium carbonate), binders (e.g., cellulose, methylcellulose, hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose or starch), disintegrants (e.g., starch, carboxymethylcellulose, hydroxypropyl starch, low-substituted hydroxypropylcellulose, sodium bicarbonate, calcium phosphate or The effective amount of the compound in the pharmaceutical composition can be at a level that will exert the desired effect, for example, for oral and parenteral administration, a unit dose of about 0.005 mg / kg to about 10 mg / kg of subject body weight.

[0194] The dosage variation range of the compound applied to the subject is quite wide, and can be subject to the judgment of the health care practitioner. Generally, the compound can be applied one to four times a day with a dosage of about 0.001mg / kg subject weight to about 10mg / kg subject weight, but the above dosage can be appropriately changed based on the age, body weight and medical condition of the subject and the type of application. In one embodiment, the dosage is about 0.001mg / kg subject weight to about 5mg / kg subject weight, about 0.01mg / kg subject weight to about 5mg / kg subject weight, about 0.05mg / kg subject weight to about 1mg / kg subject weight, about 0.1mg / kg subject weight to about 0.75mg / kg subject weight or about 0.25mg / kg subject weight to about 0.5mg / kg subject weight. In one embodiment, a dosage is given every day. In any given case, the amount of the compound applied will depend on factors such as the solubility of the active component, the formulation used and the route of administration.

[0195] In another embodiment, provided herein are methods for treating or preventing a disease or disorder comprising administering a compound to a subject in need thereof at about 0.01 mg / day to about 750 mg / day, about 0.1 mg / day to about 375 mg / day, about 0.1 mg / day to about 150 mg / day, about 0.1 mg / day to about 75 mg / day, about 0.1 mg / day to about 50 mg / day, about 0.1 mg / day to about 25 mg / day, or about 0.1 mg / day to about 10 mg / day.

[0196] In another embodiment, provided herein is a unit dosage formulation comprising between about 0.1 mg and 500 mg, between about 1 mg and 250 mg, between about 1 mg and about 100 mg, between about 1 mg and about 50 mg, between about 1 mg and about 25 mg, or between about 1 mg and about 10 mg of the compound.

[0197] In specific embodiments, provided herein are unit dosage formulations containing about 0.1 mg or 100 mg of a compound.

[0198] In another embodiment, provided herein is a unit dose formulation comprising 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 35 mg, 50 mg, 70 mg, 100 mg, 125 mg, 140 mg, 175 mg, 200 mg, 250 mg, 280 mg, 350 mg, 500 mg, 560 mg, 700 mg, 750 mg, 1000 mg or 1400 mg of the compound.

[0199] The compound can be administered once, twice, three times, four times or more per day. In a specific embodiment, a dose of 100 mg or less is administered as a once-daily dose and a dose of more than 100 mg is administered twice daily in an amount equal to half of the total daily dose.

[0200] For convenience, the compound can be administered orally. In one embodiment, when administered orally, the compound is administered with a meal and water. In another embodiment, the compound is dispersed in water or juice (e.g., apple juice or orange juice) or any other liquid and administered orally as a solution or suspension.

[0201] The compounds can also be administered intradermally, intramuscularly, intraperitoneally, percutaneously, intravenously, subcutaneously, intranasally, epidurally, sublingually, intracerebrally, intravaginally, transdermally, rectally, mucosally, by inhalation, or topically to the ear, nose, eye, or skin. The mode of administration is at the discretion of the health care practitioner and may depend in part on the site of the medical condition.

[0202] In one embodiment, provided herein are capsules containing a compound but no additional carriers, excipients, or vehicles.

[0203] In another embodiment, provided herein is a composition comprising an effective amount of a compound and a pharmaceutically acceptable carrier or vehicle, wherein the pharmaceutically acceptable carrier or vehicle may comprise an excipient, a diluent, or a mixture thereof. In one embodiment, the composition is a pharmaceutical composition.

[0204] Composition can be in the form of tablet, chewable tablet, capsule, solution, parenteral solution, lozenge, suppository and suspension. Composition can be formulated as a portable portion containing daily dose or daily dose in a dosage unit, which can be a single tablet or capsule or a portable volume of liquid. In one embodiment, solution is prepared from water-soluble salt (e.g., hydrochloride). Generally, all compositions are prepared according to known methods in pharmaceutical chemistry. Capsules can be prepared by mixing compound with suitable carrier or diluent and filling appropriate amount of mixture in capsule. Common carrier and diluent include but are not limited to inert powdery substances, such as starch of various different types, powdered cellulose (especially crystal and microcrystalline cellulose), sugar (e.g., fructose, mannitol and sucrose), cereal flour and similar edible powder.

[0205] Tablets can be prepared by direct compression, wet granulation or dry granulation. Its formulations are usually mixed with diluents, binders, lubricants and disintegrants and the compound. Typical diluents include, for example, different types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts (such as sodium chloride) and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are the following substances, such as starch, gelatin and sugar (such as lactose, fructose, glucose, etc.). Natural gums and synthetic gums are also very convenient, including gum arabic, alginate, methylcellulose, polyvinyl pyrrolidone, etc. Polyethylene glycol, ethyl cellulose and wax can also be used as binders.

[0206] To prevent the tablet and the punch from sticking in the die, a lubricant may be necessary in the tablet formulation. Lubricants may be selected from smooth solids such as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils. Tablet disintegrants are substances that swell when damp, decompose the tablet and release the compound. Tablet disintegrants include starch, clay, cellulose, alginate and glue. More particularly, for example corn and potato starch, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponges, cation exchange gums, alginic acid, guar gum, citrus pulp and carboxymethyl cellulose, and sodium lauryl sulfate may be used. Tablets may be coated with sugars as flavorings and sealants, or film-forming protective agents may be used to change the dissolution characteristics of the tablets. These compositions may also be formulated into chewable tablets, for example by using substances such as mannitol in the formulation.

[0207] When it is desired to administer the compound as a suppository, typical bases may be used. Cocoa butter is a traditional suppository base, which may be modified by the addition of waxes to slightly increase its melting point. Water-miscible suppository bases, particularly those containing polyethylene glycols of varying molecular weights, are widely used.

[0208] The action of the compound can be delayed or prolonged by proper formulation. For example, slowly dissolving pellets of the compound can be prepared and incorporated into tablets or capsules, or as an implantable sustained-release device. The technology also includes preparing several pellets with different dissolution rates and filling the pellet mixture into a capsule. Tablets or capsules can be coated with a film that resists dissolution for a predictable period of time. Even parenteral preparations can be made into long-acting preparations by dissolving or suspending the compound in an oily or emulsified vehicle that slowly disperses it in the serum.

[0209] Examples of Examples

[0210] The invention can be defined by reference to the following numbered illustrative examples.

[0211] 1. A compound having formula I

[0212]

[0213] or a pharmaceutically acceptable salt, tautomer, isotopomer, or stereoisomer thereof, wherein

[0214] R N It is H;

[0215] n is 0-4;

[0216] Each R 1 independently selected from halogen, CN and C 1-3 alkyl;

[0217] a is 1 or 2;

[0218] R 2 and R 3 Each independently selected from H and C 1-3 Alkyl, or R 2 and R 3 and the carbon to which they are attached to form substituted or unsubstituted C 3-6 Cycloalkyl;

[0219] m is 0-8;

[0220] Each R 4 are independently substituted or unsubstituted C 1-3 Alkyl, or two R 4The groups, together with the same carbon atom or adjacent carbon atoms to which they are attached, form a substituted or unsubstituted C 3-6 Cycloalkyl, or two R 4 The groups, together with the non-adjacent carbon atoms to which they are attached, form a substituted or unsubstituted 4-7 membered heterocyclyl;

[0221] X is N or CR X ;

[0222] R X is hydrogen, halogen, -O(C 1-6 alkyl) or -(C 1-9 alkyl);

[0223] L is substituted or unsubstituted -O(C 1-6 Alkyl)-, -(C 1-6 Alkyl)O-, -O(C 1-6 alkyl)O-, or -(C 1-9 alkyl)-;

[0224] V is

[0225]

[0226] in

[0227] B is N, CH or CR B ;

[0228] Each R B are independently selected from halogen, and substituted or unsubstituted C 1-6 alkyl;

[0229] R C is halogen, CF3 or SF5;

[0230] R 5 and R 6 It is C 1-3 Alkyl, or R 5 and R 6 Together with the carbon atom to which they are attached, they form a substituted or unsubstituted C 3-6 Cycloalkyl, or 3-6 membered heterocyclic group; and

[0231] b is 0-2.

[0232] 2. The compound as described in embodiment 1, wherein n is 0.

[0233] 3. The compound of embodiment 1 or 2, wherein a is 1, and R 2 and R 3 Both are H.

[0234] 4. A compound as described in any one of embodiments 1 to 3, wherein each R4 is a substituted or unsubstituted methyl group.

[0235] 5. A compound as described in any one of embodiments 1 to 4, wherein each R 4 Independently selected from methyl and CF3.

[0236] 6. The compound of any one of embodiments 1 to 5, wherein m is 0, 1, 2, 3 or 4.

[0237] 7. The compound of any one of embodiments 1 to 5, wherein m is 1 or 2.

[0238] 8. The compound of any one of embodiments 1 to 7, wherein X is N.

[0239] 9. The compound of any one of embodiments 1 to 7, wherein X is CR X , where R X is hydrogen, halogen, -O(C 1-6 alkyl) or -(C 1-9 alkyl).

[0240] 10. A compound as described in any one of embodiments 1 to 9, wherein L is substituted or unsubstituted -O(CH2) p -、-O(CH2) p O- or -(CH2) p -, and p is 1-4.

[0241] 11. A compound as described in any one of embodiments 1 to 9, wherein L is substituted or unsubstituted -O(CH2) p -, and p is 2 or 3.

[0242] 12. A compound as described in any one of embodiments 1 to 9, wherein L is substituted or unsubstituted -(CH2) p -, and p is 3 or 4.

[0243] 13. A compound as described in any one of embodiments 1 to 9, wherein L is -O(CH2)(CH2)-, -O(CH2)(CH2)(CH2)-, -O(CH2)(CH2)O-, -(CH2)(CH2)-, -(CH2)(CH2)(CH2)-, or -(CH2)(CH2)(CH2)(CH2)-.

[0244] 14. The compound of any one of embodiments 1 to 9, wherein L is -O(CH2)(CH2)- or -(CH2)(CH2)(CH2)-.

[0245] 15. The compound of any one of embodiments 1 to 14, wherein B is CH.

[0246] 16. The compound of any one of embodiments 1 to 14, wherein B is N.

[0247] 17. The compound of any one of embodiments 1 to 16, wherein b is 0.

[0248] 18. A compound as described in any one of embodiments 1 to 17, wherein R C It is CF3, Cl or SF5.

[0249] 19. A compound as described in any one of embodiments 1 to 17, wherein R C It's CF3.

[0250] 20. A compound as described in any one of embodiments 1 to 19, wherein R 5 and R 6 It's methyl.

[0251] 21. The compound of embodiment 1, which has formula II,

[0252]

[0253] or a pharmaceutically acceptable salt, tautomer, isotopomer, or stereoisomer thereof, wherein

[0254] R N It is H;

[0255] Each R 4m are independently hydrogen or substituted or unsubstituted methyl, wherein these substituents when present are selected from 1 to 5 halo;

[0256] X is N or CR X ;

[0257] R x is hydrogen, halogen, -O(C 1-6 alkyl) or -(C 1-9 alkyl);

[0258] L is substituted or unsubstituted -O(C 1-3 Alkyl)-, -O(C 1-3 alkyl)O- or -(C 1-4 alkyl)-;

[0259] V is

[0260]

[0261] B is N or CH;

[0262] R C is halogen, CF3 or SF5; and

[0263] R 5 and R 6 It is C 1-3 alkyl.

[0264] 22. The compound of embodiment 1, which has formula III,

[0265]

[0266] or a pharmaceutically acceptable salt, tautomer, isotopomer, or stereoisomer thereof, wherein

[0267] R N It is H;

[0268] X is N or CR X ;

[0269] R X is hydrogen, halogen, -O(C 1-6 alkyl) or -(C 1-9 alkyl);

[0270] L is substituted or unsubstituted -O(C 1-3 Alkyl)-, -O(C 1-3 alkyl)O- or -(C 1-4 alkyl)-;

[0271] V is

[0272]

[0273] B is N or CH;

[0274] R C is halogen, CF3 or SF5; and

[0275] R 5 and R 6 It is C 1-3 alkyl.

[0276] 23. The compound of embodiment 1, which has formula IV,

[0277]

[0278] or a pharmaceutically acceptable salt, tautomer, isotopomer, or stereoisomer thereof, wherein

[0279] R N It is H;

[0280] X is N or CR X ;

[0281] R Xis hydrogen, halogen, -O(C 1-6 alkyl) or -(C 1-9 alkyl);

[0282] L is substituted or unsubstituted -O(C 1-3 Alkyl)-, -O(C 1-3 alkyl)O- or -(C 1-4 alkyl)-;

[0283] V is

[0284]

[0285] B is N or CH;

[0286] R C is halogen, CF3 or SF5; and

[0287] R 5 and R 6 It is C 1-3 alkyl.

[0288] 24. The compound of embodiment 1, wherein the compound is selected from Table 1 or a pharmaceutically acceptable salt, tautomer, isotopomer, or stereoisomer thereof.

[0289] 25. A pharmaceutical composition comprising an effective amount of the compound of any one of Examples 1 to 24, or a pharmaceutically acceptable salt, tautomer, isotopomer, or stereoisomer thereof, and a pharmaceutically acceptable carrier, excipient, or vehicle.

[0290] 26. A method for treating an androgen receptor-mediated disease, the method comprising administering to a subject in need thereof an effective amount of a compound as described in any one of Examples 1 to 24.

[0291] 27. A method for treating an androgen receptor-mediated disease, the method comprising administering an effective amount of the pharmaceutical composition of Example 25 to a subject in need thereof.

[0292] 28. The method of embodiment 26 or 27, wherein the androgen-mediated disease is prostate cancer.

[0293] 29. An embodiment as described in Example 28, wherein the prostate cancer is castration-resistant prostate cancer (CRPC).

[0294] Examples

[0295] The following examples are provided by way of illustration and not limitation. Compound naming uses the automatic name generation tool provided in ChemBiodraw Ultra (Cambridgesoft), which generates systematic names for chemical structures, supporting the Cahn-Ingold-Prelog rules for stereochemistry. One skilled in the art can modify the procedures described in the illustrative examples to obtain the desired product.

[0296] Salts of compounds described herein can be prepared by standard methods, such as including an acid (e.g., TFA, formic acid, or HCl) in the mobile phase during chromatographic purification, or stirring the product with an acid solution (e.g., aqueous HCl) after chromatographic purification.

[0297] Abbreviations used:

[0298]

[0299]

[0300] Example 1: 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0301]

[0302] Trans-4-(dibenzylamino)cyclohexane-1-ol. To a mixture of trans-4-aminocyclohexane-1-ol (40 g, 347 mmol, 1.0 equiv) and cesium carbonate (339 g, 1.04 mol, 3 equiv) in acetonitrile (900 mL) was added benzyl bromide (119 g, 698 mmol, 2.01 equiv) dropwise. The reaction solution was stirred at room temperature. After 48 h, the reaction mixture was filtered and concentrated. The resulting residue was diluted with DCM (300 mL), washed with water (100 mL x 3), dried over anhydrous sodium sulfate and concentrated. Trans-4-(dibenzylamino)cyclohexane-1-ol (77 g, 261 mmol, 75% yield) was provided as a light red solid. The crude product was used without further purification. MS (ESI) m / z 116.3 [M+1] + ; 1H NMR 400MHz DMSO-d6δ7.27-7.34(m,8H),7.19-7.21(m,2H),4.42(d,J=4.8Hz,1H),3.55(s,4H),2.33 -2.36(m,1H),1.74-1.84(m,4H),1.40(dd,J=12.4Hz,2.0Hz,2H),0.98(d,J=13.2Hz,2H).

[0303] trans-N,N-dibenzyl-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexan-1-amine. To a mixture of trans-4-(dibenzylamino)cyclohexane-1-ol (60 g, 203 mmol, 1.0 eq.) and tetrabutylammonium hydrogen sulfate (13.8 g, 40.6 mmol, 0.2 eq.) in THF (400 mL) and water (200 mL) at 0°C were added 2-(2-bromoethoxy)tetrahydro-2H-pyran (84.9 g, 406 mmol, 61.5 mL, 2.0 eq.) and sodium hydroxide (200 g, 5.00 mol, 24.6 eq.). The reaction solution was heated to 65°C. After 12 h, the reaction solution was poured into ice water (1.0 L) and the aqueous phase was extracted with ethyl acetate (300 mL x 2). The combined organic layers were washed with brine (300 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The resulting crude material was purified by column chromatography (SiO2, 2%-50% ethyl acetate in petroleum ether) to give trans-N,N-dibenzyl-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl-1-amine (60 g, 142 mmol, 70% yield) as a colorless oil. 1 H NMR 400MHz CDCl3δ7.37-7.39(m,4H),.7.28-7.32(m,4H),7.22(m,2H),4.63-4.67(m,1H),3.57-3.89(m,9H),3.23-3.25(m, 1H),2.55(m,1H),2.08-2.11(m,2H),1.92-1.95(m,5H),1.58-1.64(m,6H),1.54-1.56(m,2H),1.20-1.39(m,2H).

[0304]

[0266] trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexan-1-amine. To a mixture of trans-N,N-dibenzyl-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexan-1-amine (65 g, 153 mmol, 1.0 equiv) in methanol (500 mL) was added 10% palladium on carbon (6.5 g) under N2. The suspension was degassed under vacuum and purged with hydrogen three times. The reaction solution was stirred at room temperature under a hydrogen atmosphere (15 psi). After 1 h, the reaction solution was filtered and the filtrate was concentrated to give trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexan-1-amine (46 g) as an off-white oil. The crude material was used further without further purification. 1 H NMR 400MHz CDCl3δ7.34-7.36(m,1H),.4.63-4.65(m,1H),3.82-3.91(m,3H),3.52-3.66(m,5H),3.28(m,1H),2.70-2.71(m,1H) ,2.01-2.04(m,2H),1.85-1.89(m,3H),1.58-1.59(m,1H),1.45-1.56(m,8H),1.29-1.32(m,2H),1.11-1.14(m,2H).

[0305] Methyl 2-methyl-2-((trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)amino)propanoate. To a mixture of trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexan-1-amine (25 g, 103 mmol, 1.0 eq) in acetonitrile (175 mL) was added methyl 2-bromo-2-methylpropanoate (37.2 g, 205 mmol, 26.6 mL, 2.0 eq), potassium carbonate (28.4 g, 205 mmol, 2.0 eq) and potassium iodide (1.71 g, 10.3 mmol, 0.1 eq). The reaction solution was heated to 110° C. After 16 h, the reaction solution was diluted with water (100 mL) and extracted with ethyl acetate (2× 75 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The resulting crude material was purified by column chromatography (SiO2, 0-50% ethyl acetate in petroleum ether) to give methyl 2-methyl-2-((trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)amino)propanoate (18.6 g, 54 mmol, 53% yield) as a yellow oil. MS (ESI) m / z 344.4 [M+1] + ; 1H NMR(400MHz CDCl3)δ4.63(t,J=3.2Hz,1H),.3.82-3.87(m,2H),3.70(s,3H),3.61-3.63(m,4H),3.51-3.60(m,2H),3.22-3.24(m ,1H),2.36(m,1H),1.99(m,2H),1.83-1.86(m,3H),1.62(m,1H),1.53-1.60(m,6H),1.30(m,6H),1.12-1.14(m,2H).

[0306] 4-(4,4-dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a solution of methyl 2-methyl-2-((trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)amino)propanoate (18.6 g, 54.2 mmol, 1.0 equiv) in ethyl acetate (130 mL) was added 4-isothiocyanato-2-(trifluoromethyl)benzonitrile (24.7 g, 108 mmol, 2.0 equiv) and N,N-diisopropylethylamine (14.0 g, 108 mmol, 2.0 equiv). The reaction solution was heated to 90° C. with stirring. After 12 h, the reaction solution was concentrated and the resulting crude material was purified by silica gel column chromatography (0-50% ethyl acetate in petroleum ether) to give 4-(4,4-dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (25 g, 46.3 mmol, 86% yield) as a yellow oil.

[0307] 4-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a solution of 4-(4,4-dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (42.5 g, 78.8 mmol, 1.0 equiv) in dichloromethane (300 mL) was added dropwise 4M hydrochloric acid (in 1,4-dioxane) (400 mL). The reaction solution was stirred at room temperature. After 1 h, the reaction solution was concentrated and purified by silica gel column chromatography (1%-20% THF in dichloromethane) to give 4-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (21 g, 46.1 mmol, 59% yield) as a yellow shiny oil. MS (ESI) m / z 456.4 [M+1] + ; 1 H NMR(400MHz CDCl3)δ7.95(d,J=8.0Hz,1H),7.85(m,1H),7.72(dd,J=10.0Hz,1.6Hz,1H),3.73-3.77(m,4H),3.60-3.62(m,2H),3.3 7-3.39(m,1H),2.88-2.91(m,2H),2.21-2.24(m,2H),1.97(m,1H),1.83-1.88(m,3H),1.61(s,6H),1.33-1.41(m,2H).

[0308] 4-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a mixture of 4-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (3.500 g, 7.72 mmol, 1.0 eq) in dichloromethane (80 mL) was added N,N-dimethylformamide (8 mL) and thionyl bromide (3.201 g, 15.43 mmol, 2.0 eq) at 0° C. After 12 h, the reaction solution was poured into saturated aqueous sodium bicarbonate solution (100 mL) and extracted with dichloromethane (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by column chromatography (9%-20% ethyl acetate in petroleum ether) to give 4-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (4.200 g, 8.13 mmol, crude) as a yellow solid. MS (ESI) m / z 518.1 [M+1] + .

[0309] Tert-butyl (3R, 5S) -4- (2-methoxy-2-oxoethyl) -3, 5- dimethylpiperazine-1-carboxylate. A solution of tert-butyl (3S, 5R) -3, 5- dimethylpiperazine-1-carboxylate (5. g, 23.33 mmol, 1 eq.), methyl bromoacetate (3.57 g, 23.33 mmol, 1 eq.) and triethylamine (10.2 mL, 70 mmol, 3 eq.) in THF (100 mL, 0.23 M) was stirred at 50 °C. After 18 h, the reaction solution was diluted with saturated aqueous sodium bicarbonate (50 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated. The resulting crude material was purified by silica gel column chromatography (10%-100% ethyl acetate in hexanes) to give tert-butyl (3R,5S)-4-(2-methoxy-2-oxoethyl)-3,5-dimethylpiperazine-1-carboxylate (6.2 g, 21.6 mmol, 92% yield) as a yellow oil. MS (ESI) m / z 287.2 [M+1] + .

[0310] Methyl 2-((2R,6S)-2,6-dimethylpiperazin-1-yl)acetate. To a solution of tert-butyl (3R,5S)-4-(2-methoxy-2-oxoethyl)-3,5-dimethylpiperazine-1-carboxylate (1 g, 3.49 mmol, 1 eq) in dichloromethane (3 mL) was added 4M HCl in 1,4-dioxane (8.7 mL, 34.9 mmol, 10 eq) and the reaction solution was stirred at room temperature. After 2 h, the reaction solution was concentrated, neutralized with aqueous sodium bicarbonate, and extracted with ethyl acetate (5 x 50 mL). The combined organic layers were dried over anhydrous magnesium sulfate and concentrated to provide methyl 2-((2R,6S)-2,6-dimethylpiperazin-1-yl)acetate (510 mg, 2.72 mmol, 78% yield) as a yellow oil. MS (ESI) m / z 187.5 [M+1] + .

[0311] Methyl 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)acetate. To 4-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (208 To a solution of 1,4-dimethylformamide (3.2 mL, 0.13 M) and N,N-diisopropylethylamine (0.17 mL, 0.960 mmol, 2.4 equiv) was added 1,4-dimethylformamide (3.2 mL, 0.13 M) and 1,4-diisopropylethylamine (0.17 mL, 0.960 mmol, 2.4 equiv) to a solution of 1,4-dimethylformamide (3.2 mL, 0.13 M) and 1,4-dimethylpiperazin-1-yl)acetate (1,16 mg, 0.520 mmol, 1.3 equiv). The reaction was stirred at 60 °C. After 48 h, the reaction solution was concentrated and the crude material was purified by silica gel column chromatography (0-100% ethyl acetate in hexanes) to give methyl 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)acetate (250 mg, 0.40 mmol, 97% yield) as a yellow solid. MS (ESI) m / z 624.0 [M+1] + .

[0312] 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)acetic acid. To a solution of methyl 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)acetate (250 mg, 0.400 mmol, 1 eq) in 3:1 water / THF (5 mL) was added lithium hydroxide (100 mg, 4.17 mmol, 10 eq) and the reaction solution was stirred at room temperature. After 1 h, the reaction solution was diluted with water and the pH was adjusted to about 4 by adding 1 M hydrochloric acid. The solution was extracted with ethyl acetate (4 x 50 mL), and the combined organic layers were dried over anhydrous sodium sulfate and concentrated to give 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)acetic acid (218 mg, 0.358 mmol, 90% yield) as a light orange solid. MS (ESI) m / z 610.0 [M+1] + .

[0313] Tert-butyl (3-((2,6-dioxopiperidin-3-yl)amino)phenyl)carbamate. To a solution of tert-butyl N-(3-aminophenyl)carbamate (290 g, 1.39 mol, 1 eq.) and 3-bromopiperidine-2,6-dione (294 g, 1.53 mol, 1.1 eq.) in N,N-dimethylformamide (1500 mL, 0.93 M) was added sodium bicarbonate (117 g, 1.9 mol, 1.4 eq.). The reaction mixture was stirred at 80 °C. After 16 h, the reaction solution was cooled to 25 °C and poured into ice water (4 L), forming a precipitate, which was filtered and dried. The solid was washed with ethyl acetate / petroleum ether (1:1, 2000 mL) and dried to give tert-butyl(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)carbamate (400 g, 1.25 mol, 90% yield) as a green solid. 1H NMR(400MHz,DMSO-d6)δ10.77(s,1H),9.03(s,1H),6.95-6.83(m,2H),6.67-6.64(m,1H),6.31-6.29(m,1H),5 .79(d,J=7.6Hz,1H),4.24-4.20(m,1H),2.73-2.50(m,2H),2.11-2.09(m,1H),1.89-1.68(m,1H),1.49(s,9H).

[0314] 3-((3-aminophenyl)amino)piperidine-2,6-dione. To a suspension of tert-butyl (3-((2,6-dioxopiperidin-3-yl)amino)phenyl)carbamate (200 g, 626 mmol) in dichloromethane (1500 mL, 0.42 M) at 0°C was added trifluoroacetic acid (770 g, 6.75 mol, 10.8 eq.). The reaction solution was stirred at 25°C for 16 hours. The reaction solution was concentrated and the residue was diluted with methyl tert-butyl ether (2000 mL), stirred at room temperature for 30 min and the formed solid was filtered and dried to give a crude product as trifluoroacetate salt, about 420 g. The salt was dissolved in water (6 L) and the pH was adjusted to 7-8 by adding saturated aqueous sodium bicarbonate. The solution was filtered and the filtrate was extracted with ethyl acetate (4 x 1500 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated to give 3-((3-aminophenyl)amino)piperidine-2,6-dione (172 g, 392 mmol, 62% yield). 1 H NMR (400MHz, DMSO-d6) δ10.77(s,1H),6.73(t,J=8.0Hz,1H),5.91-5.86(m,3H),5.41(d,J=7.2H z,1H),4.72(s,2H),4.19-4.15(m,1H),2.72-2.51(m,2H),2.09-2.08(m,1H),1.20-1.85(m,1H).

[0315] 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a mixture of 3-((3-aminophenyl)amino)piperidine-2,6-dione (1.079 g, 4.92 mmol, 1.2 eq.) in N,N-dimethylformamide (50 mL) was added N,N-diisopropylethylamine (1.590 g, 12.30 mmol, 3 eq.) and HATU (2.337 g, 6.15 mmol, 1.5 eq.). The reaction was stirred at 60 °C for 12 h. The mixture was concentrated under vacuum and purified by standard methods to give 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (1.150 g, 14.1 mmol, 35% yield) as a yellow solid. MS (ESI) m / z 811.3 [M+1] + ; 1HNMR(400MHz,DMSO-d6)δ10.77(s,1H),9.33(s,1H),8.33(d,J=8.4Hz,1H),8.19(d, J=1.6Hz,1H),7.97(dd,J=1.6,8.4Hz,1H),7.04-6.93(m,2H),6.81-6.75(m,1H),6.4 0(dd,J=1.6,8.4Hz,1H),5.89(d,J=8.0Hz,1H),4.33-4.23(m,1H),3.92-3.74(m,1H ),3.53(t,J=6.0Hz,2H),3.29-3.21(m,1H),3.19(s,2H),2.88-2.55(m,8H),2.41(br t,J=6.0Hz,2H),2.12-2.02(m,3H),1.92-1.82(m,3H),1.71(br d,J=10.4Hz,2H),1.54(s,6H),1.39-1.25(m,2H),0.96(d,J=6.0Hz,6H).

[0316] Example 2: 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0317]

[0318] Tert-butyl (trans-4-formylcyclohexyl) carbamate. To a mixture of tert-butyl (trans-4-(hydroxymethyl)cyclohexyl) carbamate (240 g, 1.05 mol, 1 eq.) in acetonitrile (1.60 L) was added IBX (352 g, 1.26 mol, 1.2 eq.) at 15 °C. The reaction was stirred at 65 °C for 1 h. The two batches were combined for treatment and purification. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give tert-butyl (trans-4-formylcyclohexyl) carbamate (470 g, crude) as a white solid. The crude was used directly in the next step without further purification. 1 H NMR(400MHz CDCl3)δ9.62(s,1H),4.43(s,1H),4.41(s,1H),2.10-2.14(m,3H),2.01-2.05(m,2H),1.45(s,9H),1.38-1.41(m,2H),1.14-1.18(m,2H).

[0319] Ethyl (E)-3-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)acrylate. To a mixture of sodium hydride (49.6 g, 1.24 mol, 60% purity, 1.2 eq.) in THF (900 mL) at 0°C was added ethyl 2-(diethoxyphosphoryl)acetate (255 g, 1.14 mol, 1.1 eq.) dropwise. The reaction was stirred at 0°C for 1 h. A solution of tert-butyl (trans-4-formylcyclohexyl)carbamate (235 g, 1.03 mol, 1 eq.) in THF (500 mL) was added dropwise at 0°C. The reaction was stirred at 25°C for 2 h. The reaction solution was poured into ice water (3.0 L) and stirred for 20 min. The aqueous phase was extracted with ethyl acetate (800 mL, 500 mL). The combined organic phases were washed with brine (500 mL), dried over anhydrous sodium sulfate and concentrated to give ethyl (E)-3-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)acrylate (560 g, crude) as a light yellow solid. This material was carried forward without further purification. 1 H NMR (400MHz CDCl3) δ6.88 (dd, J=15.6Hz, 6.8Hz 1H),5.75-5.79(m,1H),4.40(s,1H),4.12-4.23(m,3H),3.39(s,1H),2.04-2.08(m,3H), 1.81-1.85(m,2H),1.44(s,9H),1.33-1.35(m,1H),1.26-1.30(m,6H),1.10-1.16(m,3H).

[0320] Tert-Butyl ((trans-4-((E)-3-hydroxyprop-1-en-1-yl)cyclohexyl)carbamate. The reaction was set up as two reactions in parallel. To a solution of compound ethyl (E)-3-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)acrylate (280 g, 942 mmol, 1 eq) in dichloromethane (1.12 L) was added diisobutylaluminum hydride (1 M, 1.88 L, 2 eq) at -78 °C under argon atmosphere. The reaction was stirred at -78 °C for 1 h. The reaction was quenched with MeOH (280 mL) at -60 °C. The two reaction mixtures were combined and poured into saturated citric acid (1.0 kg citric acid in 4.0 L) at below 10 °C. The mixture was added with ethyl acetate (2.0 L, 1.5 L). The combined organic layers were washed with aqueous sodium bicarbonate (2.0 L), brine (2.0 L), dried over anhydrous sodium sulfate and concentrated. The crude material was purified by column chromatography (SiO, petroleum ether / ethyl acetate=50 / 1 to 0 / 1) to provide tert-butyl ((trans-4-((E)-3-hydroxyprop-1-en-1-yl)cyclohexyl)carbamate (420 g, 1.645 mol, 87% yield) as a light yellow solid. 1 H NMR(400MHz CDCl3)δ5.58-5.60(m,2H),4.39(s,1H),4.06-4.07(m,2H),3.35(s,1H),1.80-2.00(m,3H),1.74-1.78(m,2H),1.42(s,9H),1.08-1.20(m,4H).

[0321] Tert-butyl ((trans-4-(3-hydroxypropyl)cyclohexyl)carbamate. The reaction was run in parallel for four batches. A mixture of tert-butyl ((trans-4-((E)-3-hydroxyprop-1-en-1-yl)cyclohexyl)carbamate (105 g, 411 mmol, 1 eq) and palladium on carbon (10.5 g, 10% purity) in MeOH (600 mL) was degassed and purged with H2 three times, and then the mixture was incubated at 25° C. under H2 (15 p The mixture was stirred for 12 h under 4% saturated sodium bicarbonate (SiO). Four batches were combined for treatment and purification. The reaction solution was filtered and concentrated under reduced pressure. The crude material was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=20 / 1 to 0 / 1). Tert-butyl (trans-4-(3-hydroxypropyl) cyclohexyl) carbamate (82g, 19% yield) and tert-butyl (trans-4-(3-oxopropyl) cyclohexyl) carbamate (200g, 48% yield) as white solid. 1H NMR(400MHz CDCl3)δ4.38(s,1H),3.63(t,J=6.4Hz,2H),3.37(s,1H),1.98-2.01(m,2H),1.60- 1.79(m,2H),1.55-1.59(m,2H),1.44(s,9H),1.22-1.28(m,3H),0.95-1.05(m,4H).

[0322] 3-(trans-4-aminocyclohexyl)propan-1-ol hydrochloride. Two reactions were carried out in parallel. 4M hydrochloric acid in methanol (500mL) was added to a solution of tert-butyl (trans-4-(3-hydroxypropyl)cyclohexyl)carbamate (115g, 447mmol, 1 equivalent) in methanol (200mL). The reaction was stirred for 6h at 15°C. Two batches were combined for treatment and purification. The reaction solution was filtered and concentrated to give 3-(trans-4-aminocyclohexyl)propan-1-ol hydrochloride (160g, 92% yield) as a light yellow solid. The material was used without further purification. 1 H NMR(400MHz DMSO-d6)δ8.09(s,4H),4.62(s,2H),3.35(t,J=6.8Hz,2H),2.87(d,J=4.4Hz,1H),1.93(d,J=10.8Hz,2 H), 1.73 (d, J = 12.8Hz, 2H), 1.38-1.42 (m, 2H), 1.29-1.31 (m, 3H), 1.13-1.17 (m, 3H), 0.89-0.92 (m, 2H).

[0323] Methyl 2-((trans-4-(3-hydroxypropyl)cyclohexyl)amino)-2-methylpropanoate. To a mixture of 3-(trans-4-aminocyclohexyl)propan-1-ol hydrochloride (120 g, 619 mmol, 1 eq) in acetonitrile (750 mL) was added potassium carbonate (428 g, 3.10 mol, 5 eq) and methyl 2-bromo-2-methylpropanoate (449 g, 2.48 mol, 4 eq). The mixture was stirred at 110 °C for 12 h. The reaction solution was filtered and concentrated. The crude material was purified by silica gel column chromatography (5%-100% ethyl acetate in petroleum ether) to give methyl 2-((trans-4-(3-hydroxypropyl)cyclohexyl)amino)-2-methylpropanoate (54 g, 210 mmol, 34% yield) as a yellow oil. MS (ESI) m / z 258.2 [M+1] + .

[0324] 4-(3-(trans-4-(3-hydroxypropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a solution of methyl 2-((trans-4-(3-hydroxypropyl)cyclohexyl)amino)-2-methylpropanoate (54 g, 210 mmol, 1 eq) and 4-isothiocyanato-2-(trifluoromethyl)benzonitrile (62.2 g, 273 mmol, 1.3 eq) in ethyl acetate (350 mL) was added N,N-diisopropylethylamine (54.2 g, 420 mmol, 2 eq). The mixture was stirred at 80 °C for 12 h. The reaction mixture was concentrated under reduced pressure and purified by column chromatography (10%-100% ethyl acetate in petroleum ether) to give 4-(3-(trans-4-(3-hydroxypropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (63 g, 139 mmol, 66% yield) as a yellow solid. 1 H NMR(400MHzCDCl3)δ7.94-7.96(m,1H),7.85(m,1H),7.72-7.75(m,1H),3.64-3.67(m,2H),2.69(s,2H ),1.95(d,J=12.8Hz,2H),1.84(d,J=11.2Hz,2H),1.61(s,7H),1.29-1.37(m,5H),1.05-1.08(m,2H).

[0325] 4-(3-(trans-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a solution of 4-(3-(trans-4-(3-hydroxypropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (0.820 g, 1.81 mmol, 1 eq) in N,N-dimethylformamide (0.800 mL) and dichloromethane (8 mL) at 0 °C was slowly added thionyl bromide (0.752 g, 3.620 mmol, 2 eq). After stirring at 0°C for 2 h, the reaction solution was concentrated and purified by silica gel column chromatography (15%-25% ethyl acetate in petroleum ether) to give 4-(3-(trans-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (0.650 g, 1.259 mmol, 70% yield) as a brown solid. MS (ESI) m / z 516.1 [M+1] + .

[0326] methyl 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)acetate. To a solution of methyl 2-((2R,6S)-2,6-dimethylpiperazin-1-yl)benzonitrile (500 mg, 0.968 mmol, 1 eq.) and methyl 2-((2R,6S)-2,6-dimethylpiperazin-1-yl)acetate (270 mg, 1.45 mmol, 1.5 eq.) in N,N-dimethylformamide (4.8 mL, 0.2 M) was added N,N-diisopropylethylamine (0.46 mL, 4.84 mmol, 5 eq.) and the reaction solution was stirred at 50°C. After 18 h, the reaction solution was diluted with ethyl acetate (100 mL) and washed with saturated aqueous sodium bicarbonate (2 x 100 mL) and brine (100 mL). The organic layer was dried over anhydrous magnesium sulfate and concentrated. The crude material was purified by silica gel column chromatography (1%-10% methanol in dichloromethane) to give methyl 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)acetate (487 mg, 0.784 mmol, 81% yield) as a light yellow oil. MS (ESI) m / z 622.3 [M+1] + .

[0327] 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)acetic acid. To a solution of methyl 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)acetate (500 mg, 0.82 mmol, 1 eq) in 5:1 THF / water (4 mL, 0.2 M) was added lithium hydroxide (59 mg, 2.46 mmol, 3 eq). The reaction solution was stirred at room temperature. After 12h, the reaction solution was diluted with water (10mL), adjusted to pH 5 by adding 2M HCl and extracted with ethyl acetate (4x 50mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated to give 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)acetic acid (364mg, 0.599mmol, 73% yield) as an off-white solid. MS (ESI) m / z 608.4[M+1] + ; 1 H NMR(400MHz CDCl3)δ8.33(d,J=8.0Hz,1H),8.19(s,1H),7.97(d,J=8.4Hz,1H),3.83(s,1H),3.37(s,2H),3.14(s,2H),2.89(s,2H),2.73(s,2H),2.40(s,2H ),2.00(s,2H),1.81(d,J=12.0Hz,2H),1.72(d,J=10.4Hz,2H),1.44-1. 54(m,8H),1.15-1.19(m,3H),1.05-1.08(m,2H),1.01(d,J=6.4Hz,6H).

[0328] 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a solution of 3-((3-aminophenyl)amino)piperidine-2,6-dione (0.108 g, 0.49 mmol, 1.5 equiv) and 1,2-dimethyl-2-nitropropy!amine (0.128 g, 0.99 mmol, 3 equiv) and HATU (0.188 g, 0.49 mmol, 1.5 equiv) in N,N-dimethylformamide (4 mL) was added N,N-diisopropylethylamine (0.128 g, 0.99 mmol, 3 equiv) and HATU (0.188 g, 0.49 mmol, 1.5 equiv). The reaction was stirred at 60 °C for 12 h. The mixture was purified by standard procedures to afford 2-((2S,6R)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.108 g, 0.036 mmol, 40% yield) as a yellow solid. MS (ESI) m / z 809.4 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ12.09-11.54(m,1H),10.79(s,1H),10.63-10.40(m,1H),8.34(d,J=8.4Hz ,1H),8.20(d,J=1.6Hz,1H),7.97(dd,J=1.6,8.4Hz,1H),7.08-7.01(m,1H),6.99(s,1H),6.86(br d,J=8.0Hz,1H),6.47(dd,J=1.2,8.4Hz,1H),4.27(dd,J=4.8,11.2Hz,4H),3.90-3.63(m,4H),3.36-3.15(m,2H),3.05(s,2H),2.82-2 .65(m,3H),2.64-2.55(m,1H),2.09(td,J=4.0,8.8Hz,1H),1.98-1.64(m,8H),1.55(s,6H),1.35(d,J=1.2Hz,6H),1.28-0.97(m,6H).

[0329] Example 3: 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0330]

[0331] (R)-3-((3-aminophenyl)amino)piperidine-2,6-dione and (S)-3-((3-aminophenyl)amino)piperidine-2,6-dione. Racemic 3-((3-aminophenyl)amino)piperidine-2,6-dione (8 g) was separated by chiral SFC and the fractions were concentrated at a temperature below 35°C to give two peaks. The absolute configuration was determined by vibrational circular dichroism spectroscopy (VCD). (R)-3-((3-aminophenyl)amino)piperidine-2,6-dione (2.80 g, 35.0% yield, 97.7% ee) and (S)-3-((3-aminophenyl)amino)piperidine-2,6-dione (2.90 g, 36.3% yield, 97.1% ee) were isolated as brown solids. SFC purification conditions (column: Chiralpak IC-H, 250 x 30 mm id5um; mobile phase: A represents CO2, and B represents EtOH:acetonitrile = 2:1; gradient: B% = 40%; flow rate: 75 g / min).

[0332] 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To a vial containing (R)-3-((3-aminophenyl)amino)piperidine-2,6-dione (107 mg, 0.49 mmol, 1.2 equiv), N,N-dimethylformamide (2.0 mL, 0.1 M), 1-methylimidazole (134 mg, 1.64 mmol, 8 equiv), and N-(chloro(dimethylamino)methylene)-N-methylmethanaminium hexafluorophosphate (230 mg, 0.82 mmol, 4 equiv). The reaction mixture was stirred at 25 °C for 90 min. The reaction was taken up in dimethyl sulfoxide and purified by semi-preparative HPLC using 5%-95% acetonitrile + 0.1% trifluoroacetic acid in water + 0.1% trifluoroacetic acid over 20 min. The fractions containing the desired product were combined and the volatile organics were removed under reduced pressure to give a brown solid. The solid was taken up in acetonitrile: water (1: 1) and 1.0 N HCl solution (0.80 mL) was added. The solution was frozen and lyophilized to give 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (139 mg, 0.157 mmol, 38% yield) as a brown solid. MS (ESI) m / z 811.4 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ10.80(s,1H),8.34(d,J=8.31Hz,1H),8.20(d,J=1.71Hz,1H),7.97(dd,J=1.71,8.19Hz,1H),7.02-7.09(m,1H),6.99(br s,1H),6.87(brd,J=7.95Hz,1H),6.47(dd,J=1.47,8.19Hz,1H),4.27(dd,J=4.89,11.37Hz,1H),3.97-4.24(m,3H),3.76-3.95(m,3H),3.69(br s,2H),3.22-3.43(m,5H),2.68-2.94(m,3H),2.55-2.65(m,1H),2.05-2.17(m,3H), 1.91(dq,J=4.71,12.12Hz,1H),1.67-1.78(m,2H),1.55(s,6H),1.27-1.45(m,8H).

[0333] Example 4: 2-((2R,6S)-4-(2-((trans-4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0334]

[0335] 2-Chloro-4-(4,4-dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)benzonitrile. To a solution of methyl 2-methyl-2-((trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)amino)propanoate (2. g, 5.82 mmol, 1 eq) in ethyl acetate (1.3234 mL) was added 2-chloro-4-isothiocyanato-benzonitrile (2.27 g, 11.65 mmol, 2 eq) and N,N-diisopropylethylamine (2.03 mL, 11.65 mmol, 2 eq). The reaction solution was heated to 90° C. with stirring. After 18 h, the reaction solution was concentrated and purified by silica gel column chromatography (0-50% ethyl acetate in hexanes) to give 2-chloro-4-(4,4-dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)benzonitrile (2 g, 3.9521 mmol, 68% yield) as a white solid. MS (ESI) m / z 506.2 [M+1] + .

[0336]

[0136] 2-Chloro-4-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile. To a solution of 2-chloro-4-(4,4-dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)benzonitrile (4.0 g, 7.9 mmol, 1 eq) in chloroform (5.7 mL) was added 4 M HCl in dioxane (39.52 mL, 158.08 mmol, 20 eq) and the reaction solution was stirred at room temperature. After 12 h, the reaction solution was concentrated and purified by silica gel column chromatography (0-40% ethyl acetate in hexanes) to give 2-chloro-4-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile (1.5 g, 2.883 mmol, 36% yield) as an off-white solid. MS (ESI) m / z 422.2 [M+1] + .

[0337] 4-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-chlorobenzonitrile. To a solution of 2-chloro-4-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile (1.51 g, 3.06 mmol) in dichloromethane (38 mL) and N,N-dimethylformamide (3.8 mL) was added thionyl bromide (0.59 mL, 7.64 mmol, 2.5 equiv) and the reaction solution was stirred at room temperature. After 1 h, the reaction solution was diluted with ethyl acetate (100 mL) and washed with saturated aqueous sodium bicarbonate (100 mL), brine (100 mL), dried over anhydrous magnesium sulfate and concentrated. The crude material was purified by silica gel column chromatography (0-80% ethyl acetate in hexanes) to give 4-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-chlorobenzonitrile (1.171 g, 2.42 mmol, 79% yield) as a light yellow solid. MS (ESI) m / z 484.0 [M+1] + .

[0338] 2-((2R,6S)-4-(tert-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)acetic acid. To a solution of tert-butyl (3R,5S)-4-(2-methoxy-2-oxoethyl)-3,5-dimethylpiperazine-1-carboxylate (2.27 g, 7.93 mmol, 1 eq) in THF (20 mL) was added lithium hydroxide (208.8 mg, 8.7 mmol, 1.1 eq) in water (5 mL), and the reaction solution was stirred at room temperature. After 18 h, the reaction solution was concentrated under vacuum and azeotroped with chloroform three times to remove residual water to provide crude 2-((2R,6S)-4-(tert-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)acetic acid (2.19 g, 7.8 mmol, 99% yield) as an off-white glassy solid. This material was used without further purification. MS (ESI) m / z 273.2 [M+1] + .

[0339] Tert-butyl (3S,5R)-4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3,5-dimethylpiperazine-1-carboxylate. To a solution of 2-((2R,6S)-4-(tert-butoxycarbonyl)-2,6-dimethylpiperazin-1-yl)acetic acid (2.00 g, 7.34 mmol, 1 eq) and 3-((3-aminophenyl)amino)piperidine-2,6-dione (1.61 g, 7.34 mmol, 1 eq) in N,N-dimethylformamide (20 mL) were added HATU (2.79 g, 7.34 mmol, 1 eq) and N,N-diisopropylethylamine (3.8 mL, 22.03 mmol, 3 eq) in one portion under nitrogen and the reaction solution was stirred at 15 °C. After 12h, the reaction solution was diluted with water (800mL) and extracted with ethyl acetate (100mL×4). The combined organic layer was washed with brine (4x 200mL), dried over anhydrous sodium sulfate, filtered and concentrated. The resulting crude material was purified by flash silica gel chromatography (0-2% methanol in dichloromethane) to give tert-butyl (3S, 5R) -4- (2- ((3- ((2,6- dioxopiperidin-3-yl) amino) phenyl) amino) -2- oxoethyl) -3,5- dimethylpiperazine -1- carboxylate (2.45g, 5.08mmol, 69% yield) as a light yellow solid. MS (ESI) m / z 474.3 [M+1] + .

[0340] 2-((2S,6R)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a solution of (3R,5S)-tert-butyl 4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3,5-dimethylpiperazine-1-carboxylate (2.30 g, 4.86 mmol, 1 eq) in dichloromethane (25 mL) was added 30% hydrogen bromide in acetic acid (2 mL, 14.57 mmol, 3 eq) in one portion under nitrogen and the reaction solution was stirred at 15 °C. After 12 h, the reaction solution was concentrated to give 2-((2S,6R)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrobromide (3.000 g, 6.603 mmol, crude) as a brown solid, which was used further without further purification. MS (ESI) m / z 374.3 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ10.80(s,1H),10.47(br s,1H),9.56-9.16(m,2H),7.06(t,J=8.1Hz,1H),6.96(s,1H),6.87(br d,J=7.9Hz,1H),6.53-6.46(m,1H),4.46-4.21(m,3H),3.94(br s,2H),3.58(brd,J=13.0Hz,2H),2.81-2.69(m,1H),2.81-2.69(m,1H),2.81-2.69(m ,1H),2.81-2.69(m,1H),2.65-2.54(m,1H),2.14-2.04(m,1H),1.90(s,4H),1.34(br s,6H).

[0341] 2-((2R,6S)-4-(2-((trans-4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To a solution of amine hydrobromide (179.5 mg, 0.40 mmol, 1.3 eq.) in N,N-dimethylformamide (3.1 mL, 0.1 M) was added 4-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-chlorobenzonitrile (150. mg, 0.31 mmol, 1 eq.) and N,N-diisopropylethylamine (0.27 mL, 1.55 mmol, 5 eq.), and the reaction solution was heated to 60° C. After 18 h, the reaction solution was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were concentrated, filtered and purified by standard methods to give 2-((2R,6S)-4-(2-((trans-4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (113.2 mg, 0.13 mmol, 42% yield) as an off-white solid. MS (ESI) m / z 777.4 [M+1] + ; 1HNMR(DMSO-d6,400MHz)δ11.82(br s,1H),10.80(s,1H),10.49(br s,1H),8.14(d,1H,J=8.2Hz),7.93(d,1H,J=1.8Hz),7.61(dd,1H,J=1.8,8.3Hz),7.05(t,1H,J=7.4Hz),7.00(br s,1H),6.87(br d,1H,J=7.7Hz),6.48(dd,1H,J=1.5,8.2Hz),4.28(br dd,1H,J=4.8,11.4Hz),4.18(br s,5H),3.8-3.9(m,3H),3.71(br dd,2H,J=4.2,8.0Hz),3.37(tt,2H,J=3.7,10.8Hz),3.31(br s,2H),2.85(q,2H,J=11.6Hz),2.75(ddd,1H,J=5.2,12.1,17.6Hz),2.60(td,1H,J =4.0,17.5Hz),2.11(td,3H,J=4.2,8.4Hz),1.92(dq,1H,J=4.7,12.1Hz),1.72(br d,2H,J=10.8Hz),1.54(s,6H),1.3-1.4(m,8H).

[0342] Example 5: 2-((2R,6S)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0343]

[0344]

[0136] 5-(4,4-Dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile. Methyl 2-methyl-2-((trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)amino)propanoate (6.70 g, 19.51 mmol, 1 eq), 5-isothiocyanato-3-(trifluoromethyl)picolinonitrile (8.94 g, 39.0 mmol, 2 eq), and N,N-diisopropylethylamine (6.8 mL, 39.0 mmol, 2 eq) were combined in ethyl acetate (56 mL, 0.35 M) and heated to 90 °C in a sealed tube for 16 h. The reaction was diluted with ethyl acetate (100 mL) and washed with water (100 mL) and brine (100 mL), dried over anhydrous magnesium sulfate and concentrated. The crude material was purified by silica gel column chromatography (10%-100% ethyl acetate in hexanes) to give 5-(4,4-dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (3.5 g, 6.4743 mmol, 33% yield) as a brown solid. MS (ESI) m / z 541.3 [M+1] + .

[0345]

[0136] 5-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile. To a solution of 5-(4,4-dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (3.50 g, 6.47 mmol, 1 eq) in dichloromethane (30 mL) was added 4 M hydrochloric acid (16.2 mL, 64.7 mmol, 10 eq) and the reaction solution was stirred at room temperature. After 3 h, the reaction solution was concentrated to provide 5-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (3.20 g, 6.4 mmol, 99% yield) as a reddish oil. The crude material was used without further purification. MS (ESI) m / z 457.0 [M+1] + .

[0346] 5-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile. To a solution of 5-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (3.20 g, 6.49 mmol) in dichloromethane (30 mL) and N,N-dimethylformamide (5 mL) was added thionyl bromide (1.26 mL, 16.2 mmol, 2.5 equiv) and the reaction solution was stirred at room temperature. After 2 h, the reaction solution was concentrated and the crude material was purified by silica gel column chromatography (5%-80% ethyl acetate in hexanes) to give 5-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (2.00 g, 3.85 mmol, 59% yield) as a reddish brown oil. MS (ESI) m / z 519.8 [M+1] + .

[0347] 2-((2R,6S)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. 5-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)

[0136] To the reaction mixture was added 1,0-dimethyl-1,2-dimethyl-piperazin-1-yl (200 mg, 0.36 mmol), 2-((2R,6S)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrobromide (192 mg, 0.47 mmol, 1.3 equiv), sodium iodide (108 mg, 0.72 mmol, 2 equiv), and N,N-diisopropylethylamine (0.38 mL, 2.16 mmol, 6 equiv) in acetonitrile (1.8 mL, 0.2 M) and heated at 60 °C. After 7 h, the reaction was partitioned between ethyl acetate and water. The organic layer was washed with brine, then dried over magnesium sulfate, filtered and concentrated. The crude material was purified by standard methods. The product fractions were treated with 4 mL of 3M HCl and then evaporated to give 2-((2R,6S)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (90 mg, 0.11 mmol, 31% yield) as a white solid. MS(ESI)m / z 812.0[M+1]+; 1HNMR(400MHz, DMSO-d6)δppm 10.73-10.84(m,1H),9.15(d,J=1.96Hz,1H),8.75(d,J=1.96Hz,1H),6.94-7.11(m,2H),6.85(br d,J=7.82Hz,1H),6.46(br d,J=8.19Hz,1H),4.27(dd,J=11.31,4.83Hz,1H),3.85(br s,4H),3.47-3.75(m,2H),3.20-3.43(m,4H),2.58-2.95(m,4H),2.03-2.20(m,4H), 1.91(qd,J=12.12,4.71Hz,1H),1.70-1.79(m,2H),1.58(s,6H),1.11-1.48(m,7H).

[0348] Example 6: 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0349]

[0350] 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. Add 2-dram vial of 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To (46.9 mg, 0.21 mmol, 1.3 equiv) and (3R)-3-(3-aminoanilino)piperidine-2,6-dione (46.9 mg, 0.21 mmol, 1.3 equiv) was added N,N-dimethylformamide (0.55 mL, 0.3 M) and the reaction solution was stirred until all solids dissolved. 1-Methylimidazole (0.13 mL, 1.65 mmol, 10 equiv) was added followed by N-(chloro(dimethylamino)methylene)-N-methylmethanium hexafluorophosphate (V) (69.25 mg, 0.2500 mmol, 1.5 equiv) and the reaction solution was stirred at room temperature. After 20 min, the reaction solution was diluted with DMSO to a total volume of 4 ml, filtered and purified by standard methods to give 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (48 mg, 0.059 mmol, 36% yield) as an off-white solid. MS (ESI) m / z 808.4 [M+1]+; 1H NMR (500MHz, DMSO-d6) δ10.77(s,1H),9.41(s,1H),8.33(d,J=8.4Hz,1H),8.19(s,1H),7.97( dd,J=1.2,8.4Hz,1H),7.06-6.92(m,2H),6.79(d,J=8.0Hz,1H),6.40(d,J=7.6Hz,1H),5.89(d ,J=7.6Hz,1H),4.33-4.22(m,1H),3.83(s,1H),3.29-3.19(m,2H),2.83-2.66(m,5H),2.64-2. 55(m,2H),2.13-2.05(m,2H),1.95-1.67(m,7H),1.55(s,9H),1.30-1.05(m,7H),1.01(s,6H).

[0351] Example 7: 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(pentafluoro-λ 6 -((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0352]

[0353] 4-Bromo-3-(pentafluoro-λ 6 -sulfanyl)aniline. Under nitrogen atmosphere, at 0 ° C, to 3-(pentafluoro-λ 6 To a solution of 4-bromo-3-(pentafluoro-λ- alkyl)aniline (2.0 g, 9.12 mmol, 1 eq.) in dimethylformamide (15 mL) was added N-bromosuccinimide (1.9 g, 10.95 mmol, 1.2 eq.) in one portion. The resulting mixture was stirred at room temperature for 4 h. The reaction solution was diluted with water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine (100 mL), dried over magnesium sulfate, filtered and concentrated. The crude material was purified by silica gel chromatography (0-20% ethyl acetate in hexanes) to give 4-bromo-3-(pentafluoro-λ- alkyl)aniline. 6 -sulfanyl)aniline (1.7 g, 5.7 mmol, 59% yield). 1 H NMR (CDCl3, 400MHz) δ7.4-7.5(m,1H),7.1-7.2(m,1H),6.6-6.7(m,1H),3.8-4.0(m,2H).

[0354] 4-amino-2-(pentafluoro-λ 6 -sulfanyl)benzonitrile. Under stirring, 4-bromo-3-(pentafluoro-λ 6 A 100 mL round-bottom flask of 2-(pentafluoro-λ6-sulfanyl)aniline (1.7 g, 5.7 mmol, 1 eq.) and copper (I) cyanide (0.61 g, 6.84 mmol, 1.2 eq.) was heated to 180 °C. After 4 h, the reaction solution was diluted with water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine, dried over magnesium sulfate and concentrated. The residue was purified by silica gel chromatography (0-20% ethyl acetate in hexane on a 50 g column) to give 4-amino-2-(pentafluoro-λ6-sulfanyl)benzonitrile (1.0 g, 4.09 mmol, 72% yield) as a white solid. MS (ESI) m / z 244.8 [M+1] +.

[0355] 4-isothiocyanato-2-(pentafluoro-λ 6 To a 100 mL round bottom flask containing thiophosgene (0.94 mL, 12.29 mmol, 1.2 eq) in water (10 mL) was added 4-amino-2-(pentafluoro-λ- thio)-1-nitropropene (0.94 mL, 12.29 mmol, 1.2 eq) in dichloromethane (10 mL) to give an orange solution. 6 -sulfanyl)benzonitrile (2.5 g, 10.24 mmol, 1 eq.). The resulting mixture was stirred at room temperature for 16 h. The reaction was diluted with water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine, dried over magnesium sulfate and concentrated to give 4-isothiocyanato-2-(pentafluoro-λ)-1,2-difluoro-4-yl ... 6 -sulfanyl)benzonitrile (1.3 g, 4.54 mmol, 44% yield) which was used without further purification. MS (ESI) m / z 286.9 [M+1]+.

[0356] 4-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(pentafluoro-λ 6 To a solution of methyl 2-methyl-2-((trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)amino)propanoate (1.0 g, 2.91 mmol, 1 eq) in ethyl acetate (10 mL) was added 4-isothiocyanato-2-(pentafluoro-λ 6 -sulfanyl)benzonitrile (1.67 g, 5.82 mmol, 1.2 eq) and N,N-diisopropylethylamine (1.02 mL, 5.82 mmol, 3 eq). The reaction solution was stirred at 80 °C. After 18 h, the reaction solution was concentrated and purified by column chromatography (0-50% ethyl acetate / hexane) to give a white solid 4-(4,4-dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-2-(pentafluoro-λ 6 -sulfanyl)benzonitrile. The intermediate solid was suspended in dichloromethane (1.5 mL), followed by addition of 4M hydrochloric acid in dioxane (4 mL, 16 mmol, 3 equivalents), and stirred at 25 ° C for 12 h. The reaction solution was concentrated, the solid was dissolved in dichloromethane and purified by silica gel column chromatography (0-40% ethyl acetate in hexane) to give 4-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(pentafluoro-λ 6-sulfanyl)benzonitrile (0.80 g, 1.33 mmol, 46% yield). MS (ESI) m / z 513.8 [M+1] +.

[0357] 4-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(pentafluoro-λ 6 -sulfanyl)benzonitrile. 4-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(pentafluoro-λ 6 -sulfanyl)benzonitrile (1.0 g, 1.95 mmol, 1 equivalent) was added to a solution of dimethylformamide (5 mL) and thionyl bromide (1.0 g, 4.87 mmol, 2.5 equivalents) in dichloromethane (30 mL). The reaction solution was stirred at room temperature overnight. After 16 h, the reaction solution was diluted with brine (100 mL) and extracted with ethyl acetate (100 mL). The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The crude material was purified by silica gel column chromatography (0-100% ethyl acetate in hexane) to obtain 4-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(pentafluoro-λ 6 -sulfanyl)benzonitrile (0.59 g, 1.02 mmol, 53% yield). MS (ESI) m / z 578.8 [M+1] + .

[0358] 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(pentafluoro-λ 6 -sulfuryl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. 6To a 1 dram vial of 2-((2R,6S)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.09 g, 0.23 mmol, 1.3 equiv) and sodium iodide (2.7 mg, 0.02 mmol, 0.1 equiv) was added acetonitrile (2 mL) followed by N,N-diisopropylethylamine (0.21 mL, 1.2 mmol, 6 equiv). The reaction vial was heated to 60 °C with stirring. After 16 h, the reaction solution was diluted with dimethyl sulfoxide to a total volume of 3 ml and purified by standard methods to give 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(pentafluoro-λ)-yl)-4 ... 6 -((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.05 g, 0.06 mmol, 31% yield). MS (ESI) m / z 869.2 [M+1] + ; 1 H NMR(DMSO-d6,400MHz)δ10.7-10.9(m,1H),8.4-8.5(m,1H),8.3-8.4(m,1H),7.9-8.0(m,1H),7.0-7.1 (m,1H),7.0-7.0(m,1H),6.8-6.9(m,1H),6.4-6.5(m,1H),4.5-4.6(m,1H),4.2-4.3(m,4H),3.8-3.9( m,4H),3.57(s,5H),3.4-3.5(m,1H),3.3-3.4(m,2H),2.8-2.9(m,2H),2.7-2.8(m,1H),2.5-2.7(m,1H ),2.1-2.2(m,3H),1.8-2.0(m,1H),1.7-1.8(m,2H),1.5-1.6(m,6H),1.3-1.4(m,2H),1.2-1.3(m,6H).

[0359] Example 8: 2-((2R,6S)-4-(3-(trans-4-(3-(5-chloro-6-cyanopyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0360]

[0361] 3-Chloro-5-isothiocyanato-pyridine-2-carbonitrile. To a solution of 5-amino-3-chloro-pyridine-2-carbonitrile (10.00 g, 65.12 mmol, 1 eq.) in toluene (20 mL) was added thiophosgene (5.96 mL, 78.14 mmol, 1.2 eq.). The mixture was stirred at 110 °C. After 16 h, the reaction solution was concentrated and purified by silica gel chromatography (20%-50% ethyl acetate in petroleum ether) to give 3-chloro-5-isothiocyanato-pyridine-2-carbonitrile (8.000 g, 40.89 mmol, 63% yield) as a red solid. MS (ESI) m / z 196.2 [M+1] + .

[0362] 3-Chloro-5-(4,4-dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)picolinonitrile. To a mixture of methyl 3-chloro-5-isothiocyanato-pyridine-2-carbonitrile (4.000 g, 20.45 mmol, 1 eq.) and methyl 2-methyl-2-((trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)amino)propanoate (7.720 g, 22.49 mmol, 1.1 eq.) in ethyl acetate (100 mL, 0.2 M) was added triethylamine (5.7 mL, 40.89 mmol, 2 eq.). The reaction solution was stirred at 90°C. After 6 hours, the reaction solution was concentrated and purified by silica gel column chromatography (10%-50% ethyl acetate in petroleum ether) to give 3-chloro-5-(4,4-dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)picolinonitrile (4.000 g, 7.89 mmol, 39% yield) as a yellow solid. MS (ESI) m / z 507.2 [M+1] + ; 1 HNMR(400MHz,DMSO-d6)δ8.92-8.72(m,1H),8.62-8.31(m,1H),4.68-4.50(m,1H),3.91-3.63(m,4H),3.62-3.52(m ,3H),3.50-3.39(m,3H),2.91-2.73(m,3H),2.10-2.03(m,2H),1.75-1.68(m,3H),1.55(s,6H),1.50-1.43(m,4H).

[0363] 3-Chloro-5-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)picolinonitrile. To a solution of 3-chloro-5-(4,4-dimethyl-5-oxo-3-(trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)picolinonitrile (4.000 g, 7.89 mmol, 1 eq.) in methanol (30 mL, 0.27 M) was added 2 M aqueous hydrochloric acid solution (3 mL, 15.78 mmol, 2 eq.). The reaction solution was stirred at 25° C. After 2 h, the pH of the mixture was adjusted to 8 by adding saturated sodium carbonate. The aqueous phase was extracted with ethyl acetate (250 mL). The combined organic layers were washed with brine (80 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by silica gel chromatography (% 33-100% ethyl acetate in petroleum ether) to give 3-chloro-5-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)picolinonitrile (2.400 g, 0.01 mmol, 69% yield) as a yellow solid. MS (ESI) m / z 423.3 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.59 (s, 1H), 7.43-7.33 (m, 2H), 7.15 (br d, J = 7.0Hz, 1H), 6.57 (br s,1H),4.40(t,J=6.7Hz,2H),2.98(s,3H),2.70-2.55(m,2H),1.53(s,5H), 1.54-1.51(m,1H),1.54-1.51(m,1H),1.54-1.51(m,1H),1.54-1.51(m,1H).

[0364] 5-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-chloropicolinonitrile. To a solution of 3-chloro-5-(3-(trans-4-(2-hydroxyethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)picolinonitrile (2.150 g, 5.08 mmol, 1 eq) in dichloromethane (5 mL, 1 M) and N,N-dimethylformamide (0.50 mL) was added thionyl bromide (0.65 mL, 10.17 mmol, 2 eq) at 0°C. The mixture was stirred at 25°C for 16 h. The pH of the mixture was adjusted to 8 with saturated sodium carbonate. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3 x 150 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by silica gel chromatography (50%-100% ethyl acetate in petroleum ether) to give 5-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-chloropicolinonitrile (2.3 g, 4.73 mmol, 93% yield) as a red solid. MS (ESI) m / z 485.1 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ8.90-8.72(m,1H),8.60-8.44(m,1H),3.93-3.81(m,1H),3.79-3.72(m,2H),3.61-3.53(m,2H),3.34(br s,1H),2.90-2.74(m,2H),2.12-2.02(m,2H),1.76-1.67(m,2H),1.59-1.52(m,6H),1.44-1.28(m,2H).

[0365] 2-((2R,6S)-4-(3-(trans-4-(3-(5-chloro-6-cyanopyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. 5-(3-(trans-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-chloropicolinonitrile (0.1 To a mixture of 2-((2R,6S)-2,6-dimethylpiperazin-1-yl)-N-(6-(2,6-dioxopiperidin-3-yl)pyridin-3-yl)acetamide hydrobromide (112 mg, 0.25 mmol, 1 eq.) and sodium iodide (0.004 g, 0.02 mmol, 8 mol%) were added N,N-dimethylformamide (4 mL, 0.06 M) and N,N-diisopropylethylamine (0.096 g, 0.74 mmol, 3 eq.). The mixture was stirred at 60°C. After 16 h, the reaction solution was diluted with DMSO (1 mL) and purified by standard methods to give 2-((2R,6S)-4-(3-(trans-4-(3-(5-chloro-6-cyanopyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.070 g, 0.09 mmol, 36% yield) as a yellow solid. MS (ESI) m / z 778.3 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δ10.87-10.80(m,1H),10.76-10.46(m,1H),8.87-8.74(m,1H),8.58-8.47(m,1H) ),7.08-7.03(m,1H),7.02-6.98(m,1H),6.91-6.86(m,1H),6.52-6.46(m,1H),4.31-4.26(m,2H),4.23 -4.13(m,2H),3.95-3.81(m,6H),3.43-3.26(m,6H),2.94-2.81(m,2H),2.79-2.70(m,1H),2.63-2.56( m,1H),2.17-2.06(m,3H),1.97-1.86(m,1H),1.76-1.67(m,2H),1.58-1.53(m,6H),1.43-1.27(m,8H).

[0366] Example 9: 2-((2R,6S)-4-(3-((trans-4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0367]

[0368] trans-N,N-dibenzyl-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexan-1-amine. To a solution of trans-4-(dibenzylamino)cyclohexanol (60.00 g, 203.1 mmol, 1 eq.) in xylene (450 mL, 0.45 M) was added 2-(2-bromoethoxy)tetrahydro-2H-pyran (113.28 g, 507.75 mmol, 2.5 eq.), tetra-n-butylammonium bromide (13.09 g, 40.62 mmol, 0.2 eq.) and potassium hydroxide (52.42 g, 934.26 mmol, 4.6 eq.) and the reaction solution was stirred at room temperature. After 24 h, the reaction solution was diluted with ethyl acetate (500 mL) and washed with water (200 mL), brine (200 mL), dried over anhydrous sodium sulfate and concentrated. The crude material was purified by silica gel column chromatography (100% petroleum ether) to give trans-N,N-dibenzyl-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexan-1-amine (40.0 g, 91.4 mmol, 45% yield) as a light yellow oil. MS (ESI) m / z 438.4 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.38-7.32(m,4H),7.31-7.28(m,4H),7.24-7.22(m,2 H),4.61-4.57(m,1H),3.88-3.84(m,2H),3.63(s,4H),3.55-3.52(m,4H),3 .51-3.16(m,1H),2.54-2.09(m,1H),2.08-2.07(m,2H),1.92-1.90(m,2H), 1.61-1.60(m,2H),1.59-1.57(m,6H),1.55-1.53(m,2H),1.38-1.16(m,2H)

[0369]

[0266] trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexan-1-amine. To a solution of trans-N,N-dibenzyl-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexan-1-amine (20.0 g, 45.7 mmol, 1 equiv) in methanol (100 mL) was added 10% palladium on carbon (10.0 g, 9.39 mmol). The reaction flask was evacuated and purged with hydrogen three times and then stirred at room temperature under a hydrogen atmosphere (15 psi). After 12 h, the reaction solution was filtered and the filtrate was concentrated to provide trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexan-1-amine (11.00 g, 42.74 mmol, 94% yield) as a light yellow oil. This material was carried forward without further purification. 1 H NMR(400MHz,DMSO-d6)δ4.52(m,1H),3.79-3.61(m,2H),3.50-3.30(m,4H),3.18-3.05(m,1H), 1.94-1.83(m,2H),1.77-1.65(m,6H),1.64-1.55(m,1H),1.53-1.38(m,4H),1.20-0.91(m,4H).

[0370] Methyl 2-methyl-2-((trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)amino)propanoate. To a solution of trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexan-1-amine (7.00 g, 27.2 mmol, 1 eq) and methyl 2-bromo-2-methyl-propanoate (12.5 mL, 108.79 mmol, 4 eq) in acetonitrile (10 mL) was added potassium iodide (0.451 g, 2.72 mmol, 0.1 eq) and potassium carbonate (7.518 g, 54.4 mmol, 2 eq). The reaction vessel was sealed and heated to 110° C. with stirring. After 12 h, the reaction solution was filtered and concentrated. The crude material was purified by silica gel column chromatography (10%-80% ethyl acetate in petroleum ether) to give methyl 2-methyl-2-((trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)amino)propanoate (8.00 g, 22.4 mmol, 82% yield) as a light yellow oil. MS (ESI) m / z 358.4 [M+1] + .

[0371] 2-Chloro-4-(4,4-dimethyl-5-oxo-3-(trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)benzonitrile. To a solution of methyl 2-methyl-2-((trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)amino)propanoate (10.0 g, 28.0 mmol, 1 eq) in ethyl acetate (100 mL, 0.28 M) was added 2-chloro-4-cyanophenyl isothiocyanate (10.9 g, 56.0 mmol, 2 eq) and triethylamine (7.8 mL, 56.0 mmol, 2 eq) and the reaction solution was stirred at 80° C. After 8 h, the reaction solution was diluted with water (100 mL) and extracted with ethyl acetate (3× 40 mL). The combined organic layers were washed with brine (40 mL), dried over anhydrous sodium sulfate and concentrated. The crude material was purified by silica gel column chromatography (9%-20% ethyl acetate in petroleum ether) to give 2-chloro-4-(4,4-dimethyl-5-oxo-3-(trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)benzonitrile (8.50 g, 16.3 mmol, 58% yield) as a red oil. MS (ESI) m / z 542.2 [M+23] + .

[0372] 4-(3-(trans-4-(3-hydroxypropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a solution of 2-chloro-4-(4,4-dimethyl-5-oxo-3-(trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)benzonitrile (6.80 g, 13.1 mmol) in methanol (50 mL) was added 1 M hydrochloric acid (5 mL, 13.07 mmol) and the reaction solution was stirred at 25 °C. After 2 h, the reaction solution was diluted with saturated aqueous sodium bicarbonate (100 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated. The crude material obtained was purified by silica gel column chromatography (20%-70% ethyl acetate in petroleum ether) to give 4-(3-(trans-4-(3-hydroxypropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (5.60 g, 12.8 mmol, 98% yield) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ8.12(d,J=8.4Hz,1H),7.92(d,J=1.6Hz,1H),7.61(dd,J=2.0,8.4Hz,1H),3.89-3.76(m,1H),3.48-3.42(m,4H),3. 24-3.16(m,1H),2.79(d,J=11.2Hz,2H),2.04(d,J=10.8Hz,2H),1.70(d,J=10.8Hz,2H),1.65-1.59(m,2H),1.53(s,6H),1.34-1.25(m,2H).

[0373] 4-(3-(trans-4-(3-bromopropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-chlorobenzonitrile. To a solution of 4-(3-(trans-4-(3-hydroxypropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (5.8 g, 13.3 mmol) in dichloromethane (50 mL) and N,N-dimethylformamide (5 mL) was added thionyl bromide (2.1 mL, 26.6 mmol, 2 equiv) at 0°C. After 8 h, the reaction solution was diluted with saturated aqueous sodium bicarbonate (100 mL) and extracted with ethyl acetate (3 x 40 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated. The crude material was purified by silica gel column chromatography (0-35% ethyl acetate in petroleum ether) to give 4-(3-(trans-4-(3-bromopropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-chlorobenzonitrile (4.8 g, 9.6 mmol, 72% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ8.14-8.11(m,1H),7.93(d,J=1.6Hz,1H),7.61(dd,J=1.6,8.0Hz,1H),3.84(s,1H),3.58-3.51(m, 4H), 3.27-3.21 (m, 1H), 2.81 (d, J = 11.6Hz, 2H), 2.06 (m, 2H), 1.71 (d, J = 11.6Hz, 2H), 1.53 (s, 6H), 1.33 (d, J = 13.2Hz, 2H).

[0374] 2-((2R,6S)-4-(3-((trans-4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To a solution of 2-((2R,6S)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.168 g, 0.450 mmol, 1.5 eq.) was added N,N-diisopropylethylamine (0.16 mL, 0.900 mmol, 3 eq.). The reaction mixture was stirred at 50 °C. After 12 h, the reaction solution was diluted with water (50 mL) and the aqueous phase was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by standard methods to give 2-((2R,6S)-4-(3-((trans-4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.087 g, 0.110 mmol, 37% yield) as a yellow solid. MS (ESI) m / z 791.3 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.80(s,1H),8.13(d,J=8.4Hz,1H),7.93(d,J=1.9Hz,1H),7.61(dd,J=1.8, 8.3Hz,1H),7.09-7.02(m,1H),6.99(s,1H),6.86(d,J=7.3Hz,1H),6.48(d,J=7.9Hz,1H),4.28(dd,J =4.8,11.3Hz,2H),4.19-4.06(m,2H),3.98-3.63(m,4H),3.52(t,J=5.8Hz,2H),3.30-3.23(m,2H),3 .12(s,2H),2.87-2.60(m,4H),2.13-1.91(m,6H),1.75-1.68(m,2H),1.53(s,6H),1.42-1.26(m,8H).

[0375] Example 10: 2-((2R,6S)-4-(3-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0376]

[0377]

[0136] 5-(4,4-dimethyl-5-oxo-3-(trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile. To a solution of methyl 2-methyl-2-((trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)amino)propanoate (5.00 g, 14.0 mmol, 1 eq.) and 5-isothiocyanato-3-(trifluoromethyl)pyridine-2-carbonitrile (6.41 g, 28.0 mmol, 2 eq.) in ethyl acetate (50 mL, 0.28 M) was added N,N-diisopropylethylamine (4.62 mL, 28.0 mmol, 2 eq.) and the reaction solution was stirred at 90 °C. After 12 h, the reaction solution was concentrated and purified by silica gel column chromatography (10%-50% ethyl acetate in petroleum ether) to give 5-(4,4-dimethyl-5-oxo-3-(trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (7.00 g, 12.6 mmol, 90% yield) as a brown oil. 1 H NMR(400MHz, CDCl3)δ8.95(s,1H),8.23(s,1H),4.55-4.51(m,1H),3.81-3.78(m,2H),3.70-3.68(m,1H),3.57-3.54(m,2H),3.4 8-3.45(m,2H),3.29-2.87(m,1H),2.85(d,J=10.8Hz,2H),1.85-1.80(m,8H),1.60(s,6H),1.56-1.52(m,4H),1.32-1.29(m,2H).

[0378] 5-(3-(trans-4-(3-hydroxypropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile. To a solution of 5-(4,4-dimethyl-5-oxo-3-(trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (7.00 g, 12.6 mmol, 1 eq) in methanol (50 mL) was added 1 M hydrogen chloride (5.0 mL, 5 mmol) and the reaction solution was stirred at room temperature. After 2 h, the reaction solution was diluted with saturated aqueous sodium bicarbonate (20 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated to give 5-(3-(trans-4-(3-hydroxypropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (5.00 g, 10.6 mmol, 84% yield) as a brown oil. MS (ESI) m / z 471.2 [M+1] + .

[0379] 5-(3-(trans-4-(3-bromopropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile. To a solution of 5-(3-(trans-4-(3-hydroxypropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (5.00 g, 10.6 mmol, 1 eq) in dichloromethane (50 mL) and N,N-dimethylformamide (5 mL) was added thionyl bromide (1.7 mL, 21.3 mmol, 2 eq) at 0° C. After stirring for 12 h, the reaction solution was diluted with saturated aqueous sodium bicarbonate (20 mL) and extracted with dichloromethane (2 x 50 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated. The resulting crude material was purified by silica gel column chromatography (10%-20% ethyl acetate in petroleum ether) to give 5-(3-(trans-4-(3-bromopropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile as a light yellow solid. (ESI) m / z 535.1 [M+1] + ; 1H NMR (400MHz, CDCl3) δ8.98(d,J=2.0Hz,1H),8.24(d,J=2.0Hz,1H),3.76-3.65(m,1H),3.62(t,J=5.6Hz,2H),3.53(t,J=6.4Hz,2H ),3.40-3.29(m,1H),2.89(s,2H),2.30-2.18(m,2H),2.16-2.05(m,2H),1.83(d,J=12.4Hz,2H),1.63(s,6H),1.45-1.24(m,2H).

[0380] 2-((2R,6S)-4-(3-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. Under nitrogen, 5-(3-(trans-4-(3-bromopropyloxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)pyridin-1-yl was added to the mixture. To a solution of pyridinecarbonitrile (0.150 g, 0.280 mmol, 1 eq.) and 2-((2R,6S)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrobromide (0.128 g, 0.280 mmol, 1 eq.) in N,N-dimethylformamide (4 mL, 0.07 M) were added N,N-diisopropylethylamine (0.24 mL, 1.41 mmol, 5 eq.) and sodium iodide (0.008 g, 0.060 mmol, 2 eq.) in one portion. The mixture was stirred at 60 °C. After 16 h, the reaction solution was diluted with water (80 mL) and extracted with ethyl acetate (4 x 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by standard methods to give 2-((2R,6S)-4-(3-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.089 g, 0.107 mmol, 38% yield) as a yellow solid. MS (ESI) m / z 826.4 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ12.76-11.23(m,1H),12.31-11.21(m,1H),10.80(s,1H),10.54(br s,1H),9.14(d,J=1.7Hz,1H),8.74(d,J=2.0Hz,1H),7.08-7.02(m,1H),6.99(br s,1H),6.86(br d,J=7.9Hz,1H),6.50-6.44(m,1H),4.27(br dd,J=4.8,11.4Hz,3H),4.16(br s,3H),3.92-3.69(m,3H),3.51(br t,J=5.8Hz,2H),3.26(br t,J=10.6Hz,2H),3.18-3.05(m,1H),3.12(br s,1H),2.90-2.76(m,1H),2.90-2.76(m,1H),2.90-2.76(m,1H),2.76-2.6 8(m,1H),2.64-2.55(m,1H),2.14-2.03(m,3H),2.02-1.85(m,3H),1.72(br d,J=10.3Hz,2H),1.57(s,6H),1.44-1.26(m,8H).

[0381] Example 11: 2-((2R,6S)-4-(3-(trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0382]

[0383]

[0136] 5-(3-(trans-4-(3-hydroxypropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile. To a solution of methyl 2-((trans-4-(3-hydroxypropyl)cyclohexyl)amino)-2-methylpropanoate (1.47 g, 5.71 mmol, 1 eq) and 5-isothiocyanato-3-(trifluoromethyl)picolinonitrile (1.44 g, 6.28 mmol, 1.1 eq) in ethyl acetate (15 mL, 0.38 M) was added N,N-diisopropylethylamine (2.21 g, 17.13 mmol, 3 eq) and the reaction solution was stirred at 80 °C. After 16 h, the reaction solution was concentrated under reduced pressure and the crude material was purified by standard methods to give 5-(3-(trans-4-(3-hydroxypropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (1.80 g, 3.96 mmol, 69% yield) as a brown solid. MS (ESI) m / z 455.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ8.99(d,J=2.0Hz,1H),8.25(d,J=2.0Hz,1H),3.80-3.72(m,1H),3.65(t,J=6.4Hz,2H),2.72-2.7 0(m,2H),1.97-1.94(m,2H),1.85-1.82(m,2H),1.63(s,6H),1.58-1.54(m,1H),1.42-1.29(m,4H),1.12-1.02(m,2H).

[0384] 5-(3-(trans-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile. To a solution of 5-(3-(trans-4-(3-hydroxypropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (1.80 g, 3.96 mmol, 1 eq) in dichloromethane (18 mL, 0.22 M) and N,N-dimethylformamide (1.8 mL) was slowly added thionyl bromide (1.650 g, 7.92 mmol, 2 eq) at 0°C. The reaction solution was stirred at 0°C. After 12 h, the reaction solution was diluted with water (30 mL) and extracted with dichloromethane (2 x 25 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated. The crude residue was purified by silica gel column chromatography (5%-80% ethyl acetate in hexanes) to give 5-(3-(trans-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (1.75 g, 3.38 mmol, 85% yield) as a brown solid. MS (ESI) m / z 516.9 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ8.99(d,J=2.0Hz,1H),8.25(d,J=2.0Hz,1H),3.80-3.71(m,1H),3.42(t,J=6. 8Hz,2H),2.74-2.72(m,2H),1.96-1.79(m,6H),1.63(s,6H),1.40-1.33(m,3H),1.13-1.04(m,2H).

[0385] 2-((2R,6S)-4-(3-(trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. Under nitrogen, 5-(3-(trans-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl) To a solution of -3-(trifluoromethyl)picolinonitrile (0.120 g, 0.232 mmol, 1 eq.) and 2-((2S,6R)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrobromide (0.158 g, 0.350 mmol, 1.5 eq.) in N,N-dimethylformamide (1 mL, 0.23 M) was added N,N-diisopropylethylamine (0.2 mL, 1.16 mmol, 5 eq.) in one portion. The mixture was stirred at 50 °C. After 12 h, the reaction solution was diluted with water (80 mL) and extracted with ethyl acetate (4 x 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by standard methods to afford 2-((2R,6S)-4-(3-(trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.129 g, 0.157 mmol, 68% yield) as a yellow solid. MS (ESI) m / z 810.3 [M+1] + ; 1HNMR (400MHz, DMSO-d6) δ12.08(br s,1H),10.80(s,1H),10.64(br s,1H),9.15(d,J=1.9Hz,1H),8.75(d,J=2.0Hz,1H),7.12-6.96(m,2H),6.88(br d,J=7.9Hz,1H),6.53-6.44(m,1H),6.53-6.44(m,1H),4.32-4.11(m,5H),3.92-3.70(m,3H),3.29(br s,2H),3.06(br s,2H),2.74(ddd,J=5.1,12.0,17.4Hz,3H),2.64-2.55(m,1H),2.09(td,J= 4.1,8.5Hz,1H),1.98-1.88(m,1H),1.87-1.70(m,6H),1.57(s,6H),1.38(br d,J=3.0Hz,6H),1.21(br d,J=7.1Hz,4H),1.16-1.06(m,1H),1.16-1.06(m,1H).

[0386] Example 12: 2-((2R,6S)-4-(3-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0387]

[0388]

[0136] 4-(4,4-dimethyl-5-oxo-3-(trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a solution of methyl 2-methyl-2-((trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)amino)propanoate (5.0 g, 14.0 mmol, 1 eq.) and 4-isothiocyanato-2-(trifluoromethyl)benzonitrile (6.4 g, 28.0 mmol, 2 eq.) in ethyl acetate (50 mL) was added N,N-diisopropylethylamine (4.6 mL, 28.0 mmol, 2 eq.) and the reaction solution was stirred at 90 °C. After 12 h, the reaction solution was concentrated and purified by silica gel column chromatography (10%-50% ethyl acetate in petroleum ether) to give 4-(4,4-dimethyl-5-oxo-3-(trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (6.5 g, 11.7 mmol, 84% yield) as a brown oil. MS (ESI) m / z 554.4 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.95(d,J=8.4Hz,1H),7.84(d,J=2.0Hz,1H),7.74-7.71(m,1 H),4.60-4.58(m,1H),3.84-3.82(m,2H),3.71-3.61(m,1H),3.60-3.52(m,2H),3.5 0-3.49(m,2H),3.47-3.32(m,1H),2.22-2.20(m,2H),2.19(d,J=12.0Hz,2H),1.88- 1.87(m,6H),1.85-1.84(m,2H),1.60(s,6H),1.56-1.55(m,2H),1.54-1.35(m,2H).

[0389] 4-(3-(trans-4-(3-hydroxypropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a solution of 4-(4,4-dimethyl-5-oxo-3-(trans-4-(3-((tetrahydro-2H-pyran-2-yl)oxy)propoxy)cyclohexyl)-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (6.5 g, 11.7 mmol) in methanol (50 mL) was added 1 M aqueous hydrochloric acid solution (5.0 mL, 5 mmol) and the reaction solution was stirred at room temperature. After 2 h, the reaction solution was diluted with saturated aqueous sodium bicarbonate (30 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated to give 4-(3-(trans-4-(3-hydroxypropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (5.0 g, 10.7 mmol, 91% yield) as a brown oil. MS (ESI) m / z 470.2 [M+1] + .

[0390] 4-(3-(trans-4-(3-bromopropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a solution of 4-(3-(trans-4-(3-hydroxypropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (5.0 g, 10.7 mmol, 1 eq.) in dichloromethane (50 mL) and N,N-dimethylformamide (5 mL) was added thionyl bromide (1.7 mL, 21.3 mmol, 4 eq.) at 0°C and the reaction solution was gradually heated to room temperature. After 12 h, the reaction solution was diluted with saturated aqueous sodium bicarbonate (50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated. The resulting crude material was purified by silica gel column chromatography to give 4-(3-(trans-4-(3-bromopropoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (5.0 g, 9.4 mmol, 88% yield) as a light yellow oil. MS (ESI) m / z 534.1 [M+1] + ; 1H NMR (400MHz, CDCl3) δ7.95(d,J=8.4Hz,1H),7.84(d,J=2.0Hz,1H),7.74-7.71(m,1H),3.71-3.61(m,1H),3.60-3.53(m,2H),3.52(t,J=6.4 Hz,2H),3.35-3.32(m,1H),2.21(d,J=12.0Hz,2H),2.19-2.05(m,2H),1.83(d,J=12.0Hz,2H),1.65(s,2H),1.60(s,6H),1.35-1.32(m,2H).

[0391] 2-((2R,6S)-4-(3-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To a solution of 2-((2R,6S)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.158 g, 0.420 mmol, 1.5 eq.) in N,N-dimethylformamide (3 mL, 0.01 M) was added N,N-diisopropylethylamine (0.15 mL, 0.85 mmol, 3 eq.). The reaction mixture was stirred at 50 °C. After 12 h, the reaction solution was diluted with water (50 mL) and the aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by standard methods to afford 2-((2R,6S)-4-(3-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.058 g, 0.069 mmol, 25% yield) as a yellow solid. MS (ESI) m / z 825.3 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ10.79(s,1H),8.34(d,J=8.3Hz,1H),8.19(d,J=1.4Hz,1H),7.97(dd ,J=1.6,8.3Hz,1H),7.12-6.94(m,2H),6.87(d,J=6.3Hz,1H),6.48(d,J=5.3Hz,1H),4.37-4 .24(m,4H),3.96-3.61(m,4H),3.51(t,J=5.7Hz,2H),3.26(t,J=10.6Hz,2H),3.12(s,2H),2 .84-2.56(m,4H),2.09-1.84(m,6H),1.72(d,J=10.6Hz,2H),1.55(s,6H),1.41-1.23(m,8H).

[0392] Example 13: 2-((2R,6S)-4-(3-(trans-4-(3-(5-chloro-6-cyanopyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0393]

[0394] 3-Chloro-5-(3-(trans-4-(3-hydroxypropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)picolinonitrile. To a mixture of methyl 3-chloro-5-isothiocyanato-pyridine-2-carbonitrile (1.600 g, 8.18 mmol, 1 eq.) and methyl 2-((trans-4-(3-hydroxypropyl)cyclohexyl)amino)-2-methylpropanoate (2.320 g, 9 mmol, 1.1 eq.) in ethyl acetate (100 mL) was added triethylamine (2.28 mL, 16.36 mmol, 2 eq.) and the reaction solution was stirred at 90 °C. After 6 h, the reaction solution was concentrated and purified by silica gel column chromatography (10%-100% ethyl acetate in petroleum ether) to give 3-chloro-5-(3-(trans-4-(3-hydroxypropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)picolinonitrile (2.000 g, 4.75 mmol, 58% yield) as a yellow solid. MS (ESI) m / z 421.2 [M+1] + ; 1H NMR (400MHz, CDCl3) δ8.67-8.50(m,1H),7.98-7.83(m,1H),3.80-3.48(m,4H),2.75-2. 52(m,2H),1.93-1.60(m,6H),1.51-1.28(m,3H),1.27-1.15(m,5H),1.06-0.89(m,3H).

[0395] 5-(3-(trans-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-chloropicolinonitrile. To a solution of 3-chloro-5-(3-(trans-4-(3-hydroxypropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)picolinonitrile (2.000 g, 4.75 mmol, 1 eq.) in dichloromethane (5 mL, 0.1 M) and N,N-dimethylformamide (0.50 mL) was added thionyl bromide (0.61 mL, 9.5 mmol, 2 eq.) at 0°C. The reaction solution was stirred at 25°C. After 16 h, the pH of the reaction solution was adjusted to 8 by adding saturated sodium carbonate. The aqueous phase was extracted with ethyl acetate (100 mL×2). The combined organic layers were washed with brine (25 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by silica gel column chromatography (50%-100% ethyl acetate in petroleum ether) to give 5-(3-(trans-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-chloropicolinonitrile (1.600 g, 3.31 mmol, 70% yield) as a red solid. MS (ESI) m / z 483.1 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ8.73-8.50(m,1H),7.98-7.82(m,1H),3.78-3.65(m,1H),3. 37-3.29(m,2H),2.77-2.49(m,2H),1.93-1.80(m,4H),1.57-1.52(m,6H),1.30(br t,J=5.6Hz,3H),1.08-0.97(m,2H).

[0396] 2-((2R,6S)-4-(3-(trans-4-(3-(5-chloro-6-cyanopyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. Under nitrogen, 5-(3-(trans-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl) To a solution of -3-chloropicolinonitrile (0.100 g, 0.210 mmol, 1 eq.) and 2-((2S,6R)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrobromide (0.141 g, 0.310 mmol, 1.5 eq.) in N,N-dimethylformamide (3 mL, 0.07 M) was added N,N-diisopropylethylamine (0.18 mL, 1.03 mmol, 5 eq.) in one portion. The mixture was stirred at 50 °C. After 12 h, the reaction mixture was diluted with water (80 mL) and extracted with ethyl acetate (4 x 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by standard methods to give 2-((2R,6S)-4-(3-(trans-4-(3-(5-chloro-6-cyanopyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.073 g, 0.094 mmol, 45% yield) as a yellow solid. MS (ESI) m / z 776.4 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ12.24-11.28(m,1H),10.79(s,1H),10.43(br s,1H),8.82(d,J=2.0Hz,1H),8.53(d,J=2.0Hz,1H),7.08-7.01(m,1H),7.08-7.01(m,1H),7.08-7.01(m,1H),6.98(s,1H),6.85(br d,J=7.9Hz,1H),6.47(br d,J=9.8Hz,1H),4.27(br dd,J=4.8,11.3Hz,1H),4.23-4.14(m,2H),3.75(br s,6H),3.21(br s,2H),3.05(br s,2H),2.74(ddd,J=5.3,12.0,17.4Hz,3H),2.64-2.55(m,1H),2.09(td,J=4.3,8.7Hz,1H),1.97-1.66(m,7H),1.55(s,6H),1.34(br s, 6H), 1.22 (br s, 3H), 1.09 (q, J = 11.0Hz, 2H).

[0397] Example 14: 2-((2S,6R)-4-(3-(trans-4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0398]

[0399] 2-Chloro-4-(3-(trans-4-(3-hydroxypropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile. To a solution of methyl 2-((trans-4-(3-hydroxypropyl)cyclohexyl)amino)-2-methylpropanoate (1.31 g, 5.1 mmol, 1 eq) and 2-chloro-4-cyanophenylisothiocyanate (1.08 g, 5.57 mmol, 1.1 eq) in ethyl acetate (25 mL) was added N,N-diisopropylethylamine (2.51 mL, 15.18 mmol, 3 eq) and the reaction mixture was stirred at 80 °C. After 18 h, the reaction solution was concentrated and purified by column chromatography (15%-50% ethyl acetate in petroleum ether) to give 2-chloro-4-(3-(trans-4-(3-hydroxypropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile (1.26 g, 3.01 mmol, 59% yield) as a brown oil. MS (ESI) m / z 420.1 [M+1] + .

[0400] 4-(3-(trans-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-chlorobenzonitrile. To a solution of 2-chloro-4-(3-(trans-4-(3-hydroxypropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile (1.26 g, 3.01 mmol) in N,N-dimethylformamide (0.30 mL) and dichloromethane (3 mL) was slowly added thionyl bromide (1.88 g, 9.03 mmol, 3 equiv) at 0 °C. After 12 h, the reaction solution was concentrated under reduced pressure and purified by silica gel column chromatography (15%-30% ethyl acetate in petroleum ether) to give 4-(3-(trans-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-chlorobenzonitrile (1.21 g, 2.50 mmol, 83% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ7.79(d,J=8.4Hz,1H),7.58(d,J=2.0Hz,1H),7.42(dd,J=8.4,2.0Hz,1H),3.87(m,1H) ,3.43(t,J=6.8Hz,2H),2.70(s,2H),1.94-1.82(m,6H),1.59(s,6H),1.39-1.36(m,3H),1.12-1.03(m,2H).

[0401] 2-((2S,6R)-4-(3-(trans-4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. Under nitrogen, 4-(3-(trans-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl) To a solution of 2-((2S,6R)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrobromide (0.141 g, 0.310 mmol, 1.5 equiv) in N,N-dimethylformamide (4 mL) was added N,N-diisopropylethylamine (0.18 mL, 1.04 mmol, 5 equiv) in one portion. The mixture was stirred at 50 °C for 6 h. The reaction mixture was diluted with water (80 mL) and extracted with ethyl acetate (4 x 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by standard methods to give 2-((2S,6R)-4-(3-(trans-4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.083 g, 0.106 mmol, 51% yield) as a yellow solid. MS (ESI) m / z 775.6 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ12.30-11.70(m,1H),10.80(s,1H),10.59(br s,1H),8.13(d,J=8.3Hz,1H),7.92(d,J=1.8Hz,1H),7.61(dd,J=1.9,8.4Hz,1H),7.09-7.02(m,1H),7.00(s,1H),6.87(br d,J=7.7Hz,1H),6.48(dd,J=1.5,8.2Hz,1H),4.28(br dd,J=4.8,11.3Hz,1H),4.01-3.58(m,7H),3.27(brs,2H),3.05(br s,2H),2.84-2.65(m,3H),2.64-2.55(m,1H),2.09(td,J=4.3,8.7Hz,1H),1.97-1.88(m,1H),1.87-1.67(m,6H),1.53(s,6H),1.37(br d,J=4.4Hz,6H),1.22(br s,3H),1.15-1.02(m,2H).

[0402] Example 15: 2-((2R,4s,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0403]

[0404] (2S,6R)-1-Benzyl-2,6-dimethylpiperidin-4-one. To a solution of 3-oxoglutaric acid (100.0 g, 684.5 mmol, 1 eq) in water (200 mL) was added acetaldehyde (150.8 g, 1368.9 mmol, 2 eq) at 20°C. The reaction was stirred at 20°C for 20 min, then cooled to 0°C and benzylamine (74.61 mL, 684.5 mmol, 1 eq) was added dropwise. The reaction solution was heated to room temperature and stirred for 48 h. The reaction solution was extracted with ethyl acetate 3000 mL (1000 mL×3) and the combined organic layers were washed with brine 500 mL. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by silica gel column chromatography to give (2S,6R)-1-benzyl-2,6-dimethylpiperidin-4-one (27.70 g, 127.5 mmol, 19% yield) as a yellow oil. 1H NMR (400MHz, CDCl3) δ7.42 (d, J = 7.2Hz, 2H), 7.37-7.29 (m, 2H), 7.27-7.20 (m, 1H), 3.8 6(s,2H),3.17-3.09(qd,J=6.4,13.2Hz,2H),2.42-2.28(m,4H),1.16(d,J=6.4Hz,6H).

[0405] Ethyl 2-((2R,6S)-1-benzyl-2,6-dimethylpiperidin-4-ylidene)acetate. To a solution of sodium hydride (8.283 g, 207.1 mmol, 1.5 eq.) in THF (50 mL) at 0°C, ethyl 2-(diethoxyphosphoryl)acetate (40.23 g, 179.5 mmol, 1.3 eq.) in THF (100 mL) was added dropwise. The mixture was stirred at 0°C for 30 min. (2S,6R)-1-benzyl-2,6-dimethylpiperidin-4-one (30.00 g, 138.1 mmol, 1 eq.) in THF (200 mL) was added dropwise to the above solution and the reaction solution was heated to room temperature. After 12 h, the reaction solution was neutralized by adding saturated ammonium chloride solution and poured into ice water (200 mL). The aqueous phase was extracted with ethyl acetate (3x 500mL). The combined organic layers were washed with brine (300mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by flash silica gel chromatography (2.0% ethyl acetate in petroleum ether) (petroleum ether: ethyl acetate = 3: 1, Rf: 0.65), and then purified again by semi-preparative reverse phase HPLC (55%-85% acetonitrile + 0.05% ammonium hydroxide in water, over 20min). The collected fractions were concentrated, and the aqueous phase was extracted with ethyl acetate (3x 500mL). The combined organic layers were washed with brine (300mL), dried over anhydrous sodium sulfate, filtered and concentrated to give ethyl 2-((2R, 6S)-1-benzyl-2,6-dimethylpiperidin-4-ylidene) acetate (11.7g, 40.7mmol, 30% yield) as a yellow oil. MS (ESI) m / z 288.2 [M+1] + ; 1H NMR (400MHz, CDCl3) δ7.45-7.35(m,2H),7.30(t,J=7.6Hz,2H),7.26-7.16(m,1H),5.63(s,1H),4.15(q,J=7.2Hz,2H),3.82( s,2H),3.57(dd,J=2.8,14.0Hz,1H),2.84-2.62(m,2H),2.29-2.08(m,3H),1.33-1.23(m,3H),1.14(dd,J=6.4,16.4Hz,6H).

[0406] Tert-butyl (2S,6R)-4-(2-ethoxy-2-oxoethyl)-2,6-dimethylpiperidin-1-carboxylate. To a solution of ethyl 2-((2R,6S)-1-benzyl-2,6-dimethylpiperidin-4-ylidene)acetate (5.300 g, 18.44 mmol, 1 eq) and di-tert-butyl dicarbonate (6.037 g, 27.66 mmol, 1.5 eq) in THF (80 mL, 0.23 M) was added 10% palladium on carbon (1.500 g, 1.84 mmol, 10 mol%) under nitrogen. The reaction mixture was stirred at room temperature for 12 h under hydrogen (50 psi). The reaction mixture was filtered and concentrated to give a residue, which was purified by flash silica gel chromatography (1% ethyl acetate in petroleum ether, petroleum ether:ethyl acetate=5:1) to give tert-butyl (2S,6R)-4-(2-ethoxy-2-oxoethyl)-2,6-dimethylpiperidine-1-carboxylate (2.630 g, 8.784 mmol, 48% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ4.26(s,1H),4.21(m,1H),4.17-4.10(m,2H),2.26-2.18(m,2H),2.13-2.05(m,1H),1.99-1.84 (m,1H),1.66-1.55(m,1H),1.47(s,9H),1.36-1.29(m,1H),1.29-1.25(m,3H),1.24-1.19(m,6H),1.15-1.02(m,2H).

[0407] Tert-butyl (2S, 6R) -4- (2-hydroxyethyl) -2,6- dimethylpiperidine -1- carboxylate. To a solution of lithium aluminum hydride (0.500 g, 13.18 mmol, 1.5 equiv) in THF (10 mL) was added a solution of tert-butyl (2S, 6R) -4- (2-ethoxy-2-oxoethyl) -2,6- dimethylpiperidine -1- carboxylate (2.630 g, 8.780 mmol, 1 equiv) in THF (40 mL) at 0 ° C. The reaction solution was slowly heated to room temperature over 1 h. The reaction solution was quenched by adding water 0.5 mL, 15% sodium hydroxide solution (1 mL) and water 1.5 mL. The slurry was stirred for 0.5 h, filtered and concentrated in vacuo. The crude material was diluted with water 100 mL and extracted with ethyl acetate 100 mL × 3. The combined organic layers were washed with brine 100 mL, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (20% ethyl acetate in petroleum ether) to provide tert-butyl (2S, 6R) -4- (2-hydroxyethyl) -2,6- dimethylpiperidine-1-carboxylate (2.180 g, 8.470 mmol, 96% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ4.40-4.25(m,1H),4.24-4.07(m,1H),3.77-3.65(m,2H),2.12-2.03(m,1H),1.68 -1.56(m,2H),1.55-1.49(m,2H),1.49-1.42(m,9H),1.33-1.26(m,1H),1.25-1.17(m,6H),1.05(m,1H).

[0408] Tert-butyl (2S, 6R) -4- (2-bromoethyl) -2,6- dimethylpiperidine -1- carboxylate. To a solution of tert-butyl (2S, 6R) -4- (2-hydroxyethyl) -2,6- dimethylpiperidine -1- carboxylate (2.180 g, 8.470 mmol, 1 eq) and triphenylphosphine (3.332 g, 12.71 mmol, 1.5 eq) in dichloromethane (40 mL, 0.21 M). To the reaction solution at 0 ° C, carbon tetrabromide (4.214 g, 12.71 mmol, 1.5 eq) was added. The reaction mixture was slowly heated to room temperature. After 2 h, the reaction solution was poured into a saturated sodium bicarbonate solution (100 mL) and the aqueous phase was extracted with dichloromethane (3 x 100 mL). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by silica gel chromatography (1% ethyl acetate in petroleum ether) to afford tert-butyl (2S,6R)-4-(2-bromoethyl)-2,6-dimethylpiperidine-1-carboxylate (2.160 g, 6.744 mmol, 80% yield) as a clear colorless oil. 1 H NMR (400MHz, CDCl3) δ4.45-4.27(m,1H),4.26-4.06(m,1H),3.51-3.29(m,2H),2.18-1.96(m,2H),1.89-1. 75(m,2H),1.73-1.53(m,2H),1.48-1.39(m,9H),1.33-1.25(m,1H),1.24-1.19(m,6H),1.13-0.97(m,1H).

[0409] Tert-butyl (2R,6S)-4-(2-((trans-4-(dibenzylamino)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate. To a solution of trans-4-(dibenzylamino)cyclohexanol (12.18 g, 41.22 mmol, 2 eq) and tert-butyl (2S,6R)-4-(2-bromoethyl)-2,6-dimethylpiperidine-1-carboxylate (6.600 g, 20.61 mmol, 1 eq) in xylene (120 mL, 0.17 M) was added potassium hydroxide (5.318 g, 94.80 mmol, 4.6 eq) and tetrabutylammonium bromide (1.328 g, 4.120 mmol, 0.2 eq). The reaction was stirred at 30 °C. After 24h, the reaction solution was diluted with water (200mL) and extracted with ethyl acetate (3x 250mL). The combined organic layer was washed with brine (150mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by flash silica gel column chromatography (2.5%-3% ethyl acetate in petroleum ether) to provide tert-butyl (2R, 6S) -4- (2- ((trans-4- (dibenzylamino) cyclohexyl) oxy) ethyl) -2,6- dimethylpiperidine -1- carboxylate (2.800g, 5.236mmol, 25% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ7.42-7.33(m,4H),7.33-7.27(m,4H),7.24-7.17(m,2H),4.36-4.23(m,2H),4.22 -4.15(m,1H),3.62(s,4H),3.48(t,J=6.4Hz,1H),3.45-3.37(m,1H),3.19-3.06(m,1H),2.53(m,1H),2 .09-2.04(m,3H),2.01-1.86(m,3H),1.63-1.59(m,1H),1.57-1.51(m,2H),1.47-1.46(m,9H),1.43-1. 33(m,2H),1.28-1.24(m,2H),1.21(s,2H),1.17(d,J=7.0Hz,6H),1.14-1.08(m,1H),1.07-0.92(m,1H).

[0410] Tert-butyl (2R,6S)-4-(2-((trans-4-aminocyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate. To a solution of tert-butyl (2R,6S)-4-(2-((trans-4-(dibenzylamino)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate (2.800 g, 5.240 mmol, 1 eq) in methanol (60 mL) was added palladium on carbon (2.000 g) under nitrogen. The reaction was stirred at room temperature under hydrogen (15 psi) for 12 h. The reaction mixture was filtered and concentrated to give tert-butyl (2R,6S)-4-(2-((trans-4-aminocyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate (1.837 g, 5.180 mmol, 98% yield) as a yellow oil which was carried forward without further purification. 1 H NMR (400MHz, DMSO-d6) δ4.23-4.08(m,2H),4.08-3.93(m,1H),3.50-3.40(m,2H),3.40-3.33(m,1H),3.18-3.04(m,1H),2.55-2.51(m,2H),2.49(br s,1H),2.05-1.83(m,4H),1.82-1.68(m,2H),1.67-1.47(m,2H),1.46- 1.32(m,16H),1.29-1.15(m,2H),1.15-1.07(m,9H),1.07-0.87(m,3H).

[0411] Tert-butyl (2S,6R)-4-(2-((trans-4-((1-methoxy-2-methyl-1-oxopropan-2-yl)amino)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate. To a solution of tert-butyl (2R,6S)-4-(2-((trans-4-aminocyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate (1.837 g, 5.180 mmol, 1 eq) in acetonitrile (10 mL, 0.5 M) was added potassium iodide (0.086 g, 0.520 mmol, 10 mol%), potassium carbonate (2.148 g, 15.54 mmol, 3 eq) and methyl 2-bromo-2-methylpropanoate (3.75 mL, 25.91 mmol, 5 eq). The reaction was stirred at 110 °C. After 48 h, the reaction solution was filtered and concentrated to give tert-butyl (2S,6R)-4-(2-((trans-4-((1-methoxy-2-methyl-1-oxopropan-2-yl)amino)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate (2.400 g, 5.279 mmol, crude) as a yellow oil, which was used further without further purification. MS (ESI) m / z 455.5 [M+1] + .

[0412] tert-Butyl (2R,4s,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-carboxylate and tert-Butyl (2R,4r,6S)-4-(2-(((1r,4R)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-carboxylate To a solution of tert-butyl (2S,6R)-4-(2-((trans-4-((1-methoxy-2-methyl-1-oxopropan-2-yl)amino)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate (2.160 g, 4.750 mmol, 1 eq) and 4-isothiocyanato-2-(trifluoromethyl)benzonitrile (1.084 g, 4.750 mmol, 1 eq) in ethyl acetate (10 mL, 0.47 M) was added N,N-diisopropylethylamine (1.660 mL, 9.500 mmol, 2 eq). The reaction was stirred at 90 °C. After 12 h, the reaction solution was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by flash silica gel column chromatography to give a diastereomeric mixture, which was separated by SFC (DAICEL CHIRAL PAK IG: 250mm*30mm.10um, 20% methanol + 0.1% NH3.H2O) to give tert-butyl (2R,4s,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate (1.060 g, 1.629 mmol, 34% yield) and tert-butyl (2R,4r,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate (0.360 g, 0.553 mmol, 12% yield). Tert-butyl (2R, 4s, 6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate: 1H NMR (400MHz, CDCl3) δ7.95(d,J=8.0Hz,1H),7.85(d,J=2.0Hz,1H),7.72(dd,J=2.0,8.0Hz,1H),4.38- 4.22(m,2H),3.72-3.59(m,1H),3.54(t,J=6.4Hz,2H),3.37-3.24(m,1H),3.03-2.75(m,2H),2.21(br d, J = 12.4 Hz, 2H), 2.03-1.90 (m, 1H), 1.89-1.77 (m, 2H), 1.61 (s, 6H), 1.58 (m, 2H), 1.54-1.48 (m, 2H), 1.47 (s, 9H), 1.40-1.26 (m, 4H), 1.19 (d, J = 7.2 Hz, 6H). Tert-butyl (2R, 4r, 6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate: 1 H NMR (400MHz, CDCl3) δ7.95(d,J=8.4Hz,1H),7.85(d,J=2.0Hz,1H),7.72(dd,J=2.0,8.4Hz,1H),4. 28-4.10(m,2H),3.76-3.58(m,1H),3.49(t,J=6.0Hz,2H),3.30(m,1H),3.03-2.76(m,2H),2.19(br d,J=12.0Hz,2H),2.12-1.98(m,2H),1.89-1.76(m,2H),1.61(s,6H),1.52(br t,J=6.4Hz,2H),1.47(s,9H),1.40-1.25(m,3H),1.22(d,J=6.8Hz,6H),1.03(m,2H).

[0413]

[0136] 4-(3-(trans-4-(2-((2R,4s,6S)-2,6-dimethylpiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a solution of tert-butyl (2R,4s,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate (1.060 g, 1.630 mmol, 1 equiv) in dichloromethane (5 mL) was added 4 M hydrochloric acid in 1,4-dioxane (20 mL, 80.00 mmol), and the reaction solution was stirred at room temperature. After 2h, the reaction solution was concentrated. The resulting yellow solid was absorbed in saturated aqueous sodium bicarbonate (50mL) and extracted with ethyl acetate (3x100mL). The combined organic layer was washed with brine (50mL), dried over anhydrous sodium sulfate and concentrated to provide 4-(3-(trans-4-(2-((2R, 4s, 6S)-2,6-dimethylpiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (0.920g, 1.67mmol, 99% yield) as a yellow solid, which was used without further purification. MS (ESI) m / z 551.4[M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.95 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 2.0 Hz, 1H), 7.72 (dd, J = 2.0, 8. 0Hz,1H),3.74-3.59(m,1H),3.51(t,J=6.8Hz,2H),3.31(m,1H),2.92(m,4H),2.20(br d,J=12.0Hz,2H),2.02-1.92(m,1H),1.82(br d,J=12.0Hz,2H),1.70(q,J=6.8Hz,2H),1.64-1.56(s,6H),1.51(br d,J=12.8Hz,2H),1.40-1.27(m,4H),1.09(br d,J=6.0Hz,6H).

[0414] 2-Chloro-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)acetamide. To a solution of 3-(7-amino-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione (1.000 g, 3.870 mmol, 1 eq) in dichloromethane (20 mL, 0.2 M) was added triethylamine (1.62 mL, 11.62 mmol, 3 eq) and 2-chloroacetyl chloride (0.46 mL, 5.810 mmol, 1.5 eq) in one portion at 0° C. under nitrogen. After 2 h, the reaction solution was diluted with water (150 mL) and extracted with ethyl acetate (4 x 40 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by flash silica gel column chromatography (0-100% ethyl acetate in dichloromethane) to afford 2-chloro-N-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-7-yl)acetamide (0.750 g, 2.240 mmol, 58% yield) as a grey solid. MS (ESI) m / z 335.1 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.91 (s, 1H), 10.27 (s, 1H), 7.65 (d, J = 7.6Hz, 1H), 7.18-7.08 (m, 2H), 4 .39(s,2H),4.21(m,1H),4.06(s,3H),2.71-2.61(m,2H),2.43-2.32(m,1H),2.21-2.14(m,1H).

[0415] 2-((2R,4s,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To a solution of 2-(((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.081 g, 0.270 mmol, 1.5 eq.) in N,N-dimethylformamide (2 mL, 0.1 M) was added N,N-diisopropylethylamine (0.16 mL, 0.910 mmol, 5 eq.) and sodium iodide (0.027 g, 0.180 mmol, 1 eq.). The reaction was stirred at 80 °C. After 13 h, the reaction solution was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated. The crude material was purified by standard methods to give 2-((2R,4s,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.081 g, 0.099 mmol, 55% yield) as a yellow solid. MS (ESI) m / z 810.3 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ10.91 (s, 1H), 10.80 (d, J = 4.0Hz, 1H), 10.60 (s, 1H), 10.17-9.89 (m, 1H), 9.04 (br s,1H),8.33(d,J=8.0Hz,1H),8.19(d,J=1.6Hz,1H),7.96(dd,J=1.6,8.0Hz,1H),7.12-6.95(m,2H) ,6.86(t,J=6.8Hz,1H),6.56-6.39(m,1H),4.27(dd,J=5.2,11.6Hz,1H),4.23-4.18(m,1H),4.15(br d,J=3.6Hz,1H),3.81-3.68(m,3H),3.62-3.54(m,1H),3.48(br t,J=6.0Hz,2H),3.22(m,1H),2.94-2.75(m,2H),2.75-2.68(m,1H),2.65-2.54(m,1H),2.15-2.01(m,3H),2.01-1 .84(m,3H),1.79-1.60(m,6H),1.54(d,J=1.2Hz,6H),1.39-1.33(m,3H),1.33-1.23(m,2H),1.19(d,J=6.4Hz,3H).

[0416] Example 16: 2-((2R,4r,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0417]

[0418]

[0136] 4-(3-(trans-4-(2-((2R,4r,6S)-2,6-dimethylpiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a solution of tert-butyl (2R,4r,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate (0.360 g, 0.550 mmol, 1 eq) in dichloromethane (3 mL, 0.12 M) was added 4 M hydrochloric acid in 1,4-dioxane (12 mL, 48 mmol), and the reaction solution was stirred at 15°C. After 14h, the reaction solution was concentrated. The obtained solid was diluted to pH 8-9 with saturated bicarbonate solution (20mL) and the aqueous layer was extracted with ethyl acetate (3x 50mL). The combined organic layer was washed with brine (30mL), dried over anhydrous sodium sulfate and concentrated to give 4-(3-(trans-4-(2-((2R, 4r, 6S)-2,6-dimethylpiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidine-1-yl)-2-(trifluoromethyl)benzonitrile (0.330g, 0.56mmol) as a yellow solid, which was continued without further purification. MS (ESI) m / z 551.4[M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.95(d,J=8.4Hz,1H),7.84(d,J=2.0Hz,1H),7.72(dd,J=2.0,8.4Hz,1H),3.73-3.59(m ,1H),3.52(t,J=6.4Hz,2H),3.30(m,1H),3.03-2.80(m,2H),2.74(m,2H),2.20(brd,J=12.4Hz,2H),1.82(br d,J=11.6Hz,2H),1.68(br d,J=13.2Hz,2H),1.61(s,6H),1.54-1.48(m,2H),1.41-1.27(m,3H),1.14(br d,J=6.4Hz,6H),0.92-0.76(m,2H).

[0419] 2-((2R,4r,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To a solution of 2-(((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.048 g, 0.160 mmol, 1.5 eq.) in N,N-dimethylformamide (1 mL, 0.11 M) was added N,N-diisopropylethylamine (0.09 mL, 0.540 mmol, 5 eq.) and sodium iodide (0.016 g, 0.110 mmol, 1 eq.). The reaction was stirred at 80 °C. After 12 h, the reaction solution was diluted with water (30 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated. The crude material was purified by standard methods to give 2-((2R,4r,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.041 g, 0.0498 mmol, 46% yield). MS (ESI) m / z 810.3 [M+1] + ; 1HNMR(400MHz,DMSO-d6)δ10.77(s,1H),10.67-10.31(m,1H),9.67-9.38(m,1H),9.06(br s,1H),8.33(d,J=8.4Hz,1H),8.18(s,1H),7.96(dd,J=1.6,8.4Hz,1H),7.10-7.00(m,1H),6.99-6.89(m,1H),6.83(br d,J=8.0Hz,1H),6.47(m,1H),4.30-4.22(m,1H),4.21-4.15(m,1H),4.0 9-4.02(m,1H),3.90-3.79(m,2H),3.53-3.42(m,4H),3.28-3.17(m,1H) ,2.90-2.68(m,3H),2.65-2.56(m,1H),2.15-2.00(m,3H),1.99-1.79(m ,3H),1.78-1.64(m,3H),1.58-1.50(m,6H),1.49-1.36(m,3H),1.34(br d,J=5.2Hz,3H),1.30-1.22(m,1H),1.20(d,J=6.4Hz,3H),1.15-1.06(m,1H).

[0420] Example 17: 2-((2R,6S)-4-(4-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)butyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0421]

[0422] Tert-butyl (trans-4-(2-(methoxy(methyl)amino)-2-oxoethyl)cyclohexyl)carbamate. To a solution of 2-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)acetic acid (2.000 g, 7.770 mmol, 1 eq) and N,O-dimethylhydroxylamine hydrochloride (0.830 g, 8.550 mmol, 1.1 eq) in N,N-dimethylformamide (20 mL, 0.38 M) were added N,N-diisopropylethylamine (6.94 mL, 38.86 mmol) and HATU (4.430 g, 11.66 mmol, 5 eq) and the reaction solution was stirred at room temperature. After 12 h, the reaction solution was diluted with water (100 mL) and extracted with ethyl acetate (2 x 60 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated. The crude material obtained was purified by silica gel column chromatography (0-30% ethyl acetate in petroleum ether) to give tert-butyl (trans-4-(2-(methoxy(methyl)amino)-2-oxoethyl)cyclohexyl)carbamate (2.200 g, 7.323 mmol, 94% yield) as a white solid. 1 H NMR (400MHz, CDCl3) δ4.41(s,1H),3.66(s,3H),3.37(s,1H),3.17(s,3H),2.31-2.29( d,J=6.4Hz,2H),2.04-1.97(m,2H),1.85-1.79(m,3H),1.43(s,9H),1.18-1.02(m,4H).

[0423] Tert-butyl (trans-4-(2-oxoethyl) cyclohexyl) carbamate. To a solution of tert-butyl (trans-4-(2-(methoxy(methyl)amino)-2-oxoethyl) cyclohexyl) carbamate (2.2 g, 7.320 mmol, 1 eq) in dichloromethane (10 mL) was added 70% sodium bis(2-methoxyethoxy)aluminum hydride in toluene (4.08 mL, 14.65 mmol, 2 eq) at 0°C. After stirring for 2 h, the reaction solution was diluted with water (20 mL) and saturated aqueous ammonium chloride (10 mL). The solution was extracted with dichloromethane (3 x 30 mL), and the combined organic layers were dried over anhydrous sodium sulfate and concentrated. The resulting crude oil was purified by silica gel column chromatography (0-25% ethyl acetate in petroleum ether) to give tert-butyl (trans-4-(2-oxoethyl)cyclohexyl)carbamate (1.450 g, 6.008 mmol, 82% yield) as a white solid. 1H NMR(400MHz, CDCl3)δ9.65-9.64(t,J=2.0Hz,1H),6.69-6.64(m,1H),3.19-3.13(m,1H),2.55-2.5 2(m,1H),2.29-2.27(m,2H),1.75-1.64(m,5H),1.36(s,9H),1.17-1.08(m,2H),1.06-0.83(m,2H).

[0424] Ethyl (E)-4-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)but-2-enoate. To a solution of tert-butyl (trans-4-(2-oxoethyl)cyclohexyl)carbamate (1.450 g, 6.010 mmol, 1 eq) in toluene (10 mL, 0.6 M) was added ethyl 2-(triphenylphosphinylidene)acetate (2.300 g, 6.610 mmol, 1.1 eq) and the reaction mixture was stirred at 80° C. After 12 h, the reaction solution was concentrated and the resulting crude material was purified by silica gel column chromatography (0-20% ethyl acetate in hexanes) to give ethyl (E)-4-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)but-2-enoate (0.890 g, 2.858 mmol, 48% yield) as a white solid. 1 H NMR (400MHz, CDCl3) δ6.95-6.88(m,1H),5.82-5.78(m,1H),4.36(s,1H),4.24-4.14(m,2H),3.37(s,1H),2.12-2.0 8(m,2H),2.05-1.99(m,2H),1.79-1.76(m,2H),1.46-1.36(m,10H),1.31-1.27(t,J=7.2Hz,3H),1.13-0.99(m,4H).

[0425] Tert-butyl (trans-4-(4-hydroxybutyl)cyclohexyl)carbamate. To a solution of sodium borohydride (0.811 g, 21.43 mmol, 7.5 eq.) in ethanol (16 mL) and THF (16 mL) at 0°C was added anhydrous lithium chloride (0.900 g, 21.43 mmol, 7.5 eq.) and the solution was stirred for 10 min. To the reaction solution was added a solution of ethyl (E)-4-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)but-2-enoate (0.890.g, 2.860 mmol, 1 eq.) in THF (8 mL) and the reaction solution was stirred at 15°C. After 12 h, the reaction solution was quenched by slowly adding 1 M aqueous hydrochloric acid solution (10 mL) and the solution was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, concentrated and purified by silica gel column chromatography (0-25% ethyl acetate in hexanes) to give tert-butyl (trans-4-(4-hydroxybutyl)cyclohexyl)carbamate (0.750 g, 2.763 mmol, 96% yield) as a white solid. 1 H NMR (400MHz, CDCl3) δ4.37 (s, 1H), 3.66-3.62 (t, J = 6.8Hz, 2H), 3.36 (s, 1H), 2.00-1.98 (m, 2H), 1.78- 1.75(m,2H),1.58-1.51(m,2H),1.44(s,9H),1.40-1.32(m,2H),1.28-1.14(m,4H),1.08-0.94(m,4H).

[0426] 4-(trans-4-aminocyclohexyl)butan-1-ol. To a solution of tert-butyl(trans-4-(4-hydroxybutyl)cyclohexyl)carbamate (0.750.g, 2.760mmol, 1 eq) in dichloromethane (2mL) was added 4M hydrochloric acid in 1,4-dioxane (4mL, 16mmol, 5.8 eq) and the reaction solution was stirred at room temperature. After 12h, the reaction solution was concentrated to remove the organic solvent, then diluted with saturated sodium bicarbonate (30mL) and extracted with ethyl acetate (2x 30mL). The combined organic layers were washed with brine (30mL), dried over anhydrous sodium sulfate and concentrated to give 4-(trans-4-aminocyclohexyl)butan-1-ol (0.410g, 2.394mmol, 87% yield) as a white solid, which was used without further purification. 1H NMR (400MHz, CDCl3) δ3.62-3.59(t,J=6.4Hz,2H),2.61-2.54(m,1H),1.85-1.81(m,2H),1.75-1.72(m ,2H),1.56-1.49(m,4H),1.39-1.31(m,2H),1.25-1.12(m,3H),1.10-1.00(m,2H),0.97-0.87(m,2H).

[0427] Methyl 2-((trans-4-(4-hydroxybutyl)cyclohexyl)amino)-2-methylpropanoate. To a solution of methyl 2-bromo-2-methylpropanoate (1.733 g, 9.570 mmol, 4 eq.) and 4-(trans-4-aminocyclohexyl)butan-1-ol (0.410. g, 2.390 mmol, 1 eq.) in acetonitrile (3 mL) were added potassium carbonate (0.993 g, 7.180 mmol, 3 eq.) and sodium iodide (0.072 g, 0.480 mmol, 0.2 eq.) and the reaction solution was stirred at 80° C. After 12 h, the reaction solution was diluted with ethyl acetate, filtered and concentrated to give crude methyl 2-((trans-4-(4-hydroxybutyl)cyclohexyl)amino)-2-methylpropanoate (1.000 g, crude) as a brown oil. MS (ESI) m / z 272.3 [M+1] + .

[0428] 4-(3-(trans-4-(4-hydroxybutyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a solution of methyl 2-((trans-4-(4-hydroxybutyl)cyclohexyl)amino)-2-methylpropanoate (1.000.g, 2.320mmol, 1 eq) and 4-isothiocyanato-2-(trifluoromethyl)benzonitrile (0.556g, 2.440mmol, 1.1 eq) in ethyl acetate (12 mL) was added N,N-diisopropylethylamine (1.15 mL, 6.960mmol, 3 eq) and the reaction mixture was stirred at 80° C. After 3 h, the reaction solution was diluted with ethyl acetate (20 mL) and concentrated. The resulting crude oil was purified by silica gel column chromatography (0-35% ethyl acetate in petroleum ether) to give 4-(3-(trans-4-(4-hydroxybutyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (0.360 g, 0.736 mmol, 32% yield) as a brown solid. MS (ESI) m / z 468.1 [M+1] + .

[0429] 4-(3-(trans-4-(4-bromobutyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile. To a solution of 4-(3-(trans-4-(4-hydroxybutyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (0.360.g, 0.770mmol, 1 eq) in dichloromethane (3 mL) were added N,N-dimethylformamide (0.30 mL) and thionyl bromide (0.400 g, 1.920mmol, 2.5 eq) and the reaction solution was stirred at 15 °C. After 12 h, the reaction solution was concentrated and purified by silica gel column chromatography (0-20% ethyl acetate in petroleum ether) to give 4-(3-(trans-4-(4-bromobutyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (0.280 g, 0.517 mmol, 67% yield) as a brown solid. MS (ESI) m / z 530.0 [M+1] + ; 1 H NMR (400MHz, CDCl3) δ7.96-7.94(d,J=8.4Hz,1H),7.86-7.85(d,J=1.6Hz,1H),7.75-7.72(d,J=8.4,1.6Hz,1H),3.85(s,1H),3.45-3.41(t,J=6.8H z,2H),2.69(s,2H),1.95-1.92(m,2H),1.88-1.83(m,4H),1.61(s,6H),1. 50-1.44(m,2H),1.36-1.34(m,1H),1.27-1.25(m,2H),1.11-1.01(m,2H).

[0430] 2-((2R,6S)-4-(4-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)butyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To a solution of 2-((2S,6R)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrobromide (0.084 g, 0.180 mmol, 1.3 equiv) in N,N-dimethylformamide (2 mL) was added N,N-diisopropylethylamine (0.12 mL, 0.710 mmol, 5 equiv) and the reaction solution was stirred at 50° C. After 12 h, the reaction solution was diluted with water (20 mL) and extracted with 20:1 dichloromethane / methanol (3 x 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, concentrated and purified by standard methods to give 2-((2R,6S)-4-(4-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)butyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.034 g, 0.041 mmol, 29% yield) as a white solid. MS (ESI) m / z 823.3 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.79(s,1H),8.35-8.33(d,J=8.4Hz,1H),8.20(s,1H),7.99-7.97(d,J=8.0H z,1H),7.06-7.02(m,1H),6.98(s,1H),6.84-6.82(d,J=8.0Hz,1H),6.46-6.44(m,1H),4.29-4.25(m, 1H),3.95-3.72(m,8H),3.04(m,4H),2.79-1.71(m,2H),2.62-2.58(m,1H),2.12-2.08(m,1H),1.95-1 .89(m,1H),1.84-1.81(m,2H),1.74-1.71(m,4H),1.55(s,6H),1.33-1.24(m,11H),1.13-1.07(m,2H).

[0431] Example 18: 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((S)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0432]

[0433] 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((S)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a 2 dram vial containing (S)-3-((3-aminophenyl)amino)piperidine-2,6-dione (93.8 mg, 0.43 mmol, 1.3 eq) was added N,N-dimethylformamide (1.65 mL, 0.2 M) and stirred until all solids dissolved. 1-Methylimidazole (0.26 mL, 3.29 mmol, 10 eq) was added followed by N-(chloro(dimethylamino)methylene)-N-methylmethanium hexafluorophosphate (V) (138.5 mg, 0.49 mmol, 1.5 eq) and the reaction solution was stirred at room temperature. After 20 min, the reaction solution was diluted with DMSO to a total volume of 4 ml, filtered, and purified by standard methods to give 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((S)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (62 mg, 0.076 mmol, 23% yield). MS (ESI) m / z 809.4 [M+1]+; 1H NMR (400MHz, DMSO-d6) δ=10.77(s,1H),9.34(s,1H),8.34(d,J=8.3Hz,1H),8.20(d,J=1.7Hz,1H),7 .98(dd,J=1.7,8.3Hz,1H),7.08-6.95(m,2H),6.81-6.77(m,1H),6.40(dd,J=1.7,8.1Hz,1H),5.90 (d,J=7.9Hz,1H),4.35-4.22(m,1H),3.90-3.72(m,1H),3.20(s,2H),2.82-2.54(m,8H),2.26-2.17 (m,2H),1.96-1.68(m,7H),1.55(s,6H),1.51-1.38(m,2H),1.30-1.03(m,5H),0.98(d,J=6.1Hz,6H)

[0434] Example 19: 2-((R)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0435]

[0436] Tert-butyl (R)-4-(2-methoxy-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate. To a 40 ml vial was added tert-butyl (R)-3-(trifluoromethyl)piperazine-1-carboxylate (0.5 g, 1.97 mmol), N,N-diisopropylethylamine (0.69 mL, 3.93 mmol, 2 eq.), methyl bromoacetate (1.09 mL, 11.8 mmol, 6 eq.) and THF (20 mL, 0.1 M). The reaction solution was stirred at room temperature. After 18, the solution was diluted with 100 ml of ethyl acetate and 100 ml of water. The organic layer was removed and the aqueous layer was extracted with 2 x 50 ml of ethyl acetate. The combined organic layers were then dried over magnesium sulfate and concentrated. The crude material was purified by silica gel column chromatography (1%-50% ethyl acetate in hexanes) to provide tert-butyl (R)-4-(2-methoxy-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate (0.557 g, 1.71 mmol, 88% yield) as a yellow oil. MS (ESI) m / z 227 [M-99] + .

[0437] Methyl (R)-2-(2-(trifluoromethyl)piperazin-1-yl)acetate. Tert-butyl (R)-3-(trifluoromethyl)piperazine-1-carboxylate (250 mg, 0.7 mmol) and trifluoroacetic acid (0.58 mL, 7.6 mmol, 10 equiv) were combined in dichloromethane (7.6 mL, 1 M) and stirred at room temperature in a screw-capped scintillation vial. After 1 h, the solution was concentrated to give methyl (R)-2-(2-(trifluoromethyl)piperazin-1-yl)acetate (255 mg, 0.75 mmol, 98% yield) as a yellow oil, which was used further without further purification. MS (ESI) m / z 227 [M+1] + .

[0438] Methyl 2-((R)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetate. To a 1 dram vial of (trifluoromethyl)benzonitrile (0.5 g, 0.96 mmol, 1 eq), methyl (S)-2-(2-(trifluoromethyl)piperazin-1-yl)acetate (0.33 g, 0.96 mmol, 1 eq) and sodium iodide (2.7 mg, 0.02 mmol, 0.1 eq) was added acetonitrile (5 mL) followed by N,N-diisopropylethylamine (0.8 mL, 4.82 mmol, 5 eq). The reaction vial was heated to 60 °C with stirring. After 16 h, the reaction solution was diluted with ethyl acetate (100 mL), washed with saturated aqueous sodium chloride (100 mL), dried over anhydrous sodium sulfate and concentrated. The crude material was purified by silica gel column chromatography (0-100% ethyl acetate in hexanes) to give methyl 2-((R)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetate (0.6 g, 0.89 mmol, 91% yield). MS (ESI) m / z 664.2 [M+1] + .

[0439] 2-((R)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetic acid. At 0°C, methyl 2-((R)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl) To a cooled solution of 2-(trifluoromethyl)piperazin-1-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetate (0.6 g, 0.9 mmol, 1 eq.) in a mixture of tetrahydrofuran / methanol / water (3:1:1, 5 mL) was added lithium hydroxide monohydrate (0.58 g, 1.3 mmol, 1.5 eq.) in one portion. The resulting solution was stirred at room temperature. After 3 h, the reaction solution was diluted with water (20 mL) and extracted with 10% methanol in dichloromethane (4 x 50 mL). The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated to give 2-((R)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetic acid (0.33 g, 0.46 mmol, 51% yield) which was used without further purification. MS (ESI) m / z 650.2 [M+1] + .

[0440] 2-((R)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To a 2 dram vial containing 1-((5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetic acid (0.12 g, 0.19 mmol, 1 eq) and 3-((3-aminophenyl)amino)piperidine-2,6-dione (0.05 g, 0.22 mmol, 1.2 eq) was added acetonitrile (1.5 mL) and N,N-dimethylformamide (1.5 mL) and the reaction solution was stirred until all solids dissolved. 1-Methylimidazole (0.07 mL, 0.84 mmol, 5 eq) was added to the reaction solution followed by N-(chloro(dimethylamino)methylene)-N-methylmethylammonium hexafluorophosphate (0.12 g, 0.41 mmol, 2.2 eq) and the reaction solution was stirred at room temperature. After 1 h, the reaction solution was diluted with dimethyl sulfoxide to a total volume of 3 ml, filtered, and purified by standard methods to give 2-((R)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.09 g, 0.11 mmol, 58% yield). MS (ESI) m / z 851.2 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ10.73(s,1H),9.68(s,1H),8.27(d,J=8.2Hz,1H),8.13(d,J=1.5Hz,1H),7.90(dd,J=1.6,8.2Hz,1H),7.04-6.89(m,2H),6.77(br d,J=6.5Hz,1H),6.36(br d,J=8.2Hz,1H),4.20(br dd,J=4.5,10.9Hz,2H),3.87-3.44(m,8H),3.30(br d,J=11.2Hz,4H),3.06(br d,J=9.7Hz,3H),2.89-2.51(m,4H),2.10-1.97(m,3H),1.84(dq,J=4.7,12.1Hz,1H),1.72-1.61(m,2H),1.48(s,6H),1.38-1.19(m,2H).

[0441] Example 20: 2-((R)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0442]

[0443] Methyl 2-((R)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetate. To a 1 dram vial of 3-(trifluoromethyl)picolinonitrile (375 mg, 0.72 mmol, 1 eq) and methyl (R)-2-(2-(trifluoromethyl)piperazin-1-yl)acetate trifluoroacetate (491.3 mg, 1.44 mmol, 2 eq) was added N,N-dimethylformamide (3.6101 mL, 0.2 M) and N,N-diisopropylethylamine (0.75 mL, 4.33 mmol, 6 eq). The reaction solution was heated to 55 °C with stirring. After 16 h, the reaction solution was diluted with 75 ml of ethyl acetate, washed with saturated aqueous sodium bicarbonate (100 mL) and brine (100 mL). The organic layer was separated and dried over magnesium sulfate to give a light yellow oil. The crude material was purified by reverse phase HPLC to provide the title compound as a formate salt. The material was taken up in ethyl acetate and washed with saturated sodium bicarbonate. The organic layer was dried over magnesium sulfate and concentrated to give methyl 2-((R)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetate (310 mg, 0.4664 mmol, 65% yield). MS (ESI) m / z 655.2 [M+1] + ; 1 H NMR (400MHz, chloroform-d) δ1.62 (s, 6H) 1.81 (br d, J = 11.86Hz, 2H) 2.20 (br d,J=10.76Hz,2H)2.48(ddd,J=11.03,7.92,3.30Hz,1H)2.52-2.69(m,4H)2.81-2.94(m,4H)2.94-3.03(m,1H)3.27-3 .38(m,1H)3.46(dd,J=17.85,0.98Hz,1H)3.56-3.70(m,5H)3.71(s,3H)8.23(d,J=2.20Hz,1H)8.97(d,J=2.20Hz,1H)

[0444] 2-((R)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetate. To a 2 dram vial of 1,4-dioxane (1 mL, 0.3 M) and 1 M solution of lithium hydroxide in water (0.36 mL, 0.36 mmol, 1.2 equiv) was added. The reaction solution was stirred at room temperature for 2 h, at which time no starting material remained as confirmed by LCMS. The reaction solution was concentrated and the resulting material was dried by azeotropic removal with dioxane to give 2-((R)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetate (193 mg, 0.29 mmol, 98% yield) as a shiny yellow oil. The material was carried forward without further purification. MS (ESI) m / z 651.2 [M+1] + .

[0445] 2-((R)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To a 1 dram vial containing N-(chloro(dimethylamino)methylene)-N-methylmethanium hexafluorophosphate (V) (112.2 mg, 0.40 mmol, 2 equiv) was added 2-((R)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. A solution of 4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetate (131.31 mg, 0.20 mmol, 1 eq) in N,N-dimethylformamide (1.0 mL, 0.2 M) was added, followed by the addition of 3-((3-aminophenyl)amino)piperidine-2,6-dione (66 mg, 0.30 mmol, 1.5 eq) and 1-methylimidazole (98.5 mg, 1.2 mmol, 6 eq). The reaction solution was stirred at room temperature for 2 h. The reaction solution was diluted with DMSO to a total volume of 2 ml, filtered, and purified by standard methods to give 2-((R)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (98 mg, 0.11 mmol, 53% yield) as an off-white solid. MS (ESI) m / z 852.2 [M+1] + ; 1 HNMR(400MHz,DMSO-d6)δ=10.80(s,1H),10.72(br s,1H),9.72(s,1H),9.15(d,J=1.8Hz,1H),8.75(d,J=2.0Hz,1H),7.06-6.94(m,2H),6.89-6.77(m,1H),6.42(br d,J=7.6Hz,1H),4.16-4.14(m,1H),3.86(br s,4H),3.62(br s,5H),3.45-3.29(m,4H),3.21-3.03(m,3H),2.95-2.66(m,3H),2.19-2.07( m,3H),1.98-1.84(m,1H),1.80-1.69(m,2H),1.58(s,6H),1.44-1.29(m,2H).

[0446] Example 21: 2-((2S,4r,6R)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0447]

[0448]

[0136] 5-(3-((trans)4-(2-((2S,4r,6R)-2,6-dimethylpiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile. To a solution of (2S,4r,6R)-tert-butyl 4-(2-(((1r,4R)-4-(3-(6-cyano-5-(1,1-difluoroethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate (2.000 g, 3.070 mmol) in DCM (5 mL) was added 45 M HCl in dioxane (30.0 mL, 120 mmol). The reaction mixture was stirred at 15 ° C for 3 hours and the reaction was concentrated to give a residue. The residue was diluted to pH 8-9 with saturated aqueous sodium bicarbonate (50 mL) and the aqueous layer was extracted with ethyl acetate (3 x 100 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated to provide 5-(3-((1R, 4r)-4-(2-((2S, 4r, 6R)-2,6-dimethylpiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (1.940 g, 3.517 mmol) as a yellow solid, which was used without further purification. MS (ESI) m / z: 552.4 [M+1] + ; 1 H NMR (400 MHz, CDCl 3)δ8.97(d,J=2.0Hz,1H),8.24(d,J=2.0Hz,1H),3.79-3.58(m,1H),3.56-3.46(m,2H),3. 30(m,1H),3.03-2.83(m,2H),2.78(m,2H),2.26-2.15(m,2H),1.89-1.75(m,2H),1.69(br d,J=13.2Hz,2H),1.62(s,6H),1.52(q,J=6.8Hz,2H),1.41-1.29(m,2H),1.27-1.11(m,6H),0.88(q,J=11.2Hz,2H).

[0449] 2-((2S,4r,6R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To 5-(3-((1R,4r)-4-(2-((2S,4r,6R)-2,6-dimethylpiperidin-4-yl)ethoxy) To a solution of 2-chloro-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.096 g, 0.330 mmol) in DMF (1 mL) was added N-ethyl-N-isopropylpropan-2-amine (0.19 mL, 1.090 mmol) and sodium iodide (0.033 g, 0.220 mmol). The reaction mixture was stirred at 80 °C for 12 hours and then diluted with water (30 mL). The aqueous layer was extracted with ethyl acetate (3 x 30 mL), and the combined organic layers were washed with brine (50 mL), dried over sodium sulfate and concentrated. The resulting residue was purified by standard methods to afford 2-((2S,4r,6R)-4-(2-(((1r,4R)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.075 g, 0.090 mmol, 41.2% yield) as a yellow solid. MS (ESI) m / z: 811.3 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ10.91(s,1H),10.80(s,1H),10.68-10.53(m,1H),10.24-9.95(m,1H),9.14(d,J=2.0Hz,1H),9.07(br s,1H),8.74(d,J=1.6Hz,1H),7.05(m,1H),6.99(br d,J=7.2Hz,1H),6.87(br d,J=8.0Hz,1H),6.57-6.36(m,1H),4.26(m,1H),4.21(br s,1H),4.12(br d,J=3.6Hz,1H),3.92-3.77(m,1H),3.70-3.56(m,1H),3.56-3.39(m,3H), 3.23(m,1H),2.92-2.68(m,3H),2.64-2.55(m,1H),2.14-2.00(m,3H),1.98 -1.82(m,2H),1.82-1.63(m,4H),1.56(d,J=1.6Hz,6H),1.50(m,1H),1.47 -1.38(m,2H),1.38-1.22(m,5H),1.20(d,J=6.4Hz,3H),1.17-1.07(m,1H).

[0450] Example 22: 2-((2S,4s,6R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0451]

[0452]

[0136] 5-(3-((trans)-4-(2-((2S,4s,6R)-2,6-dimethylpiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile. To a solution of (2S,4s,6R)-tert-butyl 4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidine-1-carboxylate (0.885 g, 1.360 mmol) in DCM (3 mL) was added 4 M HCl in dioxane (20 mL, 80 mmol) and the reaction solution was stirred at 15 °C. After 12h, the solution was concentrated and the resulting residue was diluted with aqueous sodium bicarbonate solution. The aqueous solution was extracted with ethyl acetate (3x 100mL) and the combined organic layer was washed with brine (50mL), dried over sodium sulfate and concentrated to provide 5-(3-((trans)-4-(2-((2S, 4s, 6R)-2,6-dimethylpiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (0.750g, 1.360mmol) obtained as a yellow solid, which was used without further purification. MS (ESI) m / z: 552.5[M+1] + ; 1 H NMR (400 MHz, CDCl 3 )δ8.97(d,J=2.0Hz,1H),8.24(d,J=2.0Hz,1H),3.78-3.59(m,1H),3.51(t,J=6.8Hz,2H),3.31(m,1H),3.02-2.72(m,4H),2.21(br d,J=12.4Hz,2H),2.01-1.95(m,1H),1.82(br d,J=12.0Hz,2H),1.70(q,J=6.8Hz,2H),1.63(s,6H),1.52(br d,J=13.6Hz,2H),1.41-1.26(m,4H),1.10(d,J=6.4Hz,6H).

[0453] 2-((2S,4s,6R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. 5-(3-((trans)-4-(2-((2S,4s,6R)-2,6-dimethylpiperidin-4-yl)ethoxy)cyclohexyl) To a solution of -4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (0.120 g, 0.220 mmol) and 2-chloro-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.095 g, 0.330 mmol) in DMF (0.500 mL) was added N-ethyl-N-isopropylpropan-2-amine (0.19 mL, 1.090 mmol) and sodium iodide (0.033 g, 0.220 mmol). The reaction mixture was stirred at 80 ° C for 12 hours. The reaction mixture was diluted with water (30 mL) and the aqueous layer was extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate and concentrated. The resulting residue was purified by standard methods to afford 2-((2S,4s,6R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.064 g, 0.079 mmol, 36.1% yield) as a yellow solid. MS (ESI) m / z: 811.3 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ10.95(s,1H),10.80(br d,J=3.6Hz,1H),10.62(s,1H),10.27-9.86(m,1H),9.14(d,J=1.2Hz,1H),9.08-8.97(m,1H),8.74(d,J=1 .6Hz,1H),7.17-6.94(m,2H),6.93-6.73(t,J=6.8Hz,1H),6.57-6.37(m,1H),4.30-4.25(m,1H),4.21(br s,1H),4.17(m,1H),3.87-3.78(m,2H),3.59(br s,1H),3.48(br t,J=6.0Hz,2H),3.30-3.11(m,1H),2.93-2.67(m,3H),2.63-2.57(m,1H),2.16-1.86(m,6H),1.82-1.59(m,7H),1.56(d,J=1.2Hz,6H),1.35(br s,3H),1.33-1.25(m,2H),1.19(br d,J=6.0Hz,3H).

[0454] Example 23: 2-((R)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)acetamide

[0455]

[0456] 2-((R)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)acetamide. To a solution of N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)-2-((S)-2-(trifluoromethyl)piperazin-1-yl)acetamide (0.150 g, 0.350 mmol) in DMF (3 mL) was added potassium iodide (0.048 g, 0.290 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.15 mL, 0.870 mmol). The reaction mixture was stirred at 50 °C for 12 h. The reaction solution was diluted with water (30 mL) and the aqueous phase was extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed with brine (20 mL), dried over anhydrous sodium sulfate and concentrated. The resulting residue was purified by standard methods to give 2-((R)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)acetamide (0.062 g, 0.070 mmol, 24.2% yield) as a yellow solid. MS (ESI) m / z: 869.6 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.81(s,1H),9.93(s,1H),8.34(d,J=8.4Hz,1H),8.19(d,J=1 .8Hz,1H),7.97(dd,J=1.6,8.3Hz,1H),6.80-6.59(m,2H),6.22(d,J=12.1Hz,1H),4.45 -4.31(m,1H),4.30-4.24(m,1H),3.87(s,2H),3.82-3.56(m,8H),3.25-3.03(m,4H),2. 92-2.61(m,4H),2.10-1.87(m,1H),1.75-1.67(m,2H),1.54(s,6H),1.39-1.29(m,2H).

[0457] Example 24: 2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)acetamide

[0458]

[0459] (3R)-tert-butyl 4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate. To a solution of (S)-2-(4-(tert-butoxycarbonyl)-2-(trifluoromethyl)piperazin-1-yl)acetic acid (0.263 g, 0.840 mmol) and HATU (0.641 g, 1.69 mmol) in DMF (5 mL) was added N-ethyl-N-isopropylpropan-2-amine (0.44 mL, 2.53 mmol) and 3-((3-amino-5-fluorophenyl)amino)piperidine-2,6-dione (0.200 g, 0.840 mmol). The reaction mixture was stirred at 50 °C for 12 h. The mixture was diluted with water (30 mL) and the aqueous phase was extracted with ethyl acetate (2 x 30 mL). The combined organic layers were washed with brine (2 x 20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was purified by flash silica gel column chromatography (0-4% methanol in dichloromethane) to give (3S)-tert-butyl 4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate (0.340 g, 0.640 mmol, 75.9% yield) as a brown oil. MS (ESI) m / z: 554.4 [M+23] + .

[0460] N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)-2-((R)-2-(trifluoromethyl)piperazin-1-yl)acetamide. To a solution of (3S)-tert-butyl 4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate (0.340 g, 0.640 mmol) in DCM (5 mL) was added 33% hydrogen bromide in acetic acid (0.5 mL) and the reaction mixture was stirred at 25 °C for 12 h. The mixture was concentrated under reduced pressure to give N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)-2-((S)-2-(trifluoromethyl)piperazin-1-yl)acetamide (0.270 g, 0.626 mmol, 97.8% yield) as a brown oil, which was used in the next step without further purification. MS (ESI) m / z 432.3 [M+1] + .

[0461] 2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)acetamide. To a solution of N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)-2-((S)-2-(trifluoromethyl)piperazin-1-yl)acetamide (0.100 g, 0.230 mmol) in DMF (3 mL) were added potassium iodide (0.032 g, 0.190 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.1 mL, 0.580 mmol). The reaction mixture was stirred at 50 °C for 12 h, diluted with DMSO and purified by standard methods to give 2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)acetamide (0.062 g, 0.071 mmol, 36.8% yield) as a green solid. MS (ESI) m / z 870.6 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ11.53-10.98(m,1H),10.79(s,1H),9.94(br s,1H),9.14(d,J=1.9Hz,1H),8.74(d,J=1.9Hz,1H),6.85-6.57(m,2H),6.22(d ,J=11.9Hz,1H),4.40(s,1H),4.28(dd,J=4.7,11.2Hz,3H),3.74-3.50(m,6H),3 .47-3.28(m,4H),3.20-3.11(m,2H),2.94-2.79(m,2H),2.73(ddd,J=4.7,12.2 ,17.0Hz,1H),2.63-2.54(m,1H),2.14-2.03(m,3H),1.94-1.84(m,1H),1.72(br d,J=11.3Hz,2H),1.56(s,6H),1.41-1.29(m,2H).

[0462] Example 25: 2-((R)-4-(3-((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0463]

[0464] 2-((R)-4-(3-((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a solution of 5-(3-((trans)-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (0.188 g, 0.360 mmol) in DMF (1 mL) was added N-ethyl-N-isopropylpropan-2-amine (0.32 mL, 1.820 mmol). The reaction mixture was stirred at 50° C. for 12 hours. The reaction solution was diluted with water (30 mL), extracted with ethyl acetate (3×30 mL), and the combined organic layers were dried over sodium sulfate and concentrated. The resulting crude material was purified by standard methods to give 2-((R)-4-(3-((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.078 g, 0.090 mmol, 25% yield) as a yellow solid. MS (ESI) m / z 850.3 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δ11.27-11.00(m,1H),10.79(s,1H),9.80-9.59(m,1H),9.15( d,J=2.0Hz,1H),8.75(d,J=2.0Hz,1H),7.09-6.95(m,2H),6.90-6.75(m,1H),6.43(br d,J=8.0Hz,1H),4.38(br s,1H),4.27(br dd,J=4.8,11.2Hz,1H),3.67-3.55(m,4H),3.54-3.43(m,2H),3.22-2.94(m,5H),2.90-2.68(m,3H),2.64-2.54(m ,1H),2.16-2.03(m,1H),1.96-1.81(m,3H),1.81-1.66(m,4H),1.57(s,6H),1.33-1.15(m,3H),1.15-0.99(m,2H).

[0465] Example 26: N-(3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetamide

[0466]

[0467] N-(3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetamide. To a solution of 5-(3-((trans)-4-(2-bromoethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (0.100 g, 0.190 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.026 g, 0.960 mmol) was added 1-(trifluoromethyl)-2-(trifluoromethyl)piperazin-1-yl)acetamide (0.172 g, 0.390 mmol) in DMF (1 mL). The reaction mixture was then stirred at 50° C. for 12 h. The reaction solution was diluted with DMSO and purified by standard methods to give N-(3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetamide (0.072 g, 0.075 mmol, 39% yield) as a yellow solid. MS (ESI) m / z 886.0 [M+1] + ; 1HNMR(400MHz,DMSO-d6)δ10.83-10.77(m,1H),9.97-9.66(m,1H),9.15(d,J=1.6Hz,1 H),8.74(d,J=1.6Hz,1H),7.02-6.74(m,2H),6.46(s,1H),4.43-4.25(m,2H),3.87(s, 3H),3.75-3.57(m,5H),3.36-3.32(m,2H),3.27-2.99(m,4H),2.92-2.61(m,4H),2.1 6-2.02(m,3H),1.98-1.84(m,1H),1.78-1.68(m,2H),1.57(s,6H),1.44-1.31(m,2H).

[0468] Example 27: N-(3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetamide

[0469]

[0470] (3R)-tert-Butyl 4-(2-((3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate. To a solution of 3-(3-amino-5-chloro-anilino)piperidine-2,6-dione (0.162 g, 0.640 mmol) and (R)-2-(4-(tert-butoxycarbonyl)-2-(trifluoromethyl)piperazin-1-yl)acetic acid (0.200 g, 0.640 mmol) in pyridine (1 mL) was added EDCI (0.246 g, 1.28 mmol) and the reaction solution was heated to 50°C. After 12 h, the reaction solution was concentrated, diluted with water (40 mL) and extracted with ethyl acetate (3 x 40 mL). The combined organic layers were dried over anhydrous sodium sulfate and purified by standard methods to give (3R)-tert-butyl 4-(2-((3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate (0.250 g, 0.456 mmol, 71.2% yield) as a yellow solid. MS (ESI) m / z 548.1 [M+1] + .

[0471]

[0136] (3R)-tert-Butyl 4-(2-((3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate. A solution of (3R)-tert-butyl 4-(2-((3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate (0.250 g, 0.460 mmol) in 33% HBr in AcOH (0.5 mL, 0.460 mmol) was stirred at 25 °C. After 12 h, the reaction solution was concentrated to give (3R)-tert-butyl 4-(2-((3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate (0.200 g, 0.447 mmol, 97.9% yield) as a green solid which was used further without further purification. MS (ESI) m / z 448.1 [M+1] + .

[0472] N-(3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetamide. To a solution of [0.100 g, 0.190 mmol) in DMF (1 mL) were added N-(3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-2-(trifluoromethyl)piperazin-1-yl)acetamide (0.172 g, 0.390 mmol), N-ethyl-N-isopropylpropan-2-amine (0.124 g, 0.960 mmol) and the reaction solution was heated to 50 °C. After 12 h, the reaction solution was diluted with DMSO and purified by standard methods to afford N-(3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetamide (0.083 g, 0.089 mmol, 46.0% yield) as a yellow solid. MS (ESI) m / z 885.0 [M+1] + ; 1HNMR (400MHz, DMSO-d6) δ10.80 (s, 2H), 10.01-9.67 (m, 1H), 8.34 (d, J = 8.4Hz, 1H), 8.20 (d, J = 1. 6Hz,1H),8.01-7.93(m,1H),7.05-6.72(m,2H),6.46(s,1H),4.47-4.23(m,2H),3.92-3.79(m,3 H),3.77-3.47(m,7H),3.20-3.06(m,3H,3.00-2.76(m,3H),2.75-2.66(m,1H),2.64-2.53(m,1H ),2.14-2.02(m,3H),1.98-1.83(m,1H),1.74(dd,J=12Hz,2H),1.55(s,6H),1.45-1.30(m,2H).

[0473] Example 28: 2-((R)-4-(3-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0474]

[0475] Tert-butyl (3R)-4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate. To a mixture of 3-(3-aminoanilino)piperidine-2,6-dione hydrochloride (0.737 g, 2.88 mmol) and 2-[(2R)-4-tert-butoxycarbonyl-2-(trifluoromethyl)piperazin-1-yl]acetic acid (0.600 g, 1.92 mmol) in pyridine (2 mL) was added N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (0.737 g, 3.84 mmol) and the reaction solution was heated to 50° C. After 16 h, the reaction solution was diluted with water (25 mL), extracted with ethyl acetate (100 mL), and the organic layer was dried over sodium sulfate and concentrated. The resulting crude residue was purified by standard methods to give tert-butyl (3R)-4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate (0.450 g, 0.88 mmol, 46% yield) as a yellow oil. MS (ESI) m / z 514.2 [M+1] + .

[0476] N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-2-(trifluoromethyl)piperazin-1-yl)acetamide hydrobromide. To a solution of tert-butyl (3R)-4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate (0.450 g, 0.88 mmol) in dichloromethane (10 mL) was added 30% hydrogen bromide in acetic acid (0.60 mL, 8.76 mmol) and the reaction solution was stirred at room temperature. After 16 h, the reaction solution was concentrated to provide crude N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-2-(trifluoromethyl)piperazin-1-yl)acetamide hydrobromide (0.500 g, 1.01 mmol), which was used without further purification. MS (ESI) m / z 414.1 [M+1] + .

[0477] 2-((R)-4-(3-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a mixture of 2-(((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-2-(trifluoromethyl)piperazin-1-yl)acetamide hydrobromide (0.120 g, 0.24 mmol) in N,N-dimethylformamide (2 mL) was added diisopropylethylamine (0.06 mL, 0.73 mmol) and the reaction solution was stirred at 50°C. After 16 h, the reaction solution was diluted with water (50 mL) and extracted with ethyl acetate (2 x 80 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated. The resulting crude residue was purified by standard methods to afford 2-((R)-4-(3-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.045 g, 0.05 mmol, 20.7% yield). MS (ESI) m / z 866.3 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ11.08(br d,J=5.6Hz,1H),10.80(s,1H),9.82-9.56(m,1H),8.34(d,J=8.4Hz,1H),8.20(s,1H),7.98(dd,J=1.6,8.0Hz,1H),7.01(br t,J=8.0Hz,2H),6.92-6.72(m,1H),6.43(br d,J=8.0Hz,1H),4.44-4.23(m,2H),3.91-3.76(m,1H),3.71-3.41(m,5H),3.40-2.91(m,6H),2.85-2 .67(m,3H),2.64-2.56(m,1H),2.15-2.04(m,1H),1.92-1.70(m,7H),1.55(s,6H),1.42-0.91(m,6H).

[0478] Example 29: 2-((R)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0479]

[0480] 2-((R)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. 4-(3-((1r,4r)-4-(3-bromopropyl)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)- To a mixture of 2-(trifluoromethyl)benzonitrile (0.126 g, 0.24 mmol) and tert-butyl (3R)-4-(2-((3-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate hydrobromide (0.120 g, 0.24 mmol) in N,N-dimethylformamide (2 mL) was added diisopropylethylamine (0.06 mL, 0.73 mmol) and the reaction solution was stirred at 50°C. After 16 h, the reaction solution was diluted with water (50 mL) and extracted with ethyl acetate (2 x 80 mL). The combined organic layers were dried over sodium sulfate and concentrated. The resulting crude material was purified by standard methods to afford 2-((R)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.057 g, 0.06 mmol, 26.7% yield) as a yellow solid. MS (ESI) m / z 849.3 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ11.14-10.94(m,1H),10.79(br s,1H),9.82-9.50(m,1H),9.14(br s,1H),8.74(br s,1H),7.01(br s,2H),6.90-6.73(m,1H),6.50-6.34(m,1H),4.30-4.24(m,2H),3.66-3.45(m,7H), 3.29-3.00(m,7H),2.91-2.64(m,5H),2.15-1.83(m,7H),1.77-1.68(m,2H),1.57(br d,J=3.2Hz,6H),1.42-1.24(m,2H).

[0481] Example 30: 2-((R)-4-(3-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0482]

[0483] 2-((R)-4-(3-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a solution of (trifluoromethyl)benzonitrile (0.258 g, 0.480 mmol) and N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-2-(trifluoromethyl)piperazin-1-yl)acetamide (0.200 g, 0.480 mmol) in DMF (3 mL) were added N-ethyl-N-isopropylpropan-2-amine (0.25 mL, 1.45 mmol) and potassium iodide (80.31 mg, 0.4800 mmol) and the reaction solution was stirred at 50° C. After 12 h, the reaction solution was diluted with water (50 mL) and extracted with ethyl acetate (2×30 mL). The organic layers were combined, dried over sodium sulfate, concentrated, and purified by standard methods to provide 2-((R)-4-(3-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.059 g, 0.068 mmol, 14.1% yield) as a yellow solid. MS (ESI) m / z 865.5 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ10.78(s,1H),9.71(s,1H),8.33(d,J=8.3Hz,1H),8.18(d,J=1 .6Hz,1H),7.96(dd,J=1.6,8.2Hz,1H),7.05-6.94(m,2H),6.87-6.74(m,1H),6.41(br d,J=8.5Hz,1H),4.43-4.27(m,1H),4.27-4.22(m,1H),3.91-3.74(m,2H),3.66(s,4H),3.32-3.00(m,8H),2.90-2. 61(m,4H),2.07(dd,J=2.5,6.0Hz,3H),1.99-1.82(m,3H),1.71(d,J=11.1Hz,2H),1.54(s,6H),1.36-1.25(m,2H).

[0484] Example 31: N-(3-cyano-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetamide

[0485]

[0486] (3R)-tert-butyl 4-(2-((3-cyano-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate. To a solution of (R)-2-(4-(tert-butoxycarbonyl)-2-(trifluoromethyl)piperazin-1-yl)acetic acid (0.128 g, 0.410 mmol) and HATU (311.34 mg, 0.8200 mmol) in DMF (3 mL) was added N-ethyl-N-isopropylpropan-2-amine (0.21 mL, 1.23 mmol) and 3-amino-5-((2,6-dioxopiperidin-3-yl)amino)benzonitrile (100. mg, 0.4100 mmol). The reaction mixture was stirred at 50 °C for 12 h. The mixture was diluted with water (30 mL) and the aqueous phase was extracted with ethyl acetate (2 x 30 mL). The combined organic layers were washed with brine (2 x 20 mL), dried over anhydrous sodium sulfate and concentrated. The resulting crude material was purified by standard methods to provide (3R)-tert-butyl 4-(2-((3-cyano-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate (140 mg, 0.2600 mmol, 63% yield) as a brown oil. MS (ESI) m / z 539.3 [M+1] + .

[0487] N-(3-Cyano-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-2-(trifluoromethyl)piperazin-1-yl)acetamide. To a solution of (3R)-tert-butyl 4-(2-((3-cyano-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)amino)-2-oxoethyl)-3-(trifluoromethyl)piperazine-1-carboxylate (0.470 g, 0.870 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (1.0 mL, 12.89 mmol) and the reaction mixture was stirred at 25 °C. After 12 h, the reaction solution was concentrated to afford crude N-(3-cyano-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-2-(trifluoromethyl)piperazin-1-yl)acetamide (0.380 g, 0.867 mmol, 99% yield) as a yellow solid, which was carried forward without further purification. MS (ESI) m / z 439.2 [M+1] + .

[0488] N-(3-cyano-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetamide. To a solution of 3-(trifluoromethyl)-3-(trifluoromethyl)-picolinonitrile (0.213 g, 0.410 mmol) and N-(3-cyano-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-2-(trifluoromethyl)piperazin-1-yl)acetamide (0.180 g, 0.410 mmol) in DMF (3 mL) were added potassium iodide (0.068 g, 0.410 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.21 mL, 1.23 mmol) and stirred at 50° C. After 12 h, the reaction solution was diluted with water (30 mL) and extracted with ethyl acetate (2× 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, concentrated, and purified by standard methods to provide N-(3-cyano-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetamide (0.059 g, 0.0675 mmol, 16% yield) as a green solid. MS (ESI) m / z 877.5 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ10.82(s,1H),9.76(s,1H),9.14(d,J=1.8Hz,1H),8.74(d,J=1.8Hz,1H) ,7.22(s,2H),6.77(s,1H),6.50(d,J=8.0Hz,1H),4.43-4.36(m,1H),3.94-3.81(m,1H),3.71-3 .57(m,2H),3.54(t,J=5.6Hz,2H),3.40(d,J=16.1Hz,2H),3.32-3.22(m,8H),2.90-2.75(m,4H) ,2.11-2.03(m,3H),1.96-1.86(m,1H),1.71(d,J=11.4Hz,2H),1.56(s,6H),1.36-1.24(m,2H).

[0489] Example 32: 2-((2R,4r,6S)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0490]

[0491] 2-((2R,4r,6S)-4-(3-((1r,4R)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a solution of 3-((3-aminophenyl)amino)piperidine-2,6-dione (0.079 g, 0.360 mmol) in pyridine (2 mL) was added EDCI (0.086 g, 0.480 mmol) and the reaction solution was stirred at 50 °C. After 12 h, the reaction solution was diluted with water (30 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated. The resulting crude material was purified by standard methods to afford 2-((2R,4r,6S)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.068 g, 0.080 mmol, 33.4% yield) as a grey solid. MS (ESI) m / z 824.4 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ10.80(s,1H),10.73-10.62(m,1H),10.50(s,1H),9.14(br s,1H),8.33(d,J=8.4Hz,1H),8.19(d,J=1.6Hz,1H),7.97(dd,J=1.6,8.4Hz,1H),7.05(q,J=8.0Hz,1H),6.94(br d,J=6.0Hz,1H),6.84(d,J=8.0Hz,1H),6.53-6.38(m,1H),4.29-4.22(m,1H),4.19(br s,1H),4.12(m,1H),3.93-3.73(m,2H),3.46-3.34(m,4H),2.82-2.67(m,3H),2.64-2.55(m,1H),2.19-2.03(m,3H),1.98- 1.87(m,1H),1.81(m,2H),1.77-1.61(m,3H),1.55(s,6H),1.52-1.43(m,2H),1.36(d,J=6.0Hz,2H),1.29(m,2H),1.21(br d,J=6.4Hz,6H),1.14-0.97(m,2H).

[0492] Example 33: 2-((2R,4r,6S)-4-(3-((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0493]

[0494] 2-((2R,4r,6S)-4-(3-((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyloxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To 5-(3-((trans)-4-(3-(((2R,4r,6S)-2,6-dimethylpiperidin-4-yl)oxy)propyl)cyclohexyl)-4, To a solution of 4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (0.090 g, 0.160 mmol) and 2-chloro-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.094 g, 0.320 mmol) in DMF (1 mL) were added N-ethyl-N-isopropylpropan-2-amine (0.14 mL, 0.800 mmol) and sodium iodide (0.024 g, 0.160 mmol) and the reaction solution was stirred at 80 °C. After 12 h, the reaction solution was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated. The resulting crude material was purified by standard methods to afford 2-((2R,4r,6S)-4-(3-((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.059 g, 0.070 mmol, 44% yield) as a grey solid. MS (ESI) m / z 825.3 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ10.80(s,1H),10.54-10.38(m,1H),9.15(m,2H),8.74(d,J=1.6Hz,1H),7 .11-7.00(m,1H),6.91(s,1H),6.85-6.77(m,1H),6.51-6.41(m,1H),4.30-4.22(m,1H),4.17(br s,1H),4.09-4.02(m,1H),3.90-3.78(m,1H),3.64-3.57(m,1H),3.50(br s,2H),3.41(m,2H),2.84-2.68(m,3H),2.64-2.56(m,1H),2.18-2.04(m,3H),1.99-1 .87(m,1H),1.86-1.76(m,2H),1.76-1.61(m,3H),1.57(s,6H),1.51(m,2H),1.35(br d,J=6.4Hz,2H),1.33-1.24(m,2H),1.21(br d,J=6.4Hz,6H),1.15-1.00(m,2H).

[0495] Example 34: 2-((R)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-cyano-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0496]

[0497] 2-((R)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-cyano-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a solution of 5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((R)-2-(trifluoromethyl)piperazin-1-yl)acetamide (0.180 g, 0.410 mmol) in DMF (1 mL) were added potassium iodide (68.16 mg, 0.4100 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.21 mL, 1.23 mmol) and the reaction solution was stirred at 50 °C. After 12 h, the reaction solution was diluted with water (30 mL) and extracted with ethyl acetate (2 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated. The resulting crude material was purified by standard methods to afford 2-((R)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-cyano-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.048 g, 0.054 mmol, 13% yield) as a green solid. MS (ESI) m / z 876.5 [M+1] +;1H NMR (400MHz, DMSO-d6) δ10.89-10.79(m,1H),9.76(s,1H),8.34(d,J=8.2Hz,1H),8.20(d,J=1.8Hz,1H),7.98 (dd,J=1.7,8.2Hz,1H),7.25-7.21(m,2H),6.78(s,1H),6.51(d,J=8.2Hz,1H),4.40(ddd,J=4.7,7.6,12.3Hz ,1H),3.91-3.79(m,1H),3.71-3.58(m,2H),3.55(t,J=5.7Hz,2H),3.41(d,J=16.6Hz,2H),3.33-3.22(m,8H) ,2.97-2.77(m,4H),2.10-2.01(m,3H),1.96-1.85(m,1H),1.75-1.65(m,2H),1.55(s,6H),1.34-1.24(m,2H).

[0498] Example 35: 2-((2R,4r,6S)-4-(2-((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)ethoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0499]

[0500] 2-((2R,4r,6S)-4-(2-((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)ethoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To 5-(3-((trans)-4-(2-(((2R,4r,6S)-2,6-dimethylpiperidin-4-yl)oxy)ethyl)cyclohexyl)-4, To a solution of 4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile (0.120 g, 0.220 mmol) and 2-chloro-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.129 g, 0.440 mmol) in DMF (2 mL) were added N-ethyl-N-isopropylpropan-2-amine (0.19 mL, 1.090 mmol) and sodium iodide (0.033 g, 0.220 mmol) and the reaction solution was stirred at 80 °C. After 12 h, the reaction solution was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated. The resulting crude material was purified by standard methods to afford 2-((2R,4r,6S)-4-(2-((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)ethoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (0.086 g, 0.104 mmol, 47% yield) as a yellow solid. MS (ESI) m / z 811.3 [M+1] + ; 1H NMR(400MHz,DMSO-d6)δ10.87(s,1H),10.80(s,1H),10.60(s,1H),10.36-10.0 5(m,1H),9.25-9.00(m,1H),8.74(d,J=2.0Hz,1H),7.10-7.01(m,1H),6.98(br d,J=10.4Hz,1H),6.86(d,J=8.0Hz,1H),6.52-6.39(m,1H),4.30-4.23(m,1H),4.22-4.14(m,2H),3.86-3.82(m,1H),3. 55-3.37(m,5H),2.84-2.66(m,3H),2.64-2.55(m,1H),2.22-2.12(m,1H),2.12-2.02(m,2H),1.98-1.86(m,1H),1.81(br d,J=12.0Hz,2H),1.76-1.62(m,3H),1.56(s,6H),1.47-1.27(m,7H),1.22(d,J=6.4Hz,3H),1.17-1.01(m,2H).

[0501] Example 36: 2-((2R,4r,6S)-4-(2-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)ethoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0502]

[0503] 2-((2R,4r,6S)-4-(2-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)ethoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a solution of 3-((3-aminophenyl)amino)piperidine-2,6-dione (0.065 g, 0.300 mmol) in pyridine (2 mL) was added EDCI (0.070 g, 0.390 mmol) and the reaction solution was stirred at 50° C. After 12 h, the reaction solution was diluted with water (30 mL) and extracted with ethyl acetate (3×30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated. The resulting crude material was purified by standard methods to afford 2-((2R,4r,6S)-4-(2-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)ethoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.071 g, 0.087 mmol, 44% yield) as a yellow solid. MS (ESI) m / z 810.3 [M+1] + ; 1HNMR(400MHz,DMSO-d6)δ10.88(s,1H),10.80(s,1H),10.60(s,1H),10.42-10.12(m,1H),9.13(br s,1H),8.34(d,J=8.0Hz,1H),8.20(d,J=2.0Hz,1H),7.97(dd,J=1.6,8.4Hz,1H),7.11-7.01(m,1H),6.98(br d,J=10.0Hz,1H),6.86(d,J=7.6Hz,1H),6.57-6.36(m,1H),4.25(m,1H),4.19(m,2H),3.88-3.79(m,1H),3.71- 3.62(m,1H),3.58-3.39(m,4H),2.83-2.64(m,3H),2.63-2.55(m,1H),2.21-2.02(m,3H),1.91(m,1H),1.81(br d,J=12.4Hz,2H),1.76-1.62(m,3H),1.55(s,6H),1.47-1.28(m,7H),1.22(d,J=6.4Hz,3H),1.16-0.99(m,2H).

[0504] Example 37: N-(3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((trans)-4-(3-((1r,4S)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)acetamide

[0505]

[0506] N-(3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((2R,6S)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)acetamide hydrochloride. In a flask containing 2-((3-amino-5-chlorophenyl)amino)piperidine-2,6-dione hydrochloride (52.52 mg, 0.1800 mmol), MeCN (1 mL), 1-methylimidazole (0.05 mL, 0.6600 mmol), and N-(chloro(dimethylamino)methylene)-N-methylmethanium hexafluorophosphate (92.34 mg, 0.3300 mmol) were added. The reaction mixture was stirred at 25° C. for 30 min. The reaction was diluted with DMSO (1.0 mL) and purified by standard methods to afford N-(3-chloro-5-((2,6-dioxopiperidin-3-yl)amino)phenyl)-2-((2R,6S)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)acetamide hydrochloride (76.9 mg, 0.0858 mmol, 52% yield) as a grey solid. MS (ESI) m / z 844.2 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ10.80(s,1H),8.34(d,J=8.31Hz,1H),8.19(d,J=1.59Hz,1H ),7.97(dd,J=1.65,8.25Hz,1H),6.96(s,1H),6.90(brs,1H),6.49(s,1H),4.34(br dd,J=4.89,11.62Hz,5H),3.74-3.92(m,3H),3.52-3.65(m,2H),2.90-3.11(m,4H),2.68-2.8 3(m,3H),2.54-2.63(m,1H),2.01-2.11(m,1H),1.88-1.97(m,1H),1.80-1.88(m,2H),1.74(br d,J=9.29Hz,4H),1.49-1.61(m,6H),1.16-1.33(m,9H),1.01-1.15(m,2H).

[0507] Example 38: 2-((2R,6S)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)acetamide

[0508]

[0509] 2-((2R,6S)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)acetamide. In a flask containing 2-((3-amino-5-fluorophenyl)amino)piperidine-2,6-dione (42.9 mg, 0.1800 mmol) and 2-(((3-amino-5-fluorophenyl)amino)piperidine-2,6-dione)-1-yl)-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)acetic acid (100 mg, 0.1600 mmol) was added MeCN (1 mL), 1-methylimidazole (0.05 mL, 0.6600 mmol) and N-(chloro(dimethylamino)methylene)-N-methylmethanium hexafluorophosphate (92.34 mg, 0.3300 mmol). The reaction mixture was stirred at 25° C. for 30 min. The reaction was diluted with DMSO (1.0 mL) and purified by standard methods to afford 2-((2R,6S)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)-5-fluorophenyl)acetamide hydrochloride (70.4 mg, 0.08 mmol, 49% yield) as an off-white solid. MS (ESI) m / z 827.4 [M+1] + ; 1 HNMR (400MHz, DMSO-d6) δ10.80(s,1H),8.34(d,J=8.19Hz,1H),8.19(d,J=1.59Hz,1H),7.97(dd,J=1.59,8.19Hz,1H),6.67-6.81(m,2H),6.27(br d,J=11.98Hz,1H),4.31(brdd,J=4.89,11.62Hz,1H),2.93-3.11(m,4H),2.68-2.82(m,3H),2.55-2.62(m,1H),2.03-2.13 (m,2H),1.87-1.97(m,1H),1.80-1.87(m,2H),1.68-1.80(m,4H),1.51-1.59(m,6H),1.16-1.33(m,9H),1.02-1.15(m,3H).

[0510] Example 39: 2-((2R,6S)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(5-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)acetamide

[0511]

[0512] 2-((2R,6S)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(5-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)acetamide hydrochloride. In a flask containing 2-((3-amino-4-fluorophenyl)amino)piperidine-2,6-dione (42.9 mg, 0.1800 mmol), MeCN (1 mL), 1-methylimidazole (0.05 mL, 0.6600 mmol), and N-(chloro(dimethylamino)methylene)-N-methylmethanium hexafluorophosphate (92.34 mg, 0.3300 mmol) were added. The reaction mixture was stirred at 25 ° C for 30 min. The reaction was diluted with DMSO (1.0 mL) and purified by standard methods to provide 2-((2R,6S)-4-(3-((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(5-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)acetamide hydrochloride (66 mg, 0.076 mmol, 46% yield) as a tan solid. MS (ESI) m / z 827.4 [M+1] + ; 1HNMR (400MHz, DMSO-d6) δ10.77(s,1H),8.34(d,J=8.19Hz,1H),8.19(d,J=1.59Hz,1H),7.97(dd,J=1.65,8.25Hz,1H),7.21(br d,J=3.67Hz,1H),7.01(t,J=9.78Hz,1H),6.38-6.54(m,1H),4.24(br dd,J=4.77,11.25Hz,2H),3.02(br s,3H),2.68-2.82(m,3H),2.54-2.64(m,1H),2.02-2.13(m,1H),1.87-1.95(m,1H),1.84(br d,J=11.37Hz,2H),1.68-1.79(m,4H),1.50-1.59(m,6H),1.16-1.31(m,8H),1.02-1.16(m,3H).

[0513] Example 40: 2-((S)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0514]

[0515] 2-((S)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. 2-((S)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)acetic acid (40.mg, 0.0600mmol) was added to 3 3-((3-aminophenyl)amino)piperidine-2,6-dione (16.2 mg, 0.0700 mmol), 1-methylimidazole (0.03 mL, 0.3100 mmol), N-(chloro(dimethylamino)methylene)-N-methylmethanaminium hexafluorophosphate (38.01 mg, 0.1400 mmol), and MeCN (0.7738 mL) and DMF (0.7738 mL) were combined and the reaction was stirred at 25° C. After 18 h, the reaction solution was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate, concentrated, and the resulting crude material was purified by standard methods to provide 2-((S)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (9 mg, 0.01 mmol, 16% yield) as a yellow solid. MS (ESI) m / z 851.3 [M+1] + ; 1H NMR(DMSO-d6,400MHz)δ10.9-11.0(m,1H),10.6-10.8(m,1H),9.5-9.7(m,1H),8.2-8.3(m,1H),8.0-8.2(m, 1H),7.8-8.0(m,1H),6.9-7.0(m,2H),6.7-6.8(m,1H),6.2-6.4(m,1H),4.4-4.7(m,6H),4.2-4.2(m,1H),3. 7-3.9(m,3H),3.6-3.7(m,1H),3.5-3.6(m,1H),3.4-3.5(m,1H),3.2-3.3(m,2H),3.0-3.1(m,2H),2.6-2.9( m,3H),2.5-2.6(m,1H),2.0-2.1(m,3H),1.8-1.9(m,1H),1.6-1.7(m,2H),1.4-1.5(m,6H),1.2-1.3(m,2H).

[0516] Example 41: 2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-(((S)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0517]

[0518] 2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-(((S)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To a solution of (S)-3-((3-aminophenyl)amino)piperidine-2,6-dione (1.850 g, 8.45 mmol) in DMF (50 mL) were added HATU (2.920 g, 7.68 mmol) and N-ethyl-N-isopropylpropan-2-amine (4.01 mL, 23.05 mmol) and the reaction solution was stirred at room temperature. After 12 h, the reaction solution was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated. The resulting crude material was purified by standard methods to afford 2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-(((S)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (1539.8 mg, 1.78 mmol, 23% yield) as a yellow solid. MS (ESI) m / z 852.0 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ11.62-11.15(m,1H),10.80(s,1H),9.87-9.63(m,1H),9.14(d,J=2.0Hz,1H),8.74(d,J=2.0Hz,1 H),7.14-6.97(m,2H),6.94-6.78(m,1H),6.44(d,J=8.0Hz,1H),4.42(s,1H),4.35-4.21(m,1H),3.89(s,3H),3.71(d,J=1 1.2Hz,1H),3.60(s,2H),3.51(d,J=11.2Hz,2H),3.36(d,J=10.8Hz,4H),3.25-3.08(m,3H),2.93-2.79(m,2H),2.77-2.68 (m,1H),2.65-2.55(m,1H),2.16-2.04(m,3H),1.96-1.86(m,1H),1.72(d,J=10.0Hz,2H),1.57(s,6H),1.44-1.35(m,2H).

[0519] Example 42: 2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0520]

[0521] 2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To a solution of (R)-3-((3-aminophenyl)amino)piperidine-2,6-dione (1.853 g, 8.450 mmol) in DMF (50 mL) was added HATU (2.922 g, 7.680 mmol) and N,N-diisopropylethylamine (4 mL, 23.05 mmol) and the reaction solution was stirred at room temperature. After 12 h, the reaction solution was diluted with water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated. The resulting crude material was purified by standard methods to afford 2-((R)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2-(trifluoromethyl)piperazin-1-yl)-N-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (4.594 g, 5.376 mmol, 70% yield) as an off-white solid. MS (ESI) m / z 852.1 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ10.98(br s,1H),10.80(s,1H),9.76-9.56(m,1H),9.16(d,J=1.6Hz,1H),8.76(d,J=1.6Hz,1H),7.04-6.94(m,2H),6.80(br d,J=8.0Hz,1H),6.40(br d,J=8.0Hz,1H),4.41(br s,1H),4.24(br dd,J=4.4,11.2Hz,1H),3.87(br s,3H),3.72(br d,J=11.2Hz,1H),3.61(br s,2H),3.52(br s,2H),3.45-3.26(m,1H),3.36(br s,3H),3.12(br d,J=10.4Hz,3H),2.88(br d,J=11.2Hz,2H),2.79-2.68(m,1H),2.64-2.54(m,1H),2.08(brdd,J=4.0,8.8Hz,3H),1.96-1.85(m,1H),1.72(br d,J=10.0Hz,2H),1.57(s,6H),1.42-1.31(m,2H).

[0522] Example 43: 2-((2R,4r,6S)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0523]

[0524] 2-((2R,4r,6S)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a solution of 3-((3-aminophenyl)amino)piperidine-2,6-dione (0.042 g, 0.190 mmol) in pyridine (2 mL) was added EDCI (0.098 g, 0.510 mmol) and the reaction solution was stirred at 60 °C. After 12 h, the reaction solution was diluted with water (30 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate and concentrated. The resulting crude material was purified by standard methods to afford 2-((2R,4r,6S)-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.048 g, 0.0555 mmol, 43% yield) as a green solid. MS (ESI) m / z 826.2 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ10.77(s,1H),9.48-9.39(s,1H),8.33(d,J=8.4Hz,1H),8.19(d,J=1 .2Hz,1H),8.03-7.91(m,1H),7.06-6.93(m,2H),6.85-6.77(m,1H),6.45-6.32(m,1H),5.87( d,J=8.0Hz,1H),4.34-4.20(m,1H),3.93-3.72(m,1H),3.51(s,4H),3.15(s,2H),2.89-2.75 (m,2H),2.74-2.63(m,3H),2.62-2.54(m,1H),2.13-1.98(m,3H),1.95-1.82(m,3H),1.71(br d,J=11.2Hz,2H),1.54(s,6H),1.39-1.29(m,2H),1.28-1.18(m,2H),1.18-1.09(m,2H),1.05(d,J=6.2Hz,6H).

[0525] Example 44: 2-(4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0526]

[0527]

[0136] tert-Butyl 4-(2-(((trans)-4-(dibenzylamino)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate. To a solution of tert-butyl 3,3-difluoro-4-(2-((methylsulfonyl)oxy)ethyl)piperidine-1-carboxylate (1.81 g, 5.27 mmol) in xylene (30 mL) was added (trans-4-(dibenzylamino)cyclohexane-1-ol (3.11 g, 10.54 mmol), tetrabutylammonium bromide (0.340 g, 1.054 mmol), and potassium hydroxide (1.479 g, 26.4 mmol). The reaction mixture was heated to 30 °C for 24 h. The reaction mixture was partitioned between water and ethyl acetate. The organic layer was removed and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, and filtered. The filtrate was taken out and the volatile organics were removed under reduced pressure to give a light yellow solid. The solid was absorbed in ethyl acetate and purified on a silica gel column using 0-75% ethyl acetate in hexane (over 2000 mL). The fractions containing the desired product were combined, and the volatile organics were removed under reduced pressure to give tert-butyl 4-(2-(((trans)-4-(dibenzylamino)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate (1.79 g, 3.30 mmol, 63% yield) as a colorless oil. MS (ESI) m / z 543.2 [M+1] + .

[0528] Tert-butyl 4-(2-(((trans)-4-aminocyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate. To a solution of tert-butyl 4-(2-(((trans)-4-(dibenzylamino)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate (2.65 g, 4.88 mmol) in methanol (50 ml) was added palladium on carbon (500 mg, 4.70 mmol). The air in the flask was evacuated and replaced with hydrogen (3x, 15 psi, balloon). The reaction mixture was stirred at ambient temperature for 18 h. The reaction was filtered through celite. The filter cake was washed with more methanol. The filtrate was taken and the volatile organics were removed under reduced pressure to give tert-butyl 4-(2-(((trans)-4-aminocyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate (1.72 g, 4.75 mmol, 97% yield) as a light yellow oil. MS (ESI) m / z 363.2 [M+1] + .

[0529] Tert-butyl 3,3-difluoro-4-(2-(((trans)-4-((1-methoxy-2-methyl-1-oxopropan-2-yl)amino)cyclohexyl)oxy)ethyl)piperidine-1-carboxylate. To a solution of tert-butyl 4-(2-(((trans)-4-aminocyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate (1.72 g, 4.75 mmol) in acetonitrile (20 ml) was added methyl 2-bromo-2-methylpropanoate (1.718 g, 9.49 mmol), potassium iodide (0.079 g, 0.475 mmol), and potassium carbonate (1.312 g, 9.49 mmol). The reaction mixture was stirred at 110° C. for 20 h. The reaction mixture was partitioned between water and ethyl acetate. The organic layer was removed and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The filtrate was taken and the volatile organics were removed under reduced pressure to give tert-butyl 3,3-difluoro-4-(2-(((trans)-4-((1-methoxy-2-methyl-1-oxopropan-2-yl)amino)cyclohexyl)oxy)ethyl)piperidine-1-carboxylate (2.20 g, 4.76 mmol) as a yellow oil which was used further without further purification. MS (ESI) m / z 463.2 [M+1] + .

[0530] Tert-butyl-4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate. To a solution of tert-butyl 3,3-difluoro-4-(2-(((trans)-4-((1-methoxy-2-methyl-1-oxopropan-2-yl)amino)cyclohexyl)oxy)ethyl)piperidine-1-carboxylate (0.730 g, 1.578 mmol) in ethyl acetate (7 mL) was added 4-isothiocyanato-2-(trifluoromethyl)benzonitrile (0.360 g, 1.578 mmol) and diisopropylethylamine (0.827 mL, 4.73 mmol). The reaction vial was sealed and stirred at 90 °C for 18 h. The reaction mixture is distributed between water and ethyl acetate. 5mL of saline is added to reduce emulsification. The organic layer is removed and the water layer is extracted twice more with ethyl acetate. The combined organic layer is washed with brine, dried over sodium sulfate, and filtered. The filtrate is taken out and the volatile organic matter is removed under reduced pressure to give a foamy dark orange semi-solid. The solid is absorbed in ethyl acetate and purified using 0-100% ethyl acetate in hexane (through 1000mL) on a silica gel column. The fractions containing the desired product are combined and the volatile organic matter is removed under reduced pressure to give tert-butyl 4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidine-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate (396mg, 0.601mmol, 38% yield) in a foamy orange semi-solid. MS (ESI) m / z 559.2 [M-99] + .

[0531] 4-(3-((trans)-4-(2-(3,3-difluoropiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile hydrochloride. To a solution of 4-(3-((trans)-4-(2-(3,3-difluoropiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile, HCl (395 mg, 0.664 mmol, 110% yield) in 1,4-dioxane (3.0 ml) was added HCl (2.0 ml, 8.00 mmol) (4.0 M in dioxane). The reaction was stirred at ambient temperature for 90 min. The volatile organics were removed under reduced pressure to give 4-(3-((trans)-4-(2-(3,3-difluoropiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile hydrochloride (395 mg, 0.664 mmol) as a foamy orange semisolid which was used further without further purification. MS (ESI) m / z 559.2 [M+1] + .

[0532] 2-(4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a solution of 2-chloro-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (68.8 mg, 0.233 mmol) in N,N-dimethylformamide (2 mL, 0.09 M) was added diisopropylethylamine (0.094 mL, 0.537 mmol) and sodium iodide (0.027 g, 0.180 mmol, 1 eq.). The reaction solution was stirred at 80 °C. After 22 h, the reaction solution was diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated. The crude material was purified by standard methods to give 2-(4-(2-(((trans)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (55 mg, 0.066 mmol, 37% yield). MS (ESI) m / z 818.2 [M+1] + ; 1 H NMR(DMSO-d6,400MHz)δ10.7-10.9(m,1H),10.2-10.4(m,1H),8.3-8.4(m,1H),8.2-8.2(m,1H),7.9-8. 0(m,1H),7.0-7.1(m,1H),6.9-7.0(m,1H),6.7-6.9(m,1H),6.4-6.5(m,1H),4.2-4.3(m,1H),3.9-4.2(m ,2H),3.8-3.9(m,2H),3.2-3.3(m,3H),2.7-2.9(m,3H),2.6-2.7(m,1H),2.2-2.3(m,2H),2.0-2.2(m,4 H),1.9-2.0(m,2H),1.6-1.8(m,3H),1.5-1.6(m,6H),1.4-1.5(m,1H),1.3-1.4(m,2H),1.2-1.3(m,2H).

[0533] Example 45: 2-((2R,4r,6S)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide

[0534]

[0535] 2-((2R,4r,6S)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide. To a mixture of 3-((3-aminophenyl)amino)piperidine-2,6-dione (0.042 g, 0.190 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (0.02 mL, 0.640 mmol) in pyridine (2 mL) was added 3-((3-aminophenyl)amino)piperidine-2,6-dione (0.042 g, 0.190 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (0.02 mL, 0.640 mmol) and the reaction solution was heated to 50° C. After 8 h, the reaction solution was diluted with water (80 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated. The crude material was purified by standard methods to afford 2-((2R,4r,6S)-4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethoxy)-2,6-dimethylpiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide (0.070 g, 0.083 mmol, 52% yield) as a yellow solid. MS (ESI) m / z 827.6 [M+1] + ; 1H NMR (400MHz, DMSO-d6) δ10.79(s,1H),9.41(s,1H),9.15(d,J=2.0Hz,1H),8.75(d,J=1.6Hz,1H),7.02-6.97(m,2H), 6.82(d,J=7.6Hz,1H),6.40(d,J=7.6Hz,1H),5.89(d,J=8.0Hz,1H),4.32-4.26(m,1H),3.84(d,J=8.0Hz,1H),3.52( s,4H),3.32-3.23(m,2H),3.16(s,2H),2.81(m,2H),2.74-2.65(m,3H),2.63-2.58(m,1H),2.10-2.02(m,3H),1.92- 1.85(m,3H),1.74-1.68(m,2H),1.57(s,6H),1.34(d,J=12.0Hz,2H),1.14(q,J=11.2Hz,2H),1.05(d,J=6.4Hz,6H).

[0536] Example 46: 2-(4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride

[0537]

[0538] Tert-butyl 4-(2-(((trans)-4-(dibenzylamino)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate. To a solution of tert-butyl 3,3-difluoro-4-(2-((methylsulfonyl)oxy)ethyl)piperidine-1-carboxylate (1.81 g, 5.27 mmol) in xylene (30 mL) was added (1r,4r)-4-(dibenzylamino)cyclohexane-1-ol (3.11 g, 10.54 mmol), tetrabutylammonium bromide (0.340 g, 1.054 mmol), and potassium hydroxide (1.479 g, 26.4 mmol). The reaction mixture was heated to 30 °C for 24 h. The reaction mixture was partitioned between water and ethyl acetate. The organic layer was removed and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The filtrate was taken out and the volatile organics were removed under reduced pressure to give a light yellow solid. The solid was absorbed in ethyl acetate and purified on a silica gel column using 0-75% ethyl acetate in hexanes (over 2000 mL). The fractions containing the desired product were combined and the volatile organics were removed under reduced pressure to give tert-butyl 4-(2-(((trans)-4-(dibenzylamino)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate (1.79 g, 3.30 mmol, 63% yield) as a colorless oil. MS (ESI) m / z 543.2 [M+1] + .

[0539] Tert-butyl 4-(2-(((trans)-4-aminocyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate. To a solution of tert-butyl 4-(2-(((trans)-4-(dibenzylamino)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate (2.65 g, 4.88 mmol) in methanol (50 ml) was added palladium on carbon (500 mg, 4.70 mmol). The air in the flask was evacuated and replaced with hydrogen (3x, 15 psi, balloon). The reaction mixture was stirred at ambient temperature for 18 h. The reaction was filtered through celite. The filter cake was washed with more methanol. The filtrate was taken and the volatile organics were removed under reduced pressure to give tert-butyl 4-(2-(((trans)-4-aminocyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate (1.72 g, 4.75 mmol, 97% yield) as a light yellow oil. MS (ESI) m / z 363.2 [M+1] + .

[0540] Tert-butyl 3,3-difluoro-4-(2-(((trans)-4-((1-methoxy-2-methyl-1-oxopropan-2-yl)amino)cyclohexyl)oxy)ethyl)piperidine-1-carboxylate. To a solution of tert-butyl 4-(2-(((trans)-4-aminocyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate (1.72 g, 4.75 mmol) in acetonitrile (20 ml) was added methyl 2-bromo-2-methylpropanoate (1.718 g, 9.49 mmol), potassium iodide (0.079 g, 0.475 mmol), and potassium carbonate (1.312 g, 9.49 mmol). The reaction mixture was stirred at 110° C. for 20 h. The reaction mixture was partitioned between water and ethyl acetate. The organic layer was removed and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The filtrate was taken and the volatile organics were removed under reduced pressure to give tert-butyl 3,3-difluoro-4-(2-(((trans)-4-((1-methoxy-2-methyl-1-oxopropan-2-yl)amino)cyclohexyl)oxy)ethyl)piperidine-1-carboxylate (2.20 g, 4.76 mmol) as a yellow oil which was used further without further purification. MS (ESI) m / z 463.2 [M+1] + .

[0541] Tert-butyl 4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate. To a solution of tert-butyl 3,3-difluoro-4-(2-(((trans)-4-((1-methoxy-2-methyl-1-oxopropan-2-yl)amino)cyclohexyl)oxy)ethyl)piperidine-1-carboxylate (1.47 g, 3.18 mmol) in ethyl acetate (14 mL) was added 5-isothiocyanato-3-(trifluoromethyl)picolinonitrile (0.728 g, 3.18 mmol) and diisopropylethylamine (1.665 mL, 9.53 mmol). The reaction vial was sealed and stirred at 90 °C for 18 h. The reaction mixture is distributed between water and ethyl acetate. Several mL of saline is added to reduce emulsification. The organic layer is removed and the water layer is extracted twice more with ethyl acetate. The combined organic layer is washed with brine, dried over sodium sulfate, and filtered. The filtrate is taken out and the volatile organic matter is removed under reduced pressure to give a foamy dark orange semi-solid. The solid is absorbed in ethyl acetate and purified using 0-100% ethyl acetate (through 1800mL) in hexane on a silica gel column. The fractions containing the desired product are combined and the volatile organic matter is removed under reduced pressure to give tert-butyl 4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidine-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate (1.10g, 1.667mmol, 52% yield) in a foamy light orange semi-solid. MS (ESI) m / z 560.2 [M-99] + .

[0542] 5-(3-((trans)-4-(2-(3,3-difluoropiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile hydrochloride. To a solution of tert-butyl 4-(2-(((1r,4r)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidine-1-carboxylate (1.10 g, 1.667 mmol) in 1,4-dioxane (5.0 ml) was added HCl (5.0 ml, 20.00 mmol) (4.0 M in dioxane). The reaction was stirred at ambient temperature for 90 min. The volatile organics were removed under reduced pressure to give 5-(3-((trans)-4-(2-(3,3-difluoropiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile hydrochloride (1.08 g, 1.812 mmol) as a foamy orange semisolid which was used further without further purification. MS (ESI) m / z 560.2 [M+1] + .

[0543]

[0136] 2-(4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidin-1-yl)acetate. To a solution of 5-(3-((trans)-4-(2-(3,3-difluoropiperidin-4-yl)ethoxy)cyclohexyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(trifluoromethyl)picolinonitrile, HCl (1.08 g, 1.812 mmol) in acetonitrile (15 mL) were added triethylamine (0.758 mL, 5.44 mmol) and tert-butyl 2-bromoacetate (1.338 mL, 9.06 mmol). The reaction vessel was sealed and stirred at 70 ° C for 18h. Volatile organics were removed under reduced pressure to give an orange solid. The solid was absorbed in dichloromethane and purified on a silica gel column using 0-100% ethyl acetate in hexane (over 2200mL). The fractions containing the desired product were combined, and the volatile organics were removed under reduced pressure to give tert-butyl 2-(4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidin-1-yl)acetate (0.997g, 1.480mmol, 82% yield) in a foamy orange semisolid. MS (ESI) m / z 674.2[M+1]+ .

[0544] 2-(4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidin-1-yl)acetic acid hydrochloride. To a flask containing tert-butyl 2-(4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidin-1-yl)acetate (1.0 g, 1.484 mmol) was added HCl (10.0 ml, 40.0 mmol) (4.0 M in dioxane). The reaction mixture was stirred at ambient temperature for 3 h. The volatile organics were removed under reduced pressure to give 2-(4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidin-1-yl)acetic acid hydrochloride (1.14 g, 1.743 mmol) as a light brown solid which was carried forward without further purification. MS (ESI) m / z 618.2 [M+1] + .

[0545] 2-(4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride. To a solution of 3-((3-aminophenyl)amino)piperidine-2,6-dione (40.2 mg, 0.183 mmol), 1-methyl-1H-imidazole (0.049 mL, 0.612 mmol), N-(chloro(dimethylamino)methylene)-N-methylmethanium hexafluorophosphate (86 mg, 0.306 mmol) and 1 mL of DMF were added and the reaction solution was stirred at room temperature. After 18 h, the reaction solution was diluted with DMSO and purified by standard methods to afford 2-(4-(2-(((trans)-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-3,3-difluoropiperidin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride (50 mg, 0.058 mmol, 38% yield) as a white solid. MS (ESI) m / z 819.2 [M+1] + ; 1 H NMR (DMSO-d6, 400MHz) δ10.79 (s, 1H), 9.14 (d, 1H, J = 2.0Hz), 8.74 (d, 1H, J = 2.0Hz), 7.0-7.1 (m, 1H), 6.95 (s, 1H),6.8-6.8(m,1H),6.45(dd,1H,J=1.5,8.1Hz),4.26(dd,1H,J=4.6,11.2Hz),4.0-4.2(m,1H),3.8-3.9(m, 1H),3.7-3.8(m,1H),3.4-3.6(m,3H),3.3-3.4(m,1H),3.2-3.3(m,1H),3.0-3.2(m,1H),2.7-2.9(m,3H),2.6 -2.6(m,1H),2.0-2.1(m,4H),1.8-2.0(m,2H),1.6-1.8(m,3H),1.57(s,6H),1.4-1.5(m,1H),1.3-1.4(m,2H).

[0546] Determination

[0547] Cell-based assays

[0548] VCAP AR degradation assay. Test compounds were pre-dispensed into Corning CellBind 96-well clear bottom plates (Catalog No. 3300) using an acoustic dispenser, and a 10-point concentration series was generated for each compound at a 1:3 dilution. The final maximum concentration of each compound was 5 μM. DMSO at a final concentration of 0.1% was used as a control. VCaP cells cultured in DMEM with 8% fetal bovine serum (FBS) were inoculated in a compound plate at a volume of 200 μL at 50K cells / well and incubated in a CO2 incubator at 37°C for 24h. The culture medium was carefully removed from the cells and the plates were placed on ice. One hundred μL of ice-cold 1x cell lysis buffer from Cell Signaling Technologies (Cell Signaling Technologies) (Catalog No. 9803) was added to the cells in each well and the plates were incubated on a shaker at 4°C for 1h. Fifteen μL of cell lysate was used for AR ELISA detection using PathScan Total Sandwich AR ELISA kit (Cell Signaling Technologies, Catalog No. 12580). AR levels in compound-treated wells were normalized to those of DMSO controls and expressed as percentage of control (PoC) (y). A four-parameter logistic model (sigmoidal dose-response model) was used to determine the DCs of the compounds. 50 , and EC 50 , using the following equation:

[0549] y=(A+((BA) / (1+((C / x)^D))))

[0550] A=Y Min (Minimum AR levels in response to compound treatment, normalized to DMSO control, as determined by curve fitting)

[0551] B=Y Max (Highest AR level, as determined by curve fitting)

[0552] C=EC 50

[0553] D = Hill slope

[0554] x = compound concentration

[0555] EC 50 =When y=(Y Max -Y Min ) / 2, the concentration of the compound

[0556] DC 50 = the concentration of the compound when y = 50% DMSO control (50% AR degradation)

[0557] y = AR protein level normalized to the DMSO control

[0558] The efficiency of compound-mediated AR degradation was characterized using the lowest measured AR level (termed the Y value) in response to compound treatment, normalized to the DMSO control.

[0559] Each compound in Table 1 was tested in the VCAP AR degradation assay and found to be active. All compounds in Table 1 showed having: DC 50 < 1 μM and Y < 50% of the DMSO control.

[0560] Prostate cancer cell proliferation assay. VCAP or ENZR cells were plated at 10K cells / well in 96-well CellBind (Costar) plates using DMEM + 8% FBS medium. The cells were incubated overnight at 37 °C and the test compounds were serially diluted and added to the wells. After seven days of incubation, the assay medium was removed by inversion and the plates were frozen at -80 °C overnight. The plates were thawed at room temperature and 100 μL of deionized water (ddH2O) was added to each well. The plates were incubated at 37 °C in a non-CO2 incubator for 1 h and then frozen at -80 °C overnight. The plates were thawed to room temperature and 100-μL TNE buffer (NaCl, Tris, EDTA) + Hoescht dye (1.0 mg / ml, 1:400) was added to each well. The fluorescence signal was measured at 460 nm. All data were normalized to the percentage of the DMSO control. A four-parameter logistic model (sigmoidal dose-response model) was used to determine the GI 50 value, using the following equation:

[0561] y = (A + ((B - A) / (1 + ((C / x)^D))))

[0562] A = Y Min (the lowest cell viability (in luminescence units) normalized to the DMSO control in response to compound treatment, as determined by curve fitting)

[0563] B = Y Max (the maximum cell viability measured in luminescence units, normalized to the DMSO control, as determined by curve fitting)

[0564] C = EC 50

[0565] D = Hill slope

[0566] GI 50 =When Y=(Y Max +Yt0) / 2, the concentration of the compound

[0567] EC 50 =When y=(Y Max -Y Min ) / 2, the concentration of the compound

[0568] IC 50 = when Y = 50% of DMSO control, the concentration of the compound

[0569] y = cell viability measured as luminescence units and normalized to percentage of DMSO control

[0570] t0 = time of adding compound

[0571] Yt0 = value of y at t0

[0572] Compounds provided herein have been or will be tested in a prostate cancer cell proliferation assay and have been or will be shown to be active.

[0573] In vivo assay

[0574] AR degradation assay. An in vivo AR degradation assay was performed in NSG mice bearing VCaP prostate cancer xenografts. Male NSG mice were inoculated with VCaP cells in the flank region above the right leg. After inoculation of the animals, tumors were allowed to grow to approximately 500 mm before randomization. 3 Randomized animals were administered test compounds formulated in 20% Labrasol, 80% 25 mM citrate buffer pH 3. Compounds were administered orally once a day for 3 days. After the last dose of compound, plasma and tumors were collected and processed for AR degradation assays. Intratumoral AR levels were measured using Western blot analysis. Statistical analysis was performed using one-way analysis of variance (ANOVA).

[0575] The compounds provided herein have been or will be tested in the in vivo AR degradation assay and have been or will be shown to be active.

[0576] VCaP prostate cancer xenograft model. Xenograft studies were performed using male NSG mice bearing VCaP prostate cancer xenografts. Male NSG mice were inoculated subcutaneously with VCaP cells in the flank region above the right hind leg. After inoculation of the animals, tumors were allowed to grow to approximately 200 mm before randomization. 3 During randomization, the ranges 75 and 250mm will be carried 3Mice with VCaP tumors were pooled together and randomized to different treatment groups. The test compound formulated in 20% Labrasol, 80% 25 mM citrate buffer pH 3 was administered at a dose volume of 5 mL / kg. The compound was administered orally once daily during the study. Tumors were measured twice weekly using calipers and the tumor volume was calculated using the formula W 2 x L / 2. Statistical analysis was performed using one-way or two-way analysis of variance (ANOVA).

[0577] The compounds provided herein have been or will be tested in a VCAP prostate cancer xenograft model and have shown or will show efficacy in treating prostate cancer in the model.

[0578] Activity table

[0579] Each compound in Table 1 was tested in one or more of the AR degradation assays shown above (e.g., VCAP AR degradation assay) and was found to be active.

[0580] All compounds in Table 1 were shown to have: DC 50 ≤ 1 μM and Y < 50% of the DMSO control, where some compounds have DC 50 Value C: DC 50 ≤ 0.005 μM, some have DC 50 Value B: 0.005 μM < DC 50 ≤ 0.010 μM, and others have DC 50 Value A: 0.010 μM < DC 50 ≤ 0.1 μM.

[0581] In addition, the compounds were shown to have: AR degradation efficiency Y value < 50% of the DMSO control, where some compounds have: 0 < Y ≤ 15% (shown as *), some compounds have: 15% < Y ≤ 20% (shown as **), and other compounds have: 25% < Y < 50% (shown as ***).

[0582]

[0583]

[0584]

[0585]

[0586]

[0587]

[0588]

[0589]

[0590]

[0591]

[0592]

[0593]

[0594]

[0595]

[0596]

[0597]

[0598]

[0599]

[0600]

[0601]

[0602] A number of references are cited, the disclosures of which are incorporated herein by reference in their entireties.

Claims

1. A compound selected from 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide, 2-((2S,6R)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide, 2-((2R,6S)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride, 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride, 2-((2R,6S)-4-(3-(trans-4-(3-(5-chloro-6-cyanopyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride, 2-((2R,6S)-4-(3-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride, and 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((S)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide.

2. The compound of claim 1, which is 2-((2R,6S)-4-(2-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide.

3. The compound of claim 1, which is 2-((2S,6R)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide.

4. The compound of claim 1, which is 2-((2R,6S)-4-(2-((trans-4-(3-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)ethyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride.

5. The compound of claim 1, which is 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((R)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride.

6. The compound of claim 1, which is 2-((2R,6S)-4-(3-(trans-4-(3-(5-chloro-6-cyanopyridin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride.

7. The compound of claim 1, which is 2-((2R,6S)-4-(3-((trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)oxy)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide hydrochloride.

8. The compound of claim 1, which is 2-((2R,6S)-4-(3-(trans-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)cyclohexyl)propyl)-2,6-dimethylpiperazin-1-yl)-N-(3-(((S)-2,6-dioxopiperidin-3-yl)amino)phenyl)acetamide.

9. A pharmaceutical composition comprising an effective amount of the compound according to any one of claims 1 to 8, and a pharmaceutically acceptable carrier.

10. Use of a compound according to any one of claims 1 to 8 in the preparation of a medicament for treating an androgen receptor mediated disease, wherein the androgen mediated disease is prostate cancer.

11. The use of claim 10, wherein the prostate cancer is castration-resistant prostate cancer.

Images